

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> A01K 67/00, A01N 61/00, 63/00, A61K 38/00, 48/00, C12N 5/00, 5/02, C12P 21/00, C12Q 1/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/32039 <b>(43) International Publication Date:</b> 8 June 2000 (08.06.00)
<b>(21) International Application Number:</b> PCT/US99/28764 <b>(22) International Filing Date:</b> 3 December 1999 (03.12.99)  <b>(30) Priority Data:</b> 60/110,901 4 December 1998 (04.12.98) US  <b>(71) Applicant (for all designated States except US):</b> DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, Durham, NC 27708 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> LIN, Haifan [US/US]; 2620 McDowell Road, Durham, NC 27705 (US).  <b>(74) Agent:</b> TAYLOR, Arles, A., Jr.; Jenkins & Wilson, P.A., Suite 1400, University Tower, 3100 Tower Boulevard, Durham, NC 27707 (US).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> PURIFIED AND ISOLATED <i>piwi</i> FAMILY GENES AND GENE PRODUCTS AND METHODS EMPLOYING SAME  <b>(57) Abstract</b>  A family of isolated and purified proteins and nucleic acids are disclosed. Particularly, <i>piwi</i> family proteins and cDNAs encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids, recombinant proteins and transgenic animals are also disclosed, along with methods of producing each. Isolated and purified antibodies to <i>piwi</i> family homologs, and methods of producing the same, are also disclosed. <i>piwi</i> family gene products are characterized as having activity in the growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells. Thus, therapeutic, screening, culturing and transgenic methods involving these activities are also disclosed.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

DescriptionPURIFIED AND ISOLATED *piwi* FAMILY GENES AND GENE PRODUCTS  
AND METHODS EMPLOYING SAMEPriority Application Information

5           This application claims the benefit of United States Provisional Patent  
Application 60/110,091, filed December 4, 1998, the disclosure of which is  
incorporated herein by reference in its entirety.

Grant Statement

          This work was supported by NIH grant HD 33760. The U.S.  
10       Government has certain rights in the invention.

Technical Field

          The present invention relates generally to isolated and purified proteins  
and nucleic acids which modulate stem cell renewal, growth and division and  
which modulate primordial germ cell proliferation. More particularly, the  
15       present invention relates to isolated and purified *piwi* family proteins and  
isolated and purified polynucleic acids encoding the same.

          The publications and other materials used herein to illuminate the  
background of the invention, and in particular cases, to provide additional  
details respecting the practice, are incorporated herein by reference, and for  
20       convenience, are referenced by author and year of publication in the following  
text, and respectively grouped by author in the appended list of references.

Table of Abbreviations

	APC	apical polar cell(s)
	ATCC	American Type Culture Collection
25	bFGF	basic fibroblast growth factor
	BRL	buffalo rat liver
	BSA	bovine serum albumin
	Cb	cystoblast

-2-

	CDR(s)	complementarity determining region(s)
	COOH	carboxy terminus
	CyO	a strain of <i>Drosophila</i>
	DAPI	a DNA specific dye
5	DMEM	Dulbecco's modified Eagle's medium
	DC	differentiating 16-cell cysts
	DTC	distal tip cell
	ECL	enhanced chemiluminescent
	EDTA	ethylenediamine tetraacetate
10	ES	epithelial sheath
	EST	expressed sequence tags
	FBS	fetal bovine serum
	FC	follicle cell
	<i>FRT40A</i>	a strain of <i>Drosophila</i>
15	Fu	fusome
	GC-MS	gas chromatography-mass spectroscopy
	Ge	germarium(ia)
	GSC(s)	germline stem cell(s)
	HAT	cell culture media comprising hypoxanthine,
20		aminopterin, and thymidine
	<i>hiwi/hiwi</i>	a human homolog of the <i>piwi/PIWI</i> gene and gene product
	HPLC	high pressure liquid chromatography
	hsGal4	a heat shock inducible transgene
25	IS	inner sheath
	KLH	keyhole limpet hemocyanin
	MC	mitotically active cysts
	<i>miwi/MIWI</i>	a murine homolog of the <i>piwi/PIWI</i> gene and gene product
30	MPZ	mitotic proliferation zone
	myc	human oncogene used herein as molecular tag for <i>piwi</i>



-3-

	NH2	amino terminus
	ORF	open reading frame
	PCR	polymerase chain reaction
	PGC(s)	primordial germ cell(s)
5	<i>piwi</i> /PIWI	a gene and gene product isolated from <i>Drosophila</i> and having stem cell division modulating activity
	RACE	rapid amplification of cDNA ends
	RNAi	RNA interference assay
	SSC(s)	somatic stem cell(s)
10	Sp	spectrosome
	TFC	terminal filament cells
	UTR	untranslated region
	VASA	a germline specific marker
	WT	wild type

## 15 Background Art

Stem cells are a very small number of founder cells that play a central role in tissue development and maintenance. In human bodies, stem cells are responsible for generating and/or maintaining approximately 90% of cells in the adult tissues. Over-proliferation of malignant stem cells is the leading cause of cancer while under-proliferation of stem cells or stem-like progenitor cells leads to tissue dystrophy, anemia, immunodeficiency, and male infertility. The crucial role of stem cells has long been attributed to their ability to self-renew and to generate immense number of specialized cells on demand.

The ability of stem cells to self-renew and to produce a large number of differentiated progeny is critical for the development and maintenance of a wide variety of tissues in organisms ranging from insects to mammals (reviewed in Potten, 1997; Lin, 1997; Lin and Schagat, 1997; Morrison et al., 1997). This self-renewing ability is controlled both by extrinsic signaling and by cell-autonomous mechanisms (reviewed in Morrison et al., 1997; Lin and Schagat, 1997). Cell autonomous mechanisms have been elucidated in a few stem cell models such as neuroblasts and germline stem cells in *Drosophila* (Lin and

Schagat, 1997; Deng and Lin, 1997), whereas the role of extrinsic signaling has been elucidated in several systems. For example, the proliferation and differentiation of mammalian stem cells in the hematopoietic, epidermal, and nervous systems depend on extrinsic signals that act on specific receptors on the stem cell surface (Morrison et al., 1997).

In diverse organisms ranging from invertebrates to mammals, the proliferation of germ cells, some of which possess stem cell properties, has been postulated, and, in some cases, shown to be regulated by neighboring non-mitotic somatic cells (Lin, 1997). Particularly, in *C. elegans*, cell-cell interactions between the somatic distal tip cell (DTC) at the end of each gonadal arm and the underlying mitotic germline nuclei via the *lag-2/glp-1* signaling pathway provides a paradigm for soma-germline interaction (reviewed in Kimble and Simpson, 1997). The *glp-1* pathway is required to maintain a population of mitotically active nuclei in the germline.

However, few molecules and/or mechanisms identified in a particular type of stem cells have been shown to be applicable to other stem cell systems. For example, the *glp-1* equivalent pathway in *Drosophila* does not play a role in regulating GSC division and maintenance (Ruohala et al., 1991; Xu et al., 1992).

The self-renewing asymmetric division of GSCs in the *Drosophila* ovary is known to be controlled both by an intracellular mechanism (Deng and Lin, 1997) and by cell-cell interactions (Lin and Spradling, 1993). The intracellular mechanism involves a cytoplasmic organelle termed the spectrosome that controls the orientation of GSC division (Lin et al., 1994; Deng and Lin, 1997). The cell-cell interaction mechanism involves terminal filament cells, as shown by laser ablation studies (Lin and Spradling, 1993). Recently, *dpp* has been shown as a key signaling molecule required for GSC division and maintenance (Xie and Spradling, 1998). It is possible that the *dpp* signal emanates from somatic cells. Alternatively, *dpp* signal may originate from the germline or even within GSCs, like its mammalian homologs (Zhao et al., 1996).

In mammals, primordial germ cells cultured from the genital ridge have the ability to give rise to pluripotent embryonic stem cells. For example, U.S.

Patent No. 5,690,926 issued November 25, 1997 to Hogan; U.S. Patent No. 5,670,372 issued September 23, 1997 to Hogan; and U.S. Patent No. 5,537,357 issued September 26, 1995 to Hogan each disclose pluripotential mammalian embryonic stem cells and methods of making the same. The disclosure of these patents is limited to mammalian embryonic stem cells and particularly to the culturing of murine and other mammalian embryonic stem cells using a combination of growth factors consisting of SCF, FGF and LIF.

Current prior art reports on the culture of avian primordial germ cells (PGCs) have concentrated on efforts to maintain a PGC-phenotype and to stimulate proliferation. See e.g., Chang, I. K. et al., *Cell. Biol. Int.* 1997 Aug; 21(8): 495-9; Chang, I. K. et al., *Cell. Biol. Int.* 1995 Feb; 19(2): 143-9; Allioli, N. et al., *Dev. Biol.* 1994 Sep; 165(1): 30-7 and PCT Publication No. WO 99/06533, published February 11, 1999 (Applicant - University of Massachusetts; Inventors - Ponce de Leon et al.).

As illustrated above, numerous attempts have been devoted to identify genes that control the self-renewing ability of stem cells or the proliferation of primordial germ cells. As a result, a number of growth factors and signaling molecules, such as *Steel* factor and its *c-kit* receptor, have been identified to regulate such activity in certain tissues. Despite this progress, there remains a long-felt and continuing need to identify genes that play a role in modulating the growth and self-renewing division of stem cells, particularly GSCs, and that play a role in modulating proliferation of primordial germ cells.

#### Summary of the Invention

The present invention contemplates an isolated and purified family of genes and gene products (the *piwi* family) which plays a role in the growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells. More preferably, a polypeptide of the invention is a recombinant polypeptide. Even more preferably, a polypeptide of the present invention comprises a vertebrate *piwi* family polypeptide. Even more preferably, a polypeptide of the present invention comprises a mammalian *piwi* family polypeptide. Even more preferably, a polypeptide of the present

-6-

invention comprises a human *piwi* family polypeptide. Even more preferably, a polypeptide of the present invention comprises an amino acid sequence from the amino acid residue sequences of any of SEQ ID NOs:2, 4 and 6.

5 The present invention also provides an isolated and purified polynucleotide that encodes a polypeptide that plays a role in the growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells. In a preferred embodiment, a polynucleotide of the present invention comprises a DNA molecule from a vertebrate species. Preferred vertebrates comprise mammals, birds or fish. A preferred mammal  
10 is a human. More preferably, a polynucleotide of the present invention encodes a polypeptide designated PIWI. Even more preferably, a polynucleotide of the present invention encodes a polypeptide comprising an amino acid residue sequence of any of SEQ ID NOs:2, 4 and 6. Most preferably, an isolated and purified polynucleotide of the invention comprises  
15 a nucleotide base sequence of any of SEQ ID NOs:1, 3 and 5.

In another embodiment, the present invention contemplates an antibody immunoreactive with a *piwi* family polypeptide as described above. SEQ ID NOs:3-6 set forth nucleotide and amino acid sequences from representative vertebrates, human and mouse. Also contemplated by the present invention  
20 are antibodies immunoreactive with homologues or biologically equivalent *piwi* family polynucleotides and polypeptides found in other vertebrates. Preferably, an antibody of the invention is a monoclonal antibody. More preferably, the *piwi* family polypeptide comprises human PIWI (HIWI). Even more preferably, the *piwi* polypeptide comprises an amino acid residue sequence of any of SEQ  
25 ID NOs:2, 4 and 6.

In another aspect, the present invention contemplates a method of producing an antibody immunoreactive with a *piwi* family polypeptide as described above, the method comprising the steps of (a) transfecting a recombinant host cell with a polynucleotide that encodes a biologically active  
30 *piwi* family polypeptide; (b) culturing the host cell under conditions sufficient for expression of the polypeptide; (c) recovering the polypeptide; and (d) preparing the antibody to the polypeptide. SEQ ID NOs:3-6 set forth nucleotide and

amino acid sequences from representative vertebrates, human and mouse. Preferably, the host cell is transfected with a polynucleotide of any of SEQ ID NOs:1, 3 and 5. Even more preferably, the present invention provides an antibody prepared according to the method described above. Also  
5 contemplated by the present invention is the use of homologues or biologically equivalent polynucleotides and polypeptides found in other vertebrates to produce antibodies.

Alternatively, the present invention provides a method of detecting a  
10 *piwi* family polypeptide as described above, wherein the method comprises immunoreacting the polypeptide with an antibody prepared according to the method described above to form an antibody-polypeptide conjugate, and detecting the conjugate.

In yet another embodiment, the present invention contemplates a method of detecting a messenger RNA transcript that encodes a *piwi* family  
15 polypeptide as described above, wherein the method comprises hybridizing the messenger RNA transcript with a polynucleotide sequence that encodes that polypeptide to form a duplex; and detecting the duplex. Alternatively, the present invention provides a method of detecting a DNA molecule that encodes a *piwi* family polypeptide as described above, wherein the method comprises  
20 hybridizing DNA molecules with a polynucleotide that encodes a biologically active *piwi* family polypeptide to form a duplex; and detecting the duplex.

In another aspect, the present invention contemplates an assay kit for detecting the presence of a *piwi* family polypeptide in a biological sample, where the kit comprises a first container containing a first antibody capable of  
25 immunoreacting with a biologically active *piwi* polypeptide, with the first antibody. Preferably, the first antibody is present in an amount sufficient to perform at least one assay. Also preferably, an assay kit of the invention further comprises a second container containing a second antibody that immunoreacts with the first antibody. More preferably, the antibodies used in  
30 an assay kit of the present invention are monoclonal antibodies. Even more preferably, the first antibody is affixed to a solid support. More preferably still,

the first and second antibodies comprise an indicator, and, preferably, the indicator is a radioactive label, a fluorescent label or an enzyme.

In an alternative aspect, the present invention provides an assay kit for detecting the presence, in biological samples, of a *piwi* family polypeptide, the kits comprising a first container that contains a second polynucleotide identical  
5 or complementary to a segment of at least 10 contiguous nucleotide bases of a polynucleotide that encodes a biologically active *piwi* family polypeptide.

In another embodiment, the present invention contemplates an assay kit for detecting the presence, in a biological sample, of an antibody  
10 immunoreactive with a *piwi* family polypeptide, the kit comprising a first container containing a biologically active *piwi* family polypeptide that immunoreacts with the antibody, with the polypeptide present in an amount sufficient to perform at least one assay.

In still a further embodiment, this invention pertains to transgenic,  
15 therapeutic, screening and culturing methods based upon the self-renewing division of stem cells, and proliferation of primordial germ cells function of *piwi* family polynucleotides and polypeptides as described herein. Representative therapeutic and culturing methods include administration of a soluble form of the *piwi* protein and gene therapy approaches using an isolated and purified  
20 polynucleotide of the present invention.

Thus, a key aspect of this invention pertains to the discovery of the novel *piwi* family of proteins and nucleic acids. Preferred nucleic acid and amino acid sequences are described in SEQ ID NOs:1-6.

It is thus another aspect of this invention to provide a purified and  
25 isolated *piwi* family polypeptide having a role in the growth, proliferation and/or self-renewing division of stem cells, and proliferation of primordial germ cells.

The foregoing aspects and embodiments have broad utility given the biological significance of stem cell growth, proliferation and renewal, and primordial germ cell proliferation. By way of example, the foregoing aspects  
30 and embodiments are useful in the preparation of screening assays and assay kits that are used to identify compounds that affect or modulate *piwi* family biological activity, or that are used to detect the presence of the proteins and

nucleic acids of this invention in biological samples. Additionally, it is well known that isolated and purified polypeptides have utility as feed additives for livestock and further polynucleotides encoding the polypeptides are thus useful in producing the polypeptides.

5           Some of the aspects and objects of the invention having been stated hereinabove, other aspects and objects will become evident as the description proceeds, when taken in connection with the accompanying Examples and Drawings as best described hereinbelow.

#### Brief Description of the Drawings

10           Figure 1 is a molecular map of the *piwi* locus. Restriction enzyme map for 15 kb of genomic DNA surrounding the *piwi* mutations is shown. Three transcripts are represented by thick arrows indicating their relative positions, sizes, splice sites and direction of transcription. The relative insertion sites of the P-element alleles is indicated above the restriction map with orientation of  
15           insertion indicated by black (5') and white (3') boxes. The P insertions are not shown according to the scale, with *piwi*<sup>2</sup> insertion partially mapped. Restriction sites: R, *EcoRI*; H, *HindIII*; P, *PstI*; S, *Sall*; X, *XhoI*.

            Figure 2 depicts alignment of predicted PIWI protein sequence with its homologs in the *piwi* box domain in 22 different proteins. The alignments were  
20           generated using Block Maker™ analysis (Henikoff et al., 1995) against amino acids 740-782 of the predicted *piwi* sequence. The amino acid sequences were deduced from genomic DNA sequences for *C. elegans* (Ce G) or from cDNA (EST) sequences (E) for *Rattus* sp. (Rs) and *Oryza sativa* (Os). GenBank accession numbers and cosmid designations (Ce) are indicated for  
25           each sequence. Residues identical to the consensus are highlighted. Shown below the alignments, residues which are absolutely conserved are shown as capital letters and residues which are 80% or more conserved are shown as lower case letters while dashes indicate their spacing.

            Figure 3 is a graph showing that *prg-RNAi* significantly reduces germline  
30           proliferation in *C. elegans* and that reducing *prg* activity affects fertility. The graph indicates the number of progeny produced by a single F1 worm from an

RNAi *prg-1* or pBST injected mother vs. the percentage of F1 animals which produced that given number of progeny. Comparison of *prg-RNAi* (striped bars) with pBST RNAi (solid bars) animals reveals two distinctive distributions.

Figure 4 depicts the construction of full length *hiwi* cDNA clone. The 2.3kb cDNA fragment obtained from library screening (herein named 3-12) was subcloned into a pBluescript® KS<sup>+</sup> plasmid vector, the 3-12 insert is shown as an open box, the polycloning site on the vector is shown as a dark line. The 1.4kb cDNA fragment obtained from 5'RACE (herein named 1501) was subcloned into a pGEM-T Easy™ vector. The 1501 in pGEM-T Easy™ vector was digested with SacI to construct a vector for subsequent ligation. The 3-12 in pBluescript® KS<sup>+</sup> vector was partially digested with SacI to obtain the insert. This partially digested 3-12 insert DNA was used to do ligation with 1501 in pGEM-T easy vector to construct a full length *hiwi* cDNA clone.

Figure 5 is a schematic depicting the *miwi* locus (genomic location and gene structure).

Figure 5A is a schematic depicting mouse chromosome 5.

Figure 5B is a schematic depicting the *miwi* genomic locus.

Figure 5C is a schematic depicting the location and structure on the *miwi* cDNA.

Figure 5D is a schematic depicting the location and structure of *miwi* genomic clones.

Figure 6 depicts alignment of MIWI protein sequence with HIWI, *Drosophila* PIWI and *C. elegans* PRG-1 and PRG-2. Names of the sequences are shown on the right and the positions of them are shown on the left. Amino acid residues identical among above four genes are boxed in black. The high identical C-terminal domains of 104 amino acid residues are underlined.

Figure 7 is a schematic diagram of a *Drosophila* germarium. The schematized germarium is oriented with the apical end toward the left. The numbers below the germarium in the brackets denote distinct regions within the germarium. Germarial region 1 extends from the apical terminal filament cells (TFC, including cap cells, CpC) to the zone of mitotically active cysts. Germarial regions 2a and 2b include differentiating 16-cell cysts. Two somatic



-11-

stem cells (SSC) are located at the border between regions 2a and 2b. Germarial region 3 contains a newly formed egg chamber that is preparing to bud off from the germarium and contribute to the developing string of egg chambers which comprise the rest of the ovariole. Abbreviations: GSC, germline stem cell; Sp, spectrosome; ISC, inner sheath cell; Cb, cystoblast; Fu, fusome; MC, mitotically active cysts; DC, differentiating 16-cell cysts; FC, follicle cell.

Figure 8 is a schematic diagram of the myc-PIWI and PIWI-myc constructs. The *myc-piwi* transgene encodes a 97.5 kDa protein. In the myc-PIWI construct, the myc epitope is inserted after the third amino acid residue of PIWI. In the PIWI-myc construct, the epitope is inserted 13 amino acids downstream of the highly conserved PIWI box (hatched), 48 residues away from the C-terminus. Abbreviations: NH<sub>2</sub>, the amino terminus; COOH, the carboxy terminus.

Figure 9 is a graph displaying the relative division rates of wild-type and *piwi*<sup>-</sup> GSCs and demonstrating that PIWI acts cell-autonomously in GSCs to promote their division. The number of germaria counted is given in parentheses.

Figure 10 is a graph displaying a comparison of the number of spectrosomes present per wild-type germarium versus per *piwi*-overexpressed germarium and demonstrating that somatic PIWI over-expression increases the number of germline stem cells. The number of germaria examined (n) is in parentheses.

#### Detailed Description of the Invention

The present invention discloses a novel class of genes required for the growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells. The present invention relates to the discovery of a novel class of evolutionarily conserved genes, the *piwi* family genes, that encode a novel group of basic proteins important for stem cell division, primordial germ cell proliferation and other developmental processes.

-12-

The disclosure of the present invention demonstrates that PIWI protein can localize either in the nucleoplasm or cytoplasm and that the dose of the PIWI protein determines both the number and the mitotic rate of germline stem cells, and that the PIWI protein is localized in the germplasm (the cytoplasm of  
5 future germ cells) and plays a key role in determining the initial number of germ cells in during embryogenesis. The mouse PIWI protein (i.e., MIWI protein) is also a cytoplasmic factor with very similar functions in germ cell and stem cell determination.

To identify genes essential for stem cell division, germline stem cells in  
10 the *Drosophila* ovary were established as a model by directly identifying these cells and demonstrating their self-renewing asymmetric division pattern. This stem cell model allowed applicant to effectively circumvent difficulties intrinsic to studying mammalian stem cells, such as their rarity, lack of unique morphological markers, hyper-sensitivity to *in vitro* manipulation, and  
15 inaccessibility to systematic genetic screen. Systematic genetic screens were then conducted to identify mutations that either abolish the self-renewing ability of stem cells or the asymmetry of stem cell division, or both. These screens led to the identification of the *Drosophila piwi* gene that is essential for germline stem cell self-renewal. Subsequent cloning and molecular analysis of the *piwi*  
20 gene and its homologs in *C. elegans*, the mouse, and human, and the identification of *piwi*-like genes in *Arabidopsis* led to the following novel aspects of the present invention.

#### Definitions and Techniques Affecting

##### Gene Products and Genes

25 As used in the following detailed description and in the claims, the term "*piwi* family" refers to a family or group of genes and gene products including, but not limited to, PIWI, HIWI, MIWI, PRG-1 and PRG-2 proteins, and the *piwi*, *hiwi*, *miwi*, *prg-1* and *prg-2* genes, each of which are further defined herein. The term "*piwi* family" also includes other members of the *piwi* family of genes  
30 and gene products characterized by biological activity, including but not limited

to the biological activities of modulating growth, proliferation and/or self-renewing division of stem cells, and/or proliferation of primordial germ cells.

Preferably, *piwi* family genes and gene products are isolated from eukaryotic sources. Thus, the term "*piwi* family" also includes invertebrate  
5 homologs. The term "*piwi* family" further includes vertebrate homologs of *piwi* family members, including, but not limited to, mammalian, avian and fish homologs. Preferred mammalian homologs of *piwi* family members include, but are not limited to, murine and human homologs.

The terms "*piwi* family gene product", "*piwi* family protein" and "*piwi*  
10 family polypeptide" refer to proteins having amino acid sequences which are substantially identical to the native amino acid sequences in the *piwi* family and which are biologically active in that they are capable of modulating growth, proliferation and/or self-renewing division of stem cells, and/or proliferation of primordial germ cells, or cross-reacting with anti-*piwi* family antibodies raised  
15 against a *piwi* family polypeptide.

The terms "*piwi* family gene product", "*piwi* family protein" and "*piwi*  
family polypeptide" also include analogs of *piwi* family molecules which exhibit at least some biological activity in common with native *piwi* family gene products. Furthermore, those skilled in the art of mutagenesis will appreciate  
20 that other analogs, as yet undisclosed or undiscovered, may be used to construct *piwi* family analogs. There is no need for an "*piwi* family gene product", "*piwi* family protein" or "*piwi* family polypeptide" to comprise all, or substantially all of the amino acid sequence of a native *piwi* family gene product. Shorter or longer sequences are anticipated to be of use in the  
25 invention. Thus, the term "*piwi* family gene product" also includes fusion or recombinant *piwi* family polypeptides and proteins. Methods of preparing such proteins are described herein in the Examples, among other places.

The terms "*piwi* family gene", "*piwi* family gene sequence" and "*piwi*  
family gene segment" refer to any DNA sequence that is substantially identical  
30 to a polynucleotide sequence encoding a *piwi* family gene product, *piwi* family protein or *piwi* family polypeptide as defined above. The terms also refer to RNA, or antisense sequences, compatible with such DNA sequences. A "*piwi*

-14-

family gene", "*piwi* family gene sequence" and "*piwi* family gene segment" may also comprise any combination of associated control sequences.

The term "substantially identical", when used to define either a *piwi* family gene product or *piwi* family amino acid sequence, or a *piwi* family gene or *piwi* family nucleic acid sequence, means that a particular sequence, for example, a mutant sequence, varies from the sequence of a natural *piwi* family by one or more deletions, substitutions, or additions, the net effect of which is to retain at least some of biological activity of *piwi* family. Alternatively, DNA analog sequences are "substantially identical" to specific DNA sequences disclosed herein if: (a) the DNA analog sequence is derived from coding regions of the natural *piwi* family gene; or (b) the DNA analog sequence is capable of hybridization of DNA sequences of (a) under moderately stringent conditions and which encode biologically active *piwi* family gene product; or (c) the DNA sequences are degenerative as a result of the genetic code to the DNA analog sequences defined in (a) and/or (b). Substantially identical analog proteins will be greater than about 60% identical to the corresponding sequence of the native protein. Sequences having lesser degrees of similarity but comparable biological activity are considered to be equivalents. In determining nucleic acid sequences, all subject nucleic acid sequences capable of encoding substantially similar amino acid sequences are considered to be substantially similar to a reference nucleic acid sequence, regardless of differences in codon sequences.

#### Percent Similarity

Percent similarity may be determined, for example, by comparing sequence information using the GAP computer program, available from the University of Wisconsin Geneticist Computer Group. The GAP program utilizes the alignment method of Needleman et al. 1970, as revised by Smith et al. 1981. Briefly, the GAP program defines similarity as the number of aligned symbols (i.e. nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unitary comparison matrix

(containing a value of 1 for identities and 0 for non-identities) of nucleotides and the weighted comparison matrix of Gribskov et al., 1986, as described by Schwartz et al., 1979; (2) a penalty of 3.0 for each gap and an additional 0.01 penalty for each symbol and each gap; and (3) no penalty for end gaps. Other comparison techniques are described in the Examples.

The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. Accordingly, the term "homology" is synonymous with the term "similarity" and "percent similarity" as defined above. Thus, the phrases "substantial homology" or "substantial similarity" have similar meanings.

#### Nucleic Acid Sequences

In certain embodiments, the invention concerns the use of *piwi* family genes and gene products that include within their respective sequences a sequence which is essentially that of a *piwi* family gene, or the corresponding protein. The term "a sequence essentially as that of a *piwi* family gene", means that the sequence substantially corresponds to a portion of a *piwi* family polypeptide or *piwi* family gene and has relatively few bases or amino acids (whether DNA or protein) which are not identical to those of a *piwi* family protein or *piwi* family gene, (or a biologically functional equivalent of, when referring to proteins). The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences which have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids which are identical or functionally equivalent to the amino acids of a *piwi* family protein or *piwi* family gene, will be sequences which are "essentially the same".

*piwi* family gene products and *piwi* family genes which have functionally equivalent codons are also covered by the invention. The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also to refer to codons that encode biologically equivalent amino acids (see Table 1). Thus,

-16-

when referring to the sequence examples presented in SEQ ID NOs:1-6, the substitution of functionally equivalent codons of Table 1 into the sequence examples of SEQ ID NOs:1-6 is envisioned. Thus, applicants are in possession of amino acid and nucleic acids sequences which include such substitutions but which are not set forth herein in their entirety for convenience.

**TABLE 1 - Functionally Equivalent Codons.**

Amino Acids			Codons
Alanine	Ala	A	GCA GCC GCG GCU
Cysteine	Cys	C	UGC UGU
Aspartic Acid	Asp	D	GAC GAU
Glumatic acid	Glu	E	GAA GAG
Phenylalanine	Phe	F	UUC UUU
Glycine	Gly	G	GGA GGC GGG GGU
Histidine	His	H	CAC CAU
Isoleucine	Ile	I	AUA AUC AUU
Lysine	Lys	K	AAA AAG
Leucine	Leu	L	UUA UUG CUA CUC CUG CUU
Methionine	Met	M	AUG
Asparagine	Asn	N	AAC AAU
Proline	Pro	P	CCA CCC CCG CCU
Glutamine	Gln	Q	CAA CAG
Arginine	Arg	R	AGA AGG CGA CGC CGG CGU
Serine	Ser	S	ACG AGU UCA UCC UCG UCU
Threonine	Thr	T	ACA ACC ACG ACU
Valine	Val	V	GUA GUC GUG GUU
Tryptophan	Trp	W	UGG
Tyrosine	Tyr	Y	UAC UAU

It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences which may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.

The present invention also encompasses the use of DNA segments which are complementary, or essentially complementary, to the sequences set

forth in the specification. Nucleic acid sequences which are "complementary" are those which are base-pairing according to the standard Watson-Crick complementarity rules. As used herein, the term "complementary sequences" means nucleic acid sequences which are substantially complementary, as may  
5 be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment in question under relatively stringent conditions such as those described herein. A particular example of a contemplated complementary nucleic acid segment is an antisense oligonucleotide.

10 Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions  
15 will generally include temperatures in excess of 30°C, typically in excess of 37°C, and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1,000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. (See, e.g., Wetmur & Davidson,  
20 1968). Determining appropriate hybridization conditions to identify and/or isolate sequences containing high levels of homology is well known in the art. (See e.g., Sambrook *et al.*, 1989). For the purposes of specifying conditions of high stringency, preferred conditions are salt concentration of about 200 mM and temperature of about 45°C.

25 Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

As used herein, the term "DNA segment" refers to a DNA molecule  
30 which has been isolated free of total genomic DNA of a particular species. Furthermore, a DNA segment encoding a *piwi* family polypeptide refers to a DNA segment which contains *piwi* family coding sequences, yet is isolated

away from, or purified free from, total genomic DNA of a source species, such as *Homo sapiens*. Included within the term "DNA segment" are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phages, viruses, and the like.

5           Similarly, a DNA segment comprising an isolated or purified *piwi* family gene refers to a DNA segment including *piwi* family coding sequences isolated substantially away from other naturally occurring genes or protein encoding sequences. In this respect, the term "gene" is used for simplicity to refer to a functional protein, polypeptide or peptide encoding unit. As will be understood  
10 by those in the art, this functional term includes both genomic sequences and cDNA sequences. "Isolated substantially away from other coding sequences" means that the gene of interest, in this case, the *piwi* family gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA,  
15 such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

In particular embodiments, the invention concerns isolated DNA  
20 segments and recombinant vectors incorporating DNA sequences which encode a *piwi* family polypeptide that includes within its amino acid sequence an amino acid sequence selected from any of SEQ ID NOs:2, 4 and 6. In other particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a protein that  
25 includes within its amino acid sequence the amino acid sequence of a *piwi* family polypeptide corresponding to human tissues (referred to herein as HIWI).

It will also be understood that this invention is not limited to the particular nucleic acid and amino acid sequences of any of SEQ ID NOs:1-6. Recombinant vectors and isolated DNA segments may therefore variously  
30 include the *piwi* family polypeptide-encoding region itself, include coding regions bearing selected alterations or modifications in the basic coding region, or include encoded larger polypeptides which nevertheless include *piwi* family



polypeptide-encoding regions or may encode biologically functional equivalent proteins or peptides which have variant amino acid sequences.

In certain embodiments, the invention concerns isolated DNA segments and recombinant vectors which encode a protein or peptide that includes within  
5 its amino acid sequence an amino acid sequence essentially as set forth in any of SEQ ID NOs:2, 4 and 6. Naturally, where the DNA segment or vector encodes a full length *piwi* family gene product, the most preferred nucleic acid sequence is that which is essentially as set forth in any of SEQ ID NOs:1, 3 and 5 and which encode a protein that exhibits activity in the modulation of  
10 growth, proliferation and self-renewing division of stem cells (in for example germline stem cells), and proliferation of primordial germ cells as may be determined by, for example, immunofluorescence assays, as disclosed herein.

The term "a sequence essentially as set forth in any of SEQ ID NOs:2, 4 and 6" means that the sequence substantially corresponds to a portion an  
15 amino acid sequence of any of SEQ ID NOs:2, 4 and 6 and has relatively few amino acids which are not identical to, or a biologically functional equivalent of, the amino acids of an amino acid sequence of any of SEQ ID NOs:2, 4 and 6. The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences, which have  
20 between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids which are identical or functionally equivalent to the amino acids of any of SEQ ID NOs:2, 4 and 6, will be sequences which "a sequence essentially as set forth in any of SEQ ID NOs:2, 4 and 6".

25 In particular embodiments, the invention concerns gene therapy methods that use isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a protein that includes within its amino acid sequence an amino acid sequence of any of SEQ ID NOs:2, 4 and 6, any of SEQ ID NOs:2, 4 and 6 including sequences which are derived from  
30 mammalian tissue, among other tissue. In other particular embodiments, the invention concerns isolated DNA sequences and recombinant DNA vectors incorporating DNA sequences which encode a protein that includes within its

-20-

amino acid sequence the amino acid sequence of the *piwi* family protein from human tissue (HIWI).

5 In certain other embodiments, the invention concerns isolated DNA segments and recombinant vectors that include within their sequence a nucleic acid sequence essentially as set forth in any of SEQ ID NOs:1, 3 and 5. The term "a sequence essentially as set forth in any of SEQ ID NOs:1, 3 and 5" are used in the same sense as described above and means that the nucleic acid sequence substantially corresponds to a portion of any of SEQ ID NOs:1, 3 and 5, respectively, and has relatively few codons which are not identical, or  
10 functionally equivalent, to the codons of any of SEQ ID NOs:1, 3 and 5, respectively. Again, DNA segments which encode gene products exhibiting activity in the modulation of growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells or other biological activity of the *piwi* family gene product will be most preferred. The term "functionally  
15 equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also to refer to codons that encode biologically equivalent amino acids (see Table 1).

The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA  
20 sequences, such as promoters, enhancers, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of  
25 preparation and use in the intended recombinant DNA protocol. For example, nucleic acid fragments may be prepared which include a short stretch complementary to a nucleic acid sequence set for in any of SEQ ID NOs:1, 3 and 5 respectively, such as about 10 nucleotides, and which are up to 10,000 or 5,000 base pairs in length, with segments of 3,000 being preferred in certain  
30 cases. DNA segments with total lengths of about 1,000, 500, 200, 100 and about 50 base pairs in length are also contemplated to be useful.

5 The DNA segments of the present invention encompass biologically functional equivalent *piwi* family proteins and peptides. Such sequences may rise as a consequence of codon redundancy and functional equivalency which are known to occur naturally within nucleic acid sequences and the proteins thus encoded.

10 Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged, e.g. substitution of Ile for Leu at amino acid 13, at amino acid 106 and/or at amino acid 785 for PIWI in SEQ ID NOs:1-2; substitution of Ile for Leu at amino acid 90, at amino acid 383 and/or at amino acid 816 for MIWI in SEQ ID NOs:3-4; and substitution of Ile for Leu at amino acid 76, at amino acid 303 and/or at amino acid 735 for HIWI in SEQ ID NOs:5-6. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques, e.g., to introduce improvements to the antigenicity of the protein or to test *piwi* family mutants in order to examine activity in the modulation of growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells, or other activity at the molecular level.

20 If desired, one may also prepare fusion proteins and peptides, e.g., where the *piwi* family coding region is aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection purposes (e.g., proteins which may be purified by affinity chromatography and enzyme label coding regions, respectively).

25 Recombinant vectors form important further aspects of the present invention. Particularly useful vectors are contemplated to be those vectors in which the coding portion of the DNA segment is positioned under the control of a promoter. The promoter may be in the form of the promoter which is naturally associated with the *piwi* family gene, e.g., in mammalian tissues, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and/or PCR technology, in connection with the compositions disclosed herein.

30

In other embodiments, it is contemplated that certain advantages will be gained by positioning the coding DNA segment under the control of a recombinant, or heterologous, promoter. As used herein, a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a *piwi* family gene in its natural environment. Such promoters may include promoters isolated from bacterial, viral, eukaryotic, fish, avian or mammalian cells. Naturally, it will be important to employ a promoter that effectively directs the expression of the DNA segment in the cell type chosen for expression. The use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al., 1989, specifically incorporated herein by reference. The promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins or peptides. Appropriate promoter systems contemplated for use in high-level expression include, but are not limited to, the vaccinia virus promoter and the baculovirus promoter.

In an alternative embodiment, the present invention provides an expression vector comprising a polynucleotide that encodes a *piwi* family polypeptide having activity in the modulation of growth, proliferation and self-renewing division of stem cells (including germline and somatic stem cells), cell proliferation (including activity in embryonic development as described in Example 1), proliferation of primordial germ cells, or other biological activity in accordance with the present invention. Also preferably, an expression vector of the present invention comprises a polynucleotide that encodes human *piwi* family gene product (HIWI). More preferably, an expression vector of the present invention comprises a polynucleotide that encodes a polypeptide comprising an amino acid residue sequence of any of SEQ ID NOs:2, 4 and 6. More preferably, an expression vector of the present invention comprises a polynucleotide comprising the nucleotide base sequence of any of SEQ ID NOs:1, 3 and 5. Even more preferably, an expression vector of the invention comprises a polynucleotide operatively linked to an enhancer-promoter. More

-23-

preferably still, an expression vector of the invention comprises a polynucleotide operatively linked to a prokaryotic promoter. Alternatively, an expression vector of the present invention comprises a polynucleotide operatively linked to an enhancer-promoter that is a eukaryotic promoter, and  
5 the expression vector further comprises a polyadenylation signal that is positioned 3' of the carboxy-terminal amino acid and within a transcriptional unit of the encoded polypeptide.

In yet another embodiment, the present invention provides a recombinant host cell transfected with a polynucleotide that encodes a *piwi*  
10 family polypeptide having activity in the modulation of growth, proliferation and self-renewing division of stem cells (including germline and somatic stem cells), cell proliferation (including activity in embryonic development as described in Example 1), proliferation of primordial germ cells, or other biological activity in accordance with the present invention. SEQ ID NOs:3-6 set forth nucleotide  
15 and amino acid sequences from representative vertebrates, human and mouse. Also contemplated by the present invention are homologous or biologically equivalent polynucleotides and *piwi* family polypeptides found in other vertebrates. Preferably, a recombinant host cell of the present invention is transfected with the polynucleotide that encodes human *piwi* family  
20 polypeptide. More preferably, a recombinant host cell of the present invention is transfected with the polynucleotide sequence of SEQ ID NO:3 (*miwi*) or SEQ ID NO:5 (*hiwi*). Even more preferably, a host cell of the invention is a eukaryotic host cell. Still more preferably, a recombinant host cell of the present invention is a vertebrate cell. Preferably, a recombinant host cell of the  
25 invention is a mammalian, avian or fish cell.

In another aspect, a recombinant host cell of the present invention is a prokaryotic host cell. Preferably, a recombinant host cell of the invention is a bacterial cell, preferably a strain of *Escherichia coli*. More preferably, a recombinant host cell comprises a polynucleotide under the transcriptional  
30 control of regulatory signals functional in the recombinant host cell, wherein the regulatory signals appropriately control expression of the *piwi* family

-24-

polypeptide in a manner to enable all necessary transcriptional and post-transcriptional modification.

In yet another embodiment, the present invention contemplates a method of preparing a *piwi* family polypeptide comprising transfecting a cell with polynucleotide that encodes a *piwi* family polypeptide having activity in the modulation of growth, self-renewing division of stem cells (including germline and somatic stem cells), cell proliferation (including activity in embryonic development as described in the Examples), proliferation of primordial germ cells or other biological activity in accordance with the present invention, to produce a transformed host cell; and maintaining the transformed host cell under biological conditions sufficient for expression of the polypeptide. More preferably, the transformed host cell is a eukaryotic cell. More preferably still, the eukaryotic cell is a vertebrate cell. Alternatively, the host cell is a prokaryotic cell. More preferably, the prokaryotic cell is a bacterial cell of *Escherichia coli*. Even more preferably, a polynucleotide transfected into the transformed cell comprises the nucleotide base sequence of any of SEQ ID NOs:1, 3 and 5. SEQ ID NOs:3-6 set forth nucleotide and amino acid sequences for representative vertebrates, mouse and human. Also contemplated by the present invention are homologues or biologically equivalent *piwi* family polynucleotides and polypeptides found in other vertebrates, particularly warm blooded vertebrates.

As mentioned above, in connection with expression embodiments to prepare recombinant *piwi* family proteins and peptides, it is contemplated that longer DNA segments will most often be used, with DNA segments encoding the entire *piwi* family protein, functional domains or cleavage products thereof, being most preferred. However, it will be appreciated that the use of shorter DNA segments to direct the expression of *piwi* family peptides or epitopic core regions, such as may be used to generate anti-*piwi* family antibodies, also falls within the scope of the invention.

DNA segments which encode peptide antigens from about 15 to about 50 amino acids in length, or more preferably, from about 15 to about 30 amino acids in length are contemplated to be particularly useful. DNA segments

-25-

encoding peptides will generally have a minimum coding length in the order of about 45 to about 150, or to about 90 nucleotides. DNA segments encoding full length proteins may have a minimum coding length on the order of about 4,000 nucleotides for a protein in accordance with any of SEQ ID NOs: 2, 4 and 6.

Naturally, the present invention also encompasses DNA segments which are complementary, or essentially complementary, to the sequences set forth in any of SEQ ID NOs:1, 3 and 5. The terms "complementary" and "essentially complementary" are defined above. Excepting intronic or flanking regions, and allowing for the degeneracy of the genetic code, sequences which have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of nucleotides which are identical or functionally equivalent (i.e. encoding the same amino acid) of nucleotides of any of SEQ ID NOs:1, 3 and 5, will be sequences which are "a sequence essentially as set forth in any of SEQ ID NOs:1, 3 and 5". Sequences which are essentially the same as those set forth in any of SEQ ID NOs:1, 3 and 5 may also be functionally defined as sequences which are capable of hybridizing to a nucleic acid segment containing the complement of any of SEQ ID NOs:1, 3 and 5 under relatively stringent conditions. Suitable relatively stringent hybridization conditions are described herein and will be well known to those of skill in the art.

#### Biologically Functional Equivalents

As mentioned above, modification and changes may be made in the structure of the *piwi* family proteins and peptides described herein and still obtain a molecule having like or otherwise desirable characteristics. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive capacity with structures such as, for example, in the nucleus of a cell. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence (or, of course, its underlying DNA coding sequence) and

nevertheless obtain a protein with like or even countervailing properties (e.g., antagonistic v. agonistic). It is thus contemplated by the inventor that various changes may be made in the sequence of the *piwi* family proteins and peptides (or underlying DNA) without appreciable loss of their biological utility or activity.

5           It is also well understood by the skilled artisan that, inherent in the definition of a biologically functional equivalent protein or peptide, is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. Biologically functional  
10       equivalent peptides are thus defined herein as those peptides in which certain, not most or all, of the amino acids may be substituted. Of course, a plurality of distinct proteins/peptides with different substitutions may easily be made and used in accordance with the invention.

          It is also well understood that where certain residues are shown to be  
15       particularly important to the biological or structural properties of a protein or peptide, e.g., residues in active sites, such residues may not generally be exchanged. This is the case in the present invention, where if any changes, for example, in the PIWI box of *piwi* family polypeptides, could result in a loss of an aspect of the utility of the resulting peptide for the present invention.

20           Amino acid substitutions, such as those which might be employed in modifying the *piwi* family proteins and peptides described herein, are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid side-chain substituents  
25       reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as  
30       biologically functional equivalents.

          In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the



basis of their hydrophobicity and charge characteristics, these are: isoleucine (+ 4.5); valine (+ 4.2); leucine (+ 3.8); phenylalanine (+ 2.8); cysteine/cystine (+ 2.5); methionine (+ 1.9); alanine (+ 1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2);  
5 glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982, incorporated herein by reference). It is known that  
10 certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  of the original value is preferred, those which are within  $\pm 1$  of the original value are particularly preferred, and those  
15 within  $\pm 0.5$  of the original value are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent  
20 amino acids, correlates with its immunogenicity and antigenicity, i.e. with a biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein.

As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+ 3.0); lysine (+ 3.0); aspartate (+ 3.0 $\pm$ 1); glutamate (+ 3.0 $\pm$ 1); serine (+ 0.3); asparagine (+ 0.2); glutamine (+ 0.2); glycine (0); threonine (-0.4); proline (-0.5 $\pm$ 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).  
25

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  of the original value is preferred, those which are within  $\pm 1$  of the original value are  
30

-28-

particularly preferred, and those within  $\pm 0.5$  of the original value are even more particularly preferred.

While discussion has focused on functionally equivalent polypeptides arising from amino acid changes, it will be appreciated that these changes may be effected by alteration of the encoding DNA, taking into consideration also that the genetic code is degenerate and that two or more codons may code for the same amino acid.

### Sequence Modification Techniques

Modifications to the *piwi* family proteins and peptides described herein may be carried out using techniques such as site directed mutagenesis. Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 30 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art as exemplified by publications (e.g., Adelman et al., 1983). As will be appreciated, the technique typically employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing et al., 1981). These phage are readily commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are

-29-

also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart the two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes, for example, a human *piwi* family polypeptide (HIWI). An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example by the method of Crea et al. (1978). This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected gene using site-directed mutagenesis is provided as a means of producing potentially useful *piwi* family polypeptide or other species capable of modulating growth, proliferation and self-renewing division of stem cells, and proliferation of primordial germ cells and is not meant to be limiting as there are other ways in which sequence variants of these peptides may be obtained. For example, recombinant vectors encoding the desired genes may be treated with mutagenic agents to obtain sequence variants (see, e.g., a method described by Eichenlaub, 1979) for the mutagenesis of plasmid DNA using hydroxylamine.

#### Other Structural Equivalents

In addition to the *piwi* family peptidyl compounds described herein, the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure. Such compounds may be used in the same manner as the peptides of the invention and hence are also functional equivalents. The generation of a structural functional

-30-

equivalent may be achieved by the techniques of modeling and chemical design known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

#### Introduction of Gene Products

5           Where the gene itself is employed to introduce the gene products, a convenient method of introduction will be through the use of a recombinant vector which incorporates the desired gene, together with its associated control sequences. The preparation of recombinant vectors is well known to those of skill in the art and described in many references, such as, for example,  
10       Sambrook et al. (1989), specifically incorporated herein by reference.

          In vectors, it is understood that the DNA coding sequences to be expressed, in this case those encoding the *piwi* family gene products, are positioned adjacent to and under the control of a promoter. It is understood in the art that to bring a coding sequence under the control of such a promoter,  
15       one generally positions the 5' end of the transcription initiation site of the transcriptional reading frame of the gene product to be expressed between about 1 and about 50 nucleotides "downstream" of (i.e., 3' of) the chosen promoter. One may also desire to incorporate into the transcriptional unit of the vector an appropriate polyadenylation site (e.g., 5'-AATAAA-3'), if one was not  
20       contained within the original inserted DNA. Typically, these poly A addition sites are placed about 30 to 2000 nucleotides "downstream" of the coding sequence at a position prior to transcription termination.

          While use of the control sequences of the specific gene (i.e., a *piwi* family promoter for a *piwi* family gene) will be preferred, there is no reason why  
25       other control sequences could not be employed, so long as they are compatible with the genotype of the cell being treated. Thus, one may mention other useful promoters by way of example, including, e.g., an SV40 early promoter, a long terminal repeat promoter from retrovirus, an actin promoter, a heat shock promoter, a metallothionein promoter, and the like.

30       As is known in the art, a promoter is a region of a DNA molecule typically within about 100 nucleotide pairs in front of (upstream of) the point at

-31-

which transcription begins (i.e., a transcription start site). That region typically contains several types of DNA sequence elements that are located in similar relative positions in different genes. As used herein, the term "promoter" includes what is referred to in the art as an upstream promoter region, a promoter region or a promoter of a generalized eukaryotic RNA Polymerase II transcription unit.

Another type of discrete transcription regulatory sequence element is an enhancer. An enhancer provides specificity of time, location and expression level for a particular encoding region (e.g., gene). A major function of an enhancer is to increase the level of transcription of a coding sequence in a cell that contains one or more transcription factors that bind to that enhancer. Unlike a promoter, an enhancer can function when located at variable distances from transcription start sites so long as a promoter is present.

As used herein, the phrase "enhancer-promoter" means a composite unit that contains both enhancer and promoter elements. An enhancer-promoter is operatively linked to a coding sequence that encodes at least one gene product. As used herein, the phrase "operatively linked" means that an enhancer-promoter is connected to a coding sequence in such a way that the transcription of that coding sequence is controlled and regulated by that enhancer-promoter. Means for operatively linking an enhancer-promoter to a coding sequence are well known in the art. As is also well known in the art, the precise orientation and location relative to a coding sequence whose transcription is controlled, is dependent *inter alia* upon the specific nature of the enhancer-promoter. Thus, a TATA box minimal promoter is typically located from about 25 to about 30 base pairs upstream of a transcription initiation site and an upstream promoter element is typically located from about 100 to about 200 base pairs upstream of a transcription initiation site. In contrast, an enhancer can be located downstream from the initiation site and can be at a considerable distance from that site.

An enhancer-promoter used in a vector construct of the present invention can be any enhancer-promoter that drives expression in a cell to be

-32-

transfected. By employing an enhancer-promoter with well-known properties, the level and pattern of gene product expression can be optimized.

For introduction of, for example, the human *piwi* family gene (*hiwi*), it is proposed that one will desire to preferably employ a vector construct that will deliver the desired gene to the affected cells. This will, of course, generally require that the construct be delivered to the targeted cells, for example, mammalian, avian or fish germline stem cells. It is proposed that this may be achieved most preferably by introduction of the desired gene through the use of a viral vector to carry the *piwi* family sequence to efficiently infect the cells. These vectors will preferably be an adenoviral, a retroviral, a vaccinia viral vector or adeno-associated virus. These vectors are preferred because they have been successfully used to deliver desired sequences to cells and tend to have a high infection efficiency. Suitable vector-*piwi* family gene constructs are adapted for administration as pharmaceutical compositions, as described herein below.

Commonly used viral promoters for expression vectors are derived from polyoma, cytomegalovirus, Adenovirus 2, and Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

Where a *piwi* family gene itself is employed it will be most convenient to simply use a wild type *piwi* family gene directly. However, it is contemplated

-33-

that certain regions of a *piwi* family gene may be employed exclusively without employing an entire wild type *piwi* family gene. It is proposed that it will ultimately be preferable to employ the smallest region needed to modulate stem cell growth, proliferation and self-renewing division, and/or primordial germ cell proliferation, so that one is not introducing unnecessary DNA into cells which receive a *piwi* family gene construct. Techniques well known to those of skill in the art, such as the use of restriction enzymes, will allow for the generation of small regions of an exemplary *piwi* family gene. The ability of these regions to modulate cell signaling can easily be determined by the assays reported in the Examples. In general, techniques for assessing the modulation of stem cell growth, proliferation and self-renewing division, along with primordial germ cell proliferation are known in the art.

#### Cell Culture Techniques

As disclosed herein, PIWI functions both as a cytoplasmic protein (during embryonic germline development) and as nuclear protein during stem cell division. PIWI has a cell-autonomous function to promote stem cell division in addition to its signaling function in maintaining stem cells. The dose of PIWI gene determines the number of germline stem cells formed in the embryo.

In accordance with the present invention, *piwi* family genes and gene products can thus be used to expand a primitive cell population *in vitro*. The term "primitive cell" is adopted herein for convenience to collectively refer to stem cells, primordial germ cells and to other primitive cells having totipotent or pluripotent characteristics, or other characteristics of stem cells and primordial germ cells. The term "stem cell" is meant to have its art-recognized meaning, and to include, but not be limited to, the following examples of stem cells: hematopoietic stem cells, neural stem cells, and germline stem cells. The term "primordial germ cell" is also meant to have its art-recognized meaning. Such expanded primitive cell populations are utilized for therapeutic or genetic engineering purposes in human and mammalian, avian, and fish systems.

The term "sustained" as used herein with respect to primitive cells, and cultures of the same, refers to a cell or cell culture capable of undergoing further cell division, even if the cells are eventually subject to senescence.

5 A method of culturing primitive cells is thus envisioned in accordance with the present invention. The method comprises providing a culture comprising a primitive cell, and delivering to the provided cell a *piwi* family gene product, whereby growth of the cell in the culture is accomplished. Preferably, the primitive cell is maintained in culture for a time sufficient to produce a sustained cell culture.

10 Optionally, the *piwi* family gene product is delivered to the primitive cell by delivering to the primitive cell an effective amount of a DNA molecule comprising a polynucleotide that encodes a biologically active *piwi* family polypeptide; and maintaining the primitive cell under conditions sufficient for expression of the polypeptide. Alternatively, the *piwi* family gene product is  
15 delivered to the cell by administration of a biologically active *piwi* family polypeptide to the culture via the culture media or via a feeder matrix included in the culture.

A preferred embodiment of the method comprises: (a) collecting primitive cells; (b) depositing the primitive cells in contact with a feeder matrix,  
20 the feeder matrix comprising a *piwi* family gene product; and (c) growing the primitive cells on the feeder matrix in the presence of media for a time sufficient to produce a sustained primitive cell culture.

Thus, typically, the cultures of the present invention include a feeder matrix as defined herein. A feeder matrix can either be cells or cell lines  
25 cultured for the purpose of obtaining a sustained primitive cell culture. In this case the cell line can be transformed with a *piwi* family gene product in accordance with techniques disclosed herein so as to produce the *piwi* family gene product. Alternatively, a feeder matrix can be derived from or provided by the organ or tissue in which the primitive cells are located, e.g., the gonad.  
30 Alternatively, the feeder cells comprising the feeder matrix could be substituted with extracellular matrix plus bound growth factors, and particularly including a *piwi* family gene product.



A feeder matrix as used herein is constructed in accordance with procedures known in the art. As noted above, it is preferred that the feeder matrix be preconditioned. By the term "preconditioned" it is meant that the feeder matrix is cultured in the presence of media for a period of time prior to the depositing of primitive cells in contact with the feeder matrix, e.g. a time sufficient to initiate and establish production of, for example, growth factors or other factors by the feeder matrix, and particularly including a *piwi* family gene product. Thus, a feeder matrix can be preconditioned by culturing the feeder matrix by itself for one to two days prior to the depositing of primitive cells in contact with the feeder matrix.

Candidate cells for use in the feeder matrix are disclosed in the Examples. Additionally, the feeder matrix can comprise Sertoli cells or fibroblast cells, including mouse fibroblast cells. STO fibroblasts and primary fibroblasts are suitable examples. Also, it is contemplated that feeder matrices comprising cells from other murine species (e.g., rat); other mammalian species (e.g., ungulate, bovine, and porcine species); or avian species (e.g. *Gallinacea*, chicken, turkey, duck, goose, quail and pheasant) may also be used.

The culturing method of the present invention can optionally comprise establishing a monolayer of feeder cells. Feeder cells may mitotically inactivated using standard techniques. For example, the feeder cells may be exposed to gamma radiation (e.g. 4000 Rads of gamma radiation) or may be treated with Mitomycin C (e.g. 10  $\mu$ g/ml for 2-3 hours). Procedures for mitotically inactivating cells are also detailed in the information typically sent with cells from the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209 (e.g. STO feeder cells are available under ATCC accession number 1503). Monolayers may optionally be cultured to about 80% confluency, preferably to about 90% confluency, and more preferably about 100% confluency. While configuration of the feeder cells as a monolayer is the preferred configuration for the culture, any suitable configuration is contemplated to be within the scope of the present invention. Thus, for example, layers, monolayers, clusters, aggregates or other

-36-

associations or groupings of feeder cells are contemplated to fall within the scope of the present invention and are particularly contemplated to fall with the meaning of the term "matrix".

5 Thus, the primitive cells can extend non-uniformly through the feeder cells vertically, horizontally, diagonally, or in any combination thereof, such that cell aggregates are formed. In accordance with the present invention, it is thus contemplated that the cultures can be formed by mixing primitive cells with appropriate feeder cells and inserting the mixture into a suitable culture container, such as a multi-well plate.

10 The media used in carrying out the present invention may be any suitable media. The media may be a conditioned media or a synthetic media, both of which are known in the art. Conditioned media, and particularly BRL conditioned media, is currently preferred. By way of example, BRL conditioned media is prepared according to art-recognized techniques, such as described  
15 by Smith, A. G. and Hooper, M. L., *Dev. Biol.* 1987 May; 121(1): 1-9. BRL cells are available from ATCC under accession number CRL-1442. The media can be supplemented with a *piwi* family gene product. The media can also be supplemented with growth factors, including but not limited to leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), basic fibroblast growth factor (bFGF), stem cell factor (SCF - also called  
20 steel factor or SF), transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) and anti-retinoic acid.

Cell cultures of the present invention may be formulated for administration to animals by dissociating the cells (e.g., by mechanical  
25 dissociation) and intimately admixing the cells with a pharmaceutically acceptable carrier (e.g., phosphate-buffered saline (PBS) solution). Primitive cells in such formulations may be prepared to carry a heterologous DNA sequence into a subject, preferably a vertebrate subject and more preferably a warm-blooded vertebrate subject, in the manner described in greater detail  
30 below.

The primitive cells cultured in accordance with the present invention are useful, among other things, as a tool for the study of embryological

-37-

development (i.e., by labeling the cells with a marker gene and observing their distribution after injection *in vivo*) and the production of transgenic animals. They are useful in allowing the application of homologous recombination to the production of transgenic animals.

5           The primitive cells should also be useful for the production of chimeric animals, including transgenic chimeric animals. It is contemplated that chimeric or transgenic chimeric non-human animals, including particularly chimeric or transgenic chimeric avians (i.e. birds), will be useful for the recovery of heterologous proteins from the animals. In the case of an avian, the protein  
10       can be recovered directly from the eggs of such chimeric or transgenic chimeric avians. Such avians can be thus be used for the production and recovery of therapeutic proteins and other polypeptides, including *piwi* family polypeptides themselves.

          The following U.S. Patents pertain to the culturing of stem cells an are  
15       used herein to illuminate the background of the invention, and in particular cases, to provide additional details respecting the practice. Each of the following U.S. Patent is incorporated herein by reference in its entirety: U.S. Patent No. 5,690,926 issued November 25, 1997 to Hogan; U.S. Patent No. 5,670,372 issued September 23, 1997 to Hogan; U.S. Patent No. 5,537,357  
20       issued September 26, 1995 to Hogan; U.S. Patent No. 5,340,740 issued August 23, 1994 to Petitte et al.; U.S. Patent No. 5,656,479 issued August 12, 1997 to Petitte et al.; and U.S. Patent No. 5,830,510 issued November 3, 1998 to Petitte et al.

#### Transgenic Animals

25           It is also contemplated to be within the scope of the present invention to prepare a transgenic non-human animal which expresses a *piwi* family gene of the present invention. A preferred transgenic animal is a mouse.

          The term "transgene" refers to exogenous genetic material which does not naturally form part of the genetic material of an animal to be genetically  
30       altered but can be incorporated into the germ and/or somatic cells of that animal by standard transgenic techniques. The term "heterologous DNA"

-38-

refers to DNA which has been transferred from one individual animal, species or breed to a different individual animal, species or breed. The term "transgenic" refers to cells, tissues, embryos, fetuses or animals which carry one or more transgenes. The term "chimeric" refers to an embryo, fetus or animal which consists of two or more tissues of different genetic composition.

Techniques for the preparation of transgenic animals are known in the art. Exemplary techniques are described in U.S. Patent No. 5,489,742 (transgenic rats); U.S. Patent Nos. 4,736,866, 5,550,316, 5,614,396, 5,625,125 and 5,648,061 (transgenic mice); U.S. Patent No. 5,573,933 (transgenic pigs); 5,162,215 (transgenic avian species) and U.S. Patent No. 5,741,957 (transgenic bovine species), the entire contents of each of which are herein incorporated by reference.

With respect to a representative method for the preparation of a transgenic mouse, cloned recombinant or synthetic DNA sequences or DNA segments encoding a *piwi* family gene product are injected into fertilized mouse eggs (e.g. an embryo). The injected eggs are implanted in pseudo pregnant females and are grown to term to provide transgenic mice whose cells express a *piwi* family gene product. Preferably, the injected sequences are constructed having promoter sequences connected so as to express the desired protein in germline stem cells or other primitive cells of the transgenic mouse.

Fish represent a category of animals of interest for agricultural and ecological reasons. Representative fish species include, but are not limited to, trout, salmon, carp, shark, ray, flounder, sole, tilapia, medaka, goldfish, guppy, molly, platyfish, swordtail, zebrafish, loach, catfish, and the like. Representative methods for the preparation of a transgenic fish have been described by Ozato et al, *Cell Differ.*, 19:237-244 (1986), Inoue et al, *Cell Differ. Dev.*, 29:123-128 (1990), Rokkones et al, *J. Comp. Physiol. B*, 158:751-758 (1989), and Guyomard et al, *Biochimie*, 71:857-863 (1989), describing preparation of transgenic medaka, medaka, salmon and trout, respectively.

The term "avian" as used herein refers to any avian species, including but not limited to *Gallinacea sp.*, chicken, turkey, duck, goose, quail and pheasant. Chicken is currently preferred.

5 With respect to an exemplary method for the preparation of a transgenic avian species, certain donor cell types have been isolated that retain viability when injected into recipient embryos. See Etches et al., *Poultry Science* 72:882-887 (1993); Etches et al., in *Avian Incubation*, Chapter 22, Butterworth Publishers (1990); Verrinder Gibbins et al., *Fourth World Congress on Genetics Applied to Livestock Production*, Edinburgh, (1990); Petite et al., *Development* 108, 185-189 (1990)). These studies showed that blastodermal cells derived from Stage X embryos (embryo at oviposition) remained viable when transferred to comparable recipient Stage X embryos.

15 Thus, the present invention provides a new method of altering the phenotype of an animal, such as a bird, and the animals so produced with the primitive cells cultured in accordance with techniques disclosed herein. The method comprises transfecting primitive cells cultured in accordance with the methods disclosed herein with the DNA sequence *in vitro* (e.g., by electroporation or transformation with a retroviral vector), and then injecting the transfected primitive cells into an embryo, (e.g. an egg containing an embryonic 20 bird via the yolk sac or onto the chorioallantoic membrane), with the DNA sequence being effective to cause a change in phenotype in the embryonic animal (e.g., a change in protein expression, a change in growth rate, feed efficiency, disease resistance, or a combination of all of these factors). Preferably, the primitive cells are also transfected with a *piwi* family gene to 25 facilitate production of germ cells in the transgenic or chimeric bird and thereby also facilitate germline transmission of the DNA sequence of interest.

30 Preferably, in the case of a bird, the egg into which the DNA is introduced is incubated to hatch, and the bird so produced is raised to at least an age at which the change in phenotype is expressed. It is of no deleterious consequence if the transformed embryo and bird is chimeric, so long as a physiological response is achieved in the animal after hatch sufficient to evoke a measurable phenotypic change measured in any suitable way. By way of

-40-

additional example, protein expression in the chimera, or transgenic offspring thereof produced by germ line transmission of the DNA sequence, may be established through incorporation of an inducible promoter into the introduced DNA sequence coupled with treatment of the chimera, or transgenic offspring thereof, with an agent which induces the promoter.

The mechanism of *in ovo* injection is not critical, but it is preferred that the method not unduly damage the tissues and organs of the embryo or the extraembryonic membranes surrounding it so that the treatment will not decrease hatch rate. For example, *in ovo* injections can be carried out by forming a window in a bird egg and then using a micro-pipette or needle for the injection, such a 50  $\mu$ m-diameter micro-pipette or a 50  $\mu$ m-diameter needle. If desired, the bird egg can be sealed with a substantially bacteria-impermeable sealing material such as wax or the like to prevent subsequent entry of undesirable bacteria. Suitable sealing material may optionally comprise biologically acceptable antimicrobial compositions.

The DNA sequence introduced with the primitive cells in accordance with the present invention is, in general, a construct comprised of a promoter functional in the cells of the candidate animal and a gene encoding a peptide or protein operably linked to the promoter. Preferably, the protein or peptide is physiologically active and capable of producing a phenotypic change in the animal. In general, the DNA construct may be a linear DNA sequence (introduced into the primitive cells of the invention by electroporation) or a sequence carried by a vector or other suitable carrier for transforming the primitive cells of the invention using various techniques known in the art, such as liposomes, calcium phosphate, electroporation, or DMSO. Vectors, as discussed herein, may be plasmids, viruses (including retroviruses), and phage, whether in native form or derivatives thereof.

The production of cloned genes, recombinant DNA, vectors, transformed host cells, proteins and protein fragments by genetic engineering is well known. See e.g., U.S. Pat. No. 4,761,371 to Bell et al. at Col. 6 line 3 to Col. 9 line 65; U.S. Pat. No. 4,877,729 to Clark et al. at Col. 4 line 38 to Col. 7 line 6; U.S. Pat. No. 4,912,038 to Schilling at Col. 3 line 26 to Col. 14 line 12. Protocols for

restriction endonuclease digestion, preparation of vectors, DNA purification and other such procedures are essentially as described in standard cloning manuals. See Sambrook et al., *Molecular Cloning, a Laboratory Manual*, (2d Ed., Cold Spring Harbor Press, N.Y. (1989)).

5           As disclosed herein, a vector is a replicable DNA construct used herein to either amplify and/or express DNA encoding the gene of interest. A suitable expression vector will have controlling elements capable of expressing the cloned cDNA or genomic DNA placed in the correct orientation when the vector is introduced into the correct host. Such elements typically include but are not  
10       limited to a promoter region which interacts specifically with cellular proteins involved in transcription or which may be inducible by administration of an inducing agent, enhancer elements which can stimulate transcription many-fold from linked heterologous promoters, a splice acceptor and/or donor sequence, and termination and polyadenylation signals. Also required is the sequence for  
15       a ribosome binding site capable of permitting translation and which is operably linked to the gene to be expressed. Recently, a muscle-specific promoter has been isolated which is positioned upstream of both the skeletal muscle structural gene and the essential proximal promoter element and is operably associated with each. (Mar and Ordahl, *Proc. Natl. Acad. Sci. USA* 85, 6404-6408 (1988)). Vectors comprise plasmids, viruses (e.g. adenovirus, cytomegalovirus), phage, and DNA fragments integratable into the host  
20       genome by recombination. The vector may optionally replicate and function independently of the host genome, or may in some instances integrate into the genome itself.

25           The *piwi* family genes of the present invention can thus be used to create transgenic animals with increased number of primordial germ cells. Such animals in mammalian, avian, and fish systems should provide an improved platform for germline-mediated gene transfer to create transgenic stocks.

30           The genetically modified animals could express transgenes of commercial interest, including those having therapeutic or prophylactic value to the animal itself or to its offspring. For example, the transgene of interest

-42-

can encode a protein or peptide including, but not limited to, growth hormone, thyroid releasing hormone (TRH), Marek's MDX, and immunogenic recombinant antigens such as that for coccidiosis.

5 Alternatively, the genetically modified animals can be employed in the production of therapeutic agents. For example, genetically modified avian species that can lay eggs containing drugs, proteins and antibodies to ward off illness that have been produced via the insertion the genes that make the proteins into viral and other vectors to get them into the birds. *piwi* family gene products can also be produced and isolated in this manner.

10 In accordance with the present invention, *piwi* family genes can also be inserted into such genetically modified animals to create animals with increased number of primordial germ cells, thereby enhancing the likelihood of germline transmission of the transgene encoding the therapeutic agent due to the increased number of primordial germ cells.

#### 15 Pharmaceutical Compositions

In a preferred embodiment, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide of the present invention and a physiologically acceptable carrier. More preferably, a pharmaceutical composition comprises a *piwi* family polypeptide or a  
20 polynucleotide that encodes those polypeptides.

A composition of the present invention is typically administered parenterally in dosage unit formulations containing standard, well-known nontoxic physiologically acceptable carriers, adjuvants, and vehicles as desired. The term "parenteral" as used herein includes intravenous,  
25 intra-muscular, intra-arterial injection, or infusion techniques.

Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, are formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in  
30 a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.



-43-

Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including  
5 synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Preferred carriers include neutral saline solutions buffered with phosphate, lactate, Tris, and the like. Of course, one purifies the vector sufficiently to render it essentially free of undesirable contaminants, such as  
10 defective interfering adenovirus particles or endotoxins and other pyrogens such that it does not cause any untoward reactions in the individual receiving the vector construct. A preferred means of purifying the vector involves the use of buoyant density gradients, such as cesium chloride gradient centrifugation.

A transfected cell can also serve as a carrier. By way of example, a liver  
15 cell can be removed from an organism, transfected with a polynucleotide of the present invention using methods set forth above and then the transfected cell returned to the organism (e.g. injected intra-vascularly).

#### Generation of Antibodies

In still another embodiment, the present invention provides an antibody  
20 immunoreactive with a polypeptide of the present invention. Preferably, an antibody of the invention is a monoclonal antibody. Means for preparing and characterizing antibodies are well known in the art (See, e.g., *Antibodies A Laboratory Manual*, E. Howell and D. Lane, Cold Spring Harbor Laboratory, 1988).

25 Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogen comprising a polypeptide or polynucleotide of the present invention, and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera. Typically an animal used for production of anti-antisera is a rabbit, a mouse, a rat, a  
30 hamster or a guinea pig. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

-44-

As is well known in the art, a given polypeptide or polynucleotide may vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a polypeptide or polynucleotide) of the present invention) with a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers.

Means for conjugating a polypeptide or a polynucleotide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.

As is also well known in the art, immunogenicity to a particular immunogen can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant, incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

The amount of immunogen used of the production of polyclonal antibodies varies, *inter alia*, upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen, e.g. subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal. The production of polyclonal antibodies is monitored by sampling blood of the immunized animal at various points following immunization. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored.

In another aspect, the present invention contemplates a method of producing an antibody immunoreactive with a *piwi* family polypeptide, the method comprising the steps of (a) transfecting recombinant host cells with a polynucleotide that encodes that polypeptide; (b) culturing the host cells under conditions sufficient for expression of the polypeptide; (c) recovering the polypeptide; and (d) preparing antibodies to the polypeptide. Preferably, the *piwi* family polypeptide possess a biological activity in accordance with the

present invention. Even more preferably, the present invention provides antibodies prepared according to the method described above.

A monoclonal antibody of the present invention can be readily prepared through use of well-known techniques such as those exemplified in U.S. Pat. No 4,196,265, herein incorporated by reference. Typically, a technique involves first immunizing a suitable animal with a selected antigen (e.g., a polypeptide or polynucleotide of the present invention) in a manner sufficient to provide an immune response. Rodents such as mice and rats are preferred animals. Spleen cells from the immunized animal are then fused with cells of an immortal myeloma cell. Where the immunized animal is a mouse, a preferred myeloma cell is a murine NS-1 myeloma cell.

The fused spleen/myeloma cells are cultured in a selective medium to select fused spleen/myeloma cells from the parental cells. Fused cells are separated from the mixture of non-fused parental cells, for example, by the addition of agents that block the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides. Where azaserine is used, the media is supplemented with hypoxanthine.

This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants for reactivity with an antigen-polypeptides. The selected clones can then be propagated indefinitely to provide the monoclonal antibody.

By way of specific example, to produce an antibody of the present invention, mice are injected intraperitoneally with between about 1-200  $\mu$ g of an antigen comprising a polypeptide of the present invention. B lymphocyte cells are stimulated to grow by injecting the antigen in association with an adjuvant such as complete Freund's adjuvant (a non-specific stimulator of the

-46-

immune response containing killed *Mycobacterium tuberculosis*). At some time (e.g., at least two weeks) after the first injection, mice are boosted by injection with a second dose of the antigen mixed with incomplete Freund's adjuvant.

5 A few weeks after the second injection, mice are tail bled and the sera titered by immunoprecipitation against radiolabeled antigen. Preferably, the method of boosting and titering is repeated until a suitable titer is achieved. The spleen of the mouse with the highest titer is removed and the spleen lymphocytes are obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately  $5 \times 10^7$  to  
10  $2 \times 10^8$  lymphocytes.

Mutant lymphocyte cells known as myeloma cells are obtained from laboratory animals in which such cells have been induced to grow by a variety of well-known methods. Myeloma cells lack the salvage pathway of nucleotide biosynthesis. Because myeloma cells are tumor cells, they can be propagated  
15 indefinitely in tissue culture, and are thus denominated immortal. Numerous cultured cell lines of myeloma cells from mice and rats, such as murine NS-1 myeloma cells, have been established.

Myeloma cells are combined under conditions appropriate to foster fusion with the normal antibody-producing cells from the spleen of the mouse  
20 or rat injected with the antigen/polypeptide of the present invention. Fusion conditions include, for example, the presence of polyethylene glycol. The resulting fused cells are hybridoma cells. Like myeloma cells, hybridoma cells grow indefinitely in culture.

Hybridoma cells are separated from unfused myeloma cells by culturing  
25 in a selection medium such as HAT media (hypoxanthine, aminopterin, thymidine). Unfused myeloma cells lack the enzymes necessary to synthesize nucleotides from the salvage pathway because they are killed in the presence of aminopterin, methotrexate, or azaserine. Unfused lymphocytes also do not continue to grow in tissue culture. Thus, only cells that have successfully fused  
30 (hybridoma cells) can grow in the selection media.

Each of the surviving hybridoma cells produces a single antibody. These cells are then screened for the production of the specific antibody

-47-

immunoreactive with an antigen/polypeptide of the present invention. Single cell hybridomas are isolated by limiting dilutions of the hybridomas. The hybridomas are serially diluted many times and, after the dilutions are allowed to grow, the supernatant is tested for the presence of the monoclonal antibody.

5 The clones producing that antibody are then cultured in large amounts to produce an antibody of the present invention in convenient quantity.

By use of a monoclonal antibody of the present invention, specific polypeptides and polynucleotide of the invention can be recognized as antigens, and thus identified. Once identified, those polypeptides and  
10 polynucleotide can be isolated and purified by techniques such as antibody-affinity chromatography. In antibody-affinity chromatography, a monoclonal antibody is bound to a solid substrate and exposed to a solution containing the desired antigen. The antigen is removed from the solution through an immunospecific reaction with the bound antibody. The polypeptide  
15 or polynucleotide is then easily removed from the substrate and purified.

#### Screening Assays

In yet another aspect, the present invention contemplates a method of screening substances for their ability to affect or modulate the biological activity of *piwi* family gene products. The present invention also contemplates a  
20 method of screening substances for their ability to affect or modulate the biological activity of *piwi* family gene products to thereby affect or modulate the growth, proliferation and self-renewing division of stem cells, particularly germline stem cells, and proliferation of primordial germ cells. Utilizing the methods and compositions of the present invention, screening assays for the  
25 testing of candidate substances can be derived. A candidate substance is a substance which potentially can promote or inhibit the biological activity of a *piwi* family gene product by binding, or other intermolecular interaction, with the *piwi* family gene product.

An exemplary method of screening candidate substances for their ability  
30 to modulate *piwi* family biological activity comprises the steps of: (a) establishing replicate test and control samples that comprise a biologically

active *piwi* family polypeptide; (b) administering a candidate substance to test sample but not the control sample; (c) measuring the biological activity of the *piwi* family polypeptide in the test and the control samples; and (d) determining that the candidate substance modulates *piwi* family biological activity if the biological activity of the *piwi* family polypeptide measured for the test sample is greater or less than the biological activity of the *piwi* family polypeptide measured for the control sample. The biological activities of *piwi* family that may optionally be examined in connection with a screening assay of the present invention comprise modulating the growth, proliferation and self-renewing division of stem cells, particularly germline stem cells, proliferation of primordial germ cells or other biological activity in accordance with the present invention.

The replicate test and control samples can further comprise a cell that expresses a biologically active *piwi* family polypeptide. The present invention also contemplates a recombinant cell line suitable for use in the exemplary method. A candidate substance identified according to the screening assay described herein is contemplated to have the ability to modulate *piwi* family biological activity. Such as candidate compound has utility in the treatment of disorders and conditions associated with the biological activity of *piwi* family.

In a cell-free system, the method comprises the steps of establishing a control system comprising a *piwi* family polypeptide and a ligand wherein the *piwi* family polypeptide is capable of binding to the ligand; establishing a test system comprising the *piwi* family polypeptide, the ligand, and a candidate compound; measuring the binding affinity of the *piwi* family polypeptide and the ligand in the control and the test systems; and determining that the candidate compound modulates *piwi* family activity in a cell-free system if the binding affinity measured for the test system is less than or greater than the binding affinity measured for the control system. An exemplary ligand comprises a monoclonal antibody.

A screening assay of the present invention may also involve determining the ability of a candidate substance to modulate, i.e. inhibit or promote *piwi* family biological activity and preferably, to thereby modulate the growth,

proliferation and self-renewing division of stem cells, particularly germline stem cells, proliferation of primordial germ cells or division of other target cells. Target cells can be either naturally occurring cells known to contain a polypeptide of the present invention or transformed cell produced in accordance with a method of transformation set forth hereinbefore.

As is well known in the art, a screening assay provides a cell under conditions suitable for testing the modulation of *piwi* family biological activity or of growth, proliferation and self-renewing division of stem cells, particularly germline stem cells, or of proliferation of primordial germ cells. These conditions include but are not limited to pH, temperature, tonicity, the presence of relevant metabolic factors (e.g., metal ions such as for example  $\text{Ca}^{++}$ , growth factor, interleukins, or colony stimulating factors), and relevant modifications to the polypeptide such as glycosylation or prenylation. It is contemplated that a polypeptide of the present invention can be expressed and utilized in a prokaryotic or eukaryotic cell. The host cell can also be fractionated into sub-cellular fractions where the receptor can be found. For example, cells expressing the polypeptide can be fractionated into the nuclei, the endoplasmic reticulum, vesicles, or the membrane surfaces of the cell.

In a preferred embodiment, temperature is from about 20°C. to about 50°C., more preferably from about 30°C. to about 40°C. and, even more preferably about 37°C. Osmolality is preferably from about 5 milliosmols per liter (mosm/L) to about 400 mosm/l and, more preferably from about 200 milliosmols per liter to about 400 mosm/l and, even more preferably from about 290 mosm/L to about 310 mosm/L. The presence of factors can be required for the proper testing of *piwi* family biological activity modulation in specific cells. Such factors include, for example, the presence and absence (withdrawal) of growth factor, interleukins, or colony stimulating factors. U.S. Patent Nos. 5,837,479; 5,645,999; 5,786,152; 5,739,278; and 5,352,660 also describe exemplary screening assays, and the entire contents of each are herein incorporated by reference.

In one embodiment, a screening assay is designed to be capable of discriminating candidate substances having selective ability to interact with one

or more of the polypeptides of the present invention but which polypeptides are without a substantially overlapping activity with another of those polypeptides identified herein. Exemplary assays including genetic screening assays and molecular biology screens such as a yeast two-hybrid screen which will effectively identify *piwi*-interacting genes important for *piwi*-mediated cell growth, proliferation and self-renewing division processes. One version of the yeast two-hybrid system has been described (Chien et al., 1991, *Proc. Natl. Acad. Sci. USA*, 88:9578-9582) and is commercially available from Clontech, Palo Alto, California.

## 10 Therapeutic Methods

As used herein, the terms “*piwi* family activity” and “*piwi* family biological activity” are meant to be synonymous and are meant to refer to any biological activity of a *piwi* family polypeptide. Exemplary biological activities of *piwi* family comprise activity in the modulation of growth, proliferation and self-renewing division of stem cells (including germline and somatic stem cells), cell proliferation (including activity in embryonic development as described in the Examples), proliferation of primordial germ cells or other biological activity in accordance with the present invention. The biological activity can be accomplished by endogenous *piwi* family polypeptides or by *piwi* family polypeptide administered to a subject. Indeed, an isolated and purified *piwi* family polypeptide, recombinant *piwi* family polypeptide, and/or *piwi* family analog or peptidomimetic, each prepared as described herein, can administered to a subject to impart *piwi* family biological activity in the subject and to treat a disorder associated with *piwi* family biological activity in the subject. In such case the imparted *piwi* family biological activity comprises a *piwi* family biological activity in accordance with the therapeutic methods of the present invention.

With respect to the therapeutic methods of the present invention, any subject can be treated, including animal and plant subjects. A preferred subject is a vertebrate subject. Preferred examples of vertebrates include fish and warm-blooded vertebrates. A preferred example of a warm-blooded vertebrate is a mammal. A preferred example of a mammal is a human.



-51-

Additionally, as used herein and in the claims, the term "patient" is contemplated to include both human and animal patients, and thus, veterinary therapeutic uses are contemplated in accordance with the present invention.

Accordingly, the methods of the present invention are particularly  
5 contemplated to be useful in the treatment of warm-blooded vertebrates. Therefore, the invention concerns mammals and birds.

Contemplated is the treatment of mammals such as humans, as well as those mammals of importance due to being endangered (such as Siberian tigers), of economical importance (animals raised on farms for consumption by  
10 humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also contemplated is the treatment of birds, including the treatment of those kinds of birds that are  
15 endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, contemplated is the treatment of livestock, including, but not limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.

20 Modulation of *piwi* family biological activity

In one embodiment, a therapeutic method according to the present invention comprises administering to a subject a substance that inhibits or promotes *piwi* family biological activity. Such a substance may be identified according to the screening assay set forth above. The method comprises  
25 treating a subject suffering from a disorder associated with or mediated by *piwi* family biological activity by administering to the subject an effective *piwi* family biological activity-modulating amount of a substance identified according to a screening assay described above. By the term "modulating", it is contemplated that the substance can either promote or inhibit the biological activity of *piwi*  
30 family polypeptides, depending on the disorder to be treated. For example, the administering of antibodies against a chosen PIWI family protein (e.g. HIWI,

MIWI, etc.) provides treatment of germline tumor or other developmental or tissue defects caused by *piwi* family-mediated mechanisms.

Insofar as a *piwi* family biological activity modulator can take the form of a polypeptide or of an anti-*piwi* family monoclonal antibody, or fragment thereof, it is to be appreciated that the potency, and therefore an expression of a "therapeutically effective" amount can vary. However, as shown by the present assay methods, one skilled in the art can readily assess the potency of a candidate *piwi* family biological activity modulator of this invention. A *piwi* family biological activity modulator can be measured by a variety of means including through the use of a responsive reporter, which drives expression of a reporter gene; interaction of *piwi* family polypeptides with a monoclonal antibody as described herein; and the like assays.

A preferred *piwi* family biological activity modulator has the ability to substantially interact with *piwi* family in solution at modulator concentrations of less than one (1) micro molar ( $\mu\text{M}$ ), preferably less than  $0.1 \mu\text{M}$ , and more preferably less than  $0.01 \mu\text{M}$ . By "substantially" is meant that at least a 50 percent modulation in *piwi* family biological activity is observed in the presence of the *piwi* family biological activity modulator, and a 50% modulation is referred to herein as an  $\text{IC}_{50}$  value.

A therapeutically effective amount of a *piwi* family biological activity modulator of this invention in the form of a monoclonal antibody, or fragment thereof, is typically an amount such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about  $0.01 \mu\text{g}$  per milliliter (ml) to about  $100 \mu\text{g/ml}$ , preferably from about  $1 \mu\text{g/ml}$  to about  $5 \mu\text{g/ml}$ , and usually about  $5 \mu\text{g/ml}$ .

A therapeutically effective amount of a *piwi* family biological activity modulator of this invention in the form of a polypeptide is typically an amount of polypeptide such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about  $0.001 \mu\text{g}$  per milliliter (ml) to about  $10 \mu\text{g/ml}$ , preferably from about  $0.05 \mu\text{g/ml}$  to about  $1.0 \mu\text{g/ml}$ .

The monoclonal antibodies or polypeptides of the invention can be administered parenterally by injection or by gradual infusion over time. Although the tissue to be treated can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains the target molecule. Thus, monoclonal antibodies or polypeptides of the invention can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intra-cavity, transdermally, and can be delivered by peristaltic means.

The therapeutic compositions containing a monoclonal antibody or a polypeptide of this invention are conventionally administered intravenously, as by injection of a unit dose, for example. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier or vehicle.

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for *in vivo* therapies are contemplated. Polypeptide modulators can also be modified as

described herein below with respect to biologically active *piwi* family proteins and protein therapy methods using the same.

#### Monoclonal Antibodies

5 The present invention describes, in one embodiment, *piwi* family modulators in the form of monoclonal antibodies which immunoreact with a *piwi* family polypeptide and bind the *piwi* family polypeptide to modulate biological activity as described herein. The invention also describes above cell lines which produce the antibodies, methods for producing the cell lines, and methods for producing the monoclonal antibodies.

10 The term "antibody or antibody molecule" in the various grammatical forms is used herein as a collective noun that refers to a population of immunoglobulin molecules and/or immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. An "antibody combining site" is that structural portion of an  
15 antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

Exemplary antibodies for use in the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, single chain immunoglobulins or antibodies, those portions of an  
20 immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), and also referred to as antibody fragments. Indeed, it is contemplated to be within the scope of the present invention that a monovalent modulator may optionally be used in the present method. Thus, the terms "modulate", "modulating", and "modulator"  
25 are meant to be construed to encompass such promotion.

The phrase "monoclonal antibody" in its various grammatical forms refers to a population of antibody molecules that contain only one species of antibody combining site capable of immunoreacting with a particular epitope. A monoclonal antibody thus typically displays a single binding affinity for any  
30 epitope with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g., a bispecific monoclonal

-55-

antibody. Methods of producing a monoclonal antibody, a hybridoma cell, or a hybridoma cell culture are described above.

5 It is also possible to determine, without undue experimentation, if a monoclonal antibody has the same (i.e., equivalent) specificity (immunoreaction characteristics) as a monoclonal antibody of this invention by ascertaining whether the former prevents the latter from binding to a preselected target molecule. If the monoclonal antibody being tested competes with the monoclonal antibody of the invention, as shown by a decrease in binding by the monoclonal antibody of the invention in standard competition assays for  
10 binding to the target molecule when present in the solid phase, then it is likely that the two monoclonal antibodies bind to the same, or a closely related, epitope.

Still another way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to pre-incubate the  
15 monoclonal antibody of the invention with the target molecule with which it is normally reactive, and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind the target molecule. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic  
20 specificity as the monoclonal antibody of the invention.

An additional way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to determine the amino acid residue sequence of the CDR regions of the antibodies in question. "CDRs" (complementarity determining regions) mean the three subregions of  
25 the light or heavy chain variable regions which have hypervariable sequences and form loop structures that are primarily responsible for making direct contact with antigen. Antibody molecules having identical, or functionally equivalent, amino acid residue sequences in their CDR regions have the same binding specificity. Methods for sequencing polypeptides are well known in the art.

30 The immunospecificity of an antibody, its target molecule binding capacity, and the attendant affinity the antibody exhibits for the epitope, are defined by the epitope with which the antibody immunoreacts. The epitope

specificity is defined at least in part by the amino acid residue sequence of the variable region of the heavy chain of the immunoglobulin that comprises the antibody, and in part by the light chain variable region amino acid residue sequence. Use of the terms "having the binding specificity of" or "having the binding preference of" indicates that equivalent monoclonal antibodies exhibit the same or similar immunoreaction (binding) characteristics and compete for binding to a preselected target molecule.

Humanized monoclonal antibodies offer particular advantages over murine monoclonal antibodies, particularly insofar as they can be used therapeutically in humans. Specifically, human antibodies are not cleared from the circulation as rapidly as "foreign" antigens, and do not activate the immune system in the same manner as foreign antigens and foreign antibodies. Methods of preparing "humanized" antibodies are generally well known in the art, and can readily be applied to the antibodies of the present invention. Thus, the invention contemplates, in one embodiment, a monoclonal antibody of this invention that is humanized by grafting to introduce components of the human immune system without substantially interfering with the ability of the antibody to bind antigen.

The use of a molecular cloning approach to generate antibodies, particularly monoclonal antibodies, and more particularly single chain monoclonal antibodies, is also contemplated. The production of single chain antibodies has been described in the art, see e.g., U.S. Patent No. 5,260,203, the contents of which are herein incorporated by reference. For this, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning on endothelial tissue. The advantages of this approach over conventional hybridoma techniques are that approximately  $10^4$  times as many antibodies can be produced and screened in a single round, and that new specificities are generated by H and L chain combination in a single chain, which further increases the chance of finding appropriate antibodies. Thus, an antibody of the present invention, or a "derivative" of an antibody of the present invention pertains to a single

polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody described herein.

#### Other Modulators

5           Given the disclosure of the *piwi* family activity in tissues herein, it is also contemplated that as yet undefined chemical compounds may be used to modulate *piwi* family activity in tissues in accordance with the methods of the present invention. The identification of such compounds is facilitated by the description of screening assays directed to *piwi* family activity in tissues  
10           presented above.

#### Gene Therapy

          In accordance with the present invention, *piwi* family genes can be used as a tool of gene therapy in humans and mammalian, avian, and fish systems to increase the number of stem cells and to increase proliferation of primordial  
15           germ cells *in vivo*.

          For example, over-proliferation of malignant stem cells is the leading cause of cancer while under-proliferation of stem cells or stem-like progenitor cells leads to tissue dystrophy, anemia, immunodeficiency, and male infertility. The crucial role of stem cells has long been attributed to their ability to self-renew and to generate immense number of specialized cells on demand.  
20           Thus, *piwi* family genes can be used for gene therapy in accordance with the present invention. Exemplary gene therapy methods, including liposomal transfection of nucleic acids into host cells, are described in U.S. Patent Nos. 5,279,833; 5,286,634; 5,399,346; 5,646,008; 5,651,964; 5,641,484; and  
25           5,643,567, the contents of each of which are herein incorporated by reference.

          Briefly, *piwi* family gene therapy directed toward modulation of growth, proliferation and self-renewing division in a target cell is described. Target cells include but are not limited to germline stem cells, primordial germ cells and cancerous or tumorous cells. In one embodiment, a therapeutic method of the  
30           present invention contemplates a method for modulating of growth, proliferation or self-renewing division in a cell comprising the steps of: (a) delivering to the cell an effective amount of a DNA molecule comprising a polynucleotide that

-58-

encodes a *piwi* family polypeptide that modulates growth, proliferation or self-renewing division; and (b) maintaining the cell under conditions sufficient for expression of said polypeptide.

In a preferred embodiment, the *piwi* family polypeptide is HIWI or MIWI.

5 Delivery is preferably accomplished by injecting the DNA molecule into the cell. Where the cell is in a subject delivering is preferably administering the DNA molecule into the circulatory system of the subject. In a preferred embodiment, administering comprises the steps of: (a) providing a vehicle that contains the DNA molecule; and (b) administering the vehicle to the subject.

10 A vehicle is preferably a cell transformed or transfected with the DNA molecule or a transfected cell derived from such a transformed or transfected cell. An exemplary and preferred transformed or transfected cell is a spermatogonial cell or a tumor cell from the tumor being treated. Techniques for transforming or transfecting a cell with a DNA molecule of the present invention are set forth above.

Alternatively, the vehicle is a virus or an antibody that specifically infects or immunoreacts with an antigen of the tumor. Retroviruses used to deliver the constructs to the host target tissues generally are viruses in which the 3'-LTR (linear transfer region) has been inactivated. That is, these are enhancerless  
20 3'-LTR's, often referred to as SIN (self-inactivating viruses) because after productive infection into the host cell, the 3'-LTR is transferred to the 5'-end and both viral LTR's are inactive with respect to transcriptional activity. A use of these viruses well known to those skilled in the art is to clone genes for which the regulatory elements of the cloned gene are inserted in the space  
25 between the two LTR's. An advantage of a viral infection system is that it allows for a very high level of infection into the appropriate recipient cell.

Antibodies have been used to target and deliver DNA molecules. An N-terminal modified poly-L-lysine (NPLL)-antibody conjugate readily forms a complex with plasmid DNA. A complex of monoclonal antibodies against a cell  
30 surface thrombomodulin conjugated with NPLL was used to target a foreign plasmid DNA to an antigen-expressing mouse lung endothelial cell line and



-59-

mouse lung. Those targeted endothelial cells expressed the product encoded by that foreign DNA.

It is also envisioned that this embodiment of the present invention can be practiced using alternative viral or phage vectors, including retroviral  
5 vectors, adenoviral vectors and vaccinia viruses whose genome has been manipulated in alternative ways so as to render the virus non-pathogenic. Methods for creating such a viral mutation are set forth in detail in U.S. Pat. No. 4,769,331, incorporated herein by reference.

By way of specific example, *hiwi*, *miwi*, and their homologs from warm-  
10 blooded vertebrates are introduced into isolated spermatogonial cells or other relevant cells. The re-injection of the transgene-carrying cells into the testis or other relevant tissues provides a treatment for male infertility or other relevant diseases in human and animals.

#### Protein Therapy

15 In another embodiment, the direct introduction of the *piwi* family proteins into a diseased tissue is contemplated to provide a therapeutic effect in human and animals. Such a therapeutic method comprises administering to a subject a therapeutic composition which comprises a biologically active *piwi* family polypeptide of the present invention in amount effective to modulate a *piwi*-  
20 mediated biological activity in the subject.

In one embodiment, a polypeptide for use in such a composition comprises no more than about 100 amino acid residues, preferably no more than about 60 residues, more preferably no more than about 30 residues. Peptides can be linear or cyclic.

25 A subject polypeptide includes any analog, fragment or chemical derivative of a *piwi* family polypeptide. Such a polypeptide can be subject to various changes, substitutions, insertions, and deletions where such changes provide for certain advantages in its use. In this regard, an *piwi* family polypeptide for use in a therapeutic method of the present invention  
30 corresponds to, rather than is identical to, the sequence of a native *piwi* family polypeptide where one or more changes are made and it retains the ability to function as a *piwi* family polypeptide in one or more of the assays as defined

-60-

herein. Thus, a polypeptide can be in any of a variety of forms of peptide derivatives, that include amides, conjugates with proteins, cyclized peptides, polymerized peptides, analogs, fragments, chemically modified peptides, and the like derivatives.

5           The term "analog" includes any polypeptide having an amino acid residue sequence substantially identical to a sequence of an endogenous *piwi* family polypeptide in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the *piwi* family biological activity as described herein. Examples of conservative substitutions  
10 include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another; the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine; the substitution of one basic residue such as lysine, arginine or histidine for  
15 another; or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. Such substitutions are described in detail above with respect to the isolated and purified *piwi* family polypeptide of the present invention.

20           The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such polypeptide displays the requisite biological activity.

          "Chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include for example, those molecules in which free  
25 amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The  
30 imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino

acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. Polypeptides of the present invention  
5 also include any polypeptide having one or more additions and/or deletions or residues relative to the sequence of a polypeptide whose sequence is shown herein, so long as the requisite activity is maintained.

The term "fragment" refers to any subject polypeptide having an amino acid residue sequence shorter than that of a polypeptide whose amino acid  
10 residue sequence is shown herein.

When a polypeptide of the present invention has a sequence that is not identical to the sequence of a *piwi* family endogenous polypeptide, it is typically because one or more conservative or non-conservative substitutions have been made, usually no more than about 30 number percent, and preferably no  
15 more than 10 number percent of the amino acid residues are substituted. Additional residues may also be added at either terminus of a polypeptide for the purpose of providing a "linker" by which the polypeptides of this invention can be conveniently affixed to a label or solid matrix, or carrier. Labels, solid matrices and carriers that can be used with the polypeptides of this invention  
20 are described elsewhere herein.

Amino acid residue linkers are usually at least one residue and can be 40 or more residues, more often 1 to 10 residues, but do not form *piwi* family polypeptide epitopes. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like. In addition, a subject  
25 polypeptide can differ, unless otherwise specified, from the natural sequence of a *piwi* family polypeptide by the sequence being modified by terminal-NH<sub>2</sub> acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like terminal modifications. Terminal modifications are useful, as is well known, to reduce  
30 susceptibility by proteinase digestion, and therefore serve to prolong half life of the polypeptides in solutions, particularly biological fluids where proteases may be present. In this regard, polypeptide cyclization is also a useful terminal

modification, and is particularly preferred also because of the stable structures formed by cyclization and in view of the biological activities observed for such cyclic peptides as described herein.

Any peptide of the present invention may be used in the form of a  
5 pharmaceutically acceptable salt. Suitable acids which are capable of the  
peptides with the peptides of the present invention include inorganic acids such  
as trifluoroacetic acid (TFA), hydrochloric acid (HCl), hydrobromic acid,  
perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acetic acid,  
propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid,  
10 succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid,  
naphthalene sulfonic acid, sulfanilic acid or the like. HCl and TFA salts are  
particularly preferred.

Suitable bases capable of forming salts with the peptides of the present  
invention include inorganic bases such as sodium hydroxide, ammonium  
15 hydroxide, potassium hydroxide and the like; and organic bases such as mono-  
di- and tri-alkyl and aryl amines (e.g. triethylamine, diisopropyl amine, methyl  
amine, dimethyl amine and the like), and optionally substituted ethanolamines  
(e.g. ethanolamine, diethanolamine and the like).

A peptide of the present invention, also referred to herein as a subject  
20 polypeptide, can be synthesized by any of the techniques that are known to  
those skilled in the polypeptide art, including recombinant DNA techniques.  
Synthetic chemistry techniques, such as a solid-phase Merrifield-type  
synthesis, are preferred for reasons of purity, antigenic specificity, freedom  
from undesired side products, ease of production and the like. An excellent  
25 summary of the many techniques available can be found in Steward et al.,  
"Solid Phase Peptide Synthesis", W. H. Freeman Co., San Francisco, 1969;  
Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition,  
1976; J. Meienhofer, "Hormonal Proteins and Peptides", Vol. 2, p. 46,  
Academic Press (New York), 1983; Merrifield, *Adv Enzymol*, 32:221-96, 1969;  
30 Fields et al., *Int. J. Peptide Protein Res.*, 35:161-214, 1990; and U.S. Pat. No.  
4,244,946 for solid phase peptide synthesis, and Schroder et al., "The  
Peptides", Vol. 1, Academic Press (New York), 1965 for classical solution

synthesis, each of which is incorporated herein by reference. Appropriate protective groups usable in such synthesis are described in the above texts and in J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, New York, 1973, which is incorporated herein by reference.

5           In general, the solid-phase synthesis methods contemplated comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively removable protecting group. a different, selectively  
10 removable protecting group is utilized for amino acids containing a reactive side group such as lysine.

          Using a solid phase synthesis as exemplary, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then  
15 selectively removed and the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or  
20 carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to afford the final linear polypeptide.

          The resultant linear polypeptides prepared for example as described  
25 above may be reacted to form their corresponding cyclic peptides. An exemplary method for cyclizing peptides is described by Zimmer et al., *Peptides* 1992, pp. 393-394, ESCOM Science Publishers, B. V., 1993. Typically, tertbutoxycarbonyl protected peptide methyl ester is dissolved in methanol and sodium hydroxide solution are added and the admixture is  
30 reacted at 20°C to hydrolytically remove the methyl ester protecting group. After evaporating the solvent, the tertbutoxycarbonyl protected peptide is extracted with ethyl acetate from acidified aqueous solvent. The

-64-

tert-butoxycarbonyl protecting group is then removed under mildly acidic conditions in dioxane cosolvent. The unprotected linear peptide with free amino and carboxy termini so obtained is converted to its corresponding cyclic peptide by reacting a dilute solution of the linear peptide, in a mixture of  
5 dichloromethane and dimethylformamide, with dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole and N-methylmorpholine. The resultant cyclic peptide is then purified by chromatography.

#### Antisense Oligonucleotide Therapy

In another embodiment, the administering of antisense RNA against a  
10 chosen *piwi* family gene (e.g. *hiwi*, *miwi*, etc.) provides treatment of germline tumor or other developmental or tissue defects caused by *piwi* family-mediated mechanisms. In accordance with the present invention such a therapeutic method may alternatively comprise promoting or inhibiting *piwi* family in a  
15 subject by administering an effective amount of a substance that inhibits or promotes expression of a *piwi* family-encoding nucleic acid segment in the subject. Examples of such a substance, include, for example, an antisense oligonucleotide derived from SEQ ID NOs:1, 3 or 5. Therapeutic methods utilizing antisense oligonucleotides have been described in the art, for example  
20 in U.S. Patent Nos. 5,627,158 and 5,734,033, the contents of each of which are herein incorporated by reference.

#### Formulation of Therapeutic Compositions

The *piwi* family biological activity modulating substances, gene therapy vectors, biologically active *piwi* family gene products, and substances that inhibit or promote expression of a *piwi* family-encoding nucleic acid segment  
25 described above are adapted for administration as a pharmaceutical compositions as described above. Additional formulation and dose preparation techniques have been described in the art, see for example, those described in U.S. Patent No. 5,326,902 issued to Seipp et al. on July 5, 1994, U.S. Patent No. 5,234,933 issued to Marnett et al. on August 10, 1993, and PCT  
30 Publication WO 93/25521 of Johnson et al. published December 23, 1993, the entire contents of each of which are herein incorporated by reference.

For the purposes described above, the identified substances may normally be administered systemically or partially, usually by oral or parenteral administration. The doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In a human adult, the doses per person per administration are generally between 1 mg and 500 mg, by oral administration, up to several times per day, and between 1 mg and 100 mg, by parenteral administration up to several times per day. Since the doses to be used depend upon various conditions, as mentioned above, there may be a case in which doses are lower than or greater than the ranges specified above.

Solid compositions for oral administration include compressed tablets, pills, dispersible powders, capsules, and granules. In such compositions, one or more of the active substance(s) is or are, admixed with at least one inert diluent (lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate alminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (magnesium stearate, etc.), disintegrating agents (cellulose, calcium glycolate etc.), and assisting agent for dissolving (glutamic acid, aspartic acid, etc.) stabilizing agent (lactose etc.). The tablets or pills may, if desired, be coated with gastric or enteric material (sugar, gelatin, hydroxypropylcellulose or hydroxypropylmethyl cellulose phthalate, etc.). Capsules include soft ones and hard ones.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs. In such compositions, one or more of the active substance(s) is or are admixed with inert diluent(s) commonly used in the art (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active substance(s). Spray compositions may comprise additional substances other than inert diluents: e.g. preserving agents (sodium sulfite, etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in U.S. Patent Nos. 2,868,691 or 3,095,355 may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solution, suspensions and emulsions. In such compositions, one or more of active substance(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution etc.) or inert non-aqueous diluent(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80® etc.). Injections may comprise additional other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (lactose, etc.), assisting agents such as for dissolving (glutamic acid, aspartic acid, etc.). They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They also be manufactured in the form of sterile solid compositions, for example, by freeze-drying, and which can be dissolved in sterile water or some other sterile diluents for injection immediately before use.

Other compositions for administration include liquids for external use, and endermic linaments (ointment, etc.), suppositories and pessaries which comprise one or more of the active substance(s) and may be prepared by known methods.

#### Detecting a Polynucleotide or a Polypeptide of the Present Invention

Alternatively, the present invention provides a method of detecting a polypeptide of the present invention, wherein the method comprises immunoreacting the polypeptides with antibodies prepared according to the method described above to form antibody-polypeptide conjugates, and detecting the conjugates.



-67-

In yet another embodiment, the present invention contemplates a method of detecting messenger RNA transcripts that encode a polypeptide of the present invention, wherein the method comprises hybridizing the messenger RNA transcripts with polynucleotide sequences that encode the polypeptide to form duplexes; and detecting the duplex. Alternatively, the present invention provides a method of detecting DNA molecules that encode a polypeptide of the present invention, wherein the method comprises hybridizing DNA molecules with a polynucleotide that encodes that polypeptide to form duplexes; and detecting the duplexes.

The detection and screening assays disclosed herein can be used as a prognosis tool. *hiwi*, *miwi* and their mammalian homologous genes as well as their protein products can be readily used in clinical setting as a prognostic indicator for screening infertility, germline cancer, or other heritable *piwi*-related diseases in human and animals.

The detection and screening assays disclosed herein can be also used as a part of a diagnostic method. *hiwi*, *miwi*, and their mammalian homologs as well as their proteins can be readily used in clinical practice to diagnose the cause of infertility, testicular cancer, or other heritable *piwi*-related diseases in human and animals.

#### Screening Assays for a Polypeptide of the Present Invention

The present invention provides a method of screening a biological sample for the presence of a *piwi* family polypeptide. Preferably, the *piwi* family polypeptide possesses a biological activity in accordance with the present invention. A biological sample to be screened can be a biological fluid such as extracellular or intracellular fluid or a cell or tissue extract or homogenate. A biological sample can also be an isolated cell (e.g., in culture) or a collection of cells such as in a tissue sample or histology sample. A tissue sample can be suspended in a liquid medium or fixed onto a solid support such as a microscope slide.

-68-

In accordance with a screening assay method, a biological sample is exposed to an antibody immunoreactive with the polypeptide whose presence is being assayed. Typically, exposure is accomplished by forming an admixture in a liquid medium that contains both the antibody and the candidate polypeptide. Either the antibody or the sample with the polypeptide can be affixed to a solid support (e.g., a column or a microtiter plate).

The biological sample is exposed to the antibody under biological reaction conditions and for a period of time sufficient for antibody-polypeptide conjugate formation. Biological reaction conditions include ionic composition and concentration, temperature, pH and the like.

Ionic composition and concentration can range from that of distilled water to a 2 molal solution of NaCl. Preferably, osmolality is from about 100 mosmols/l to about 400 mosmols/l and, more preferably from about 200 mosmols/l to about 300 mosmols/l. Temperature preferably is from about 4°C. to about 100°C., more preferably from about 15°C. to about 50°C. and, even more preferably from about 25°C to about 40°C. pH is preferably from about a value of 4.0 to a value of about 9.0, more preferably from about a value of 6.5 to a value of about 8.5 and, even more preferably from about a value of 7.0 to a value of about 7.5. The only limit on biological reaction conditions is that the conditions selected allow for antibody-polypeptide conjugate formation and that the conditions do not adversely affect either the antibody or the polypeptide.

Exposure time will vary *inter alia* with the biological conditions used, the concentration of antibody and polypeptide and the nature of the sample (e.g., fluid or tissue sample). Means for determining exposure time are well known to one of ordinary skill in the art. Typically, where the sample is fluid and the concentration of polypeptide in that sample is about  $10^{-10}$ M, exposure time is from about 10 minutes to about 200 minutes.

The presence of polypeptide in the sample is detected by detecting the formation and presence of antibody-polypeptide conjugates. Means for detecting such antibody-antigen (e.g., receptor polypeptide) conjugates or complexes are well known in the art and include such procedures as

-69-

centrifugation, affinity chromatography and the like, binding of a secondary antibody to the antibody-candidate receptor complex.

In one embodiment, detection is accomplished by detecting an indicator affixed to the antibody. Exemplary and well known such indicators include  
5 radioactive labels (e.g.,  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^{14}\text{C}$ ), a second antibody or an enzyme such as horse radish peroxidase. Means for affixing indicators to antibodies are well known in the art. Commercial kits are available.

#### Screening Assay for Anti-Polypeptide Antibody

In another aspect, the present invention provides a method of screening  
10 a biological sample for the presence of antibodies immunoreactive with a *piwi* family polypeptide. Preferably the *piwi* family polypeptide has a biological activity in accordance with the present invention. In accordance with such a method, a biological sample is exposed to a *piwi* family polypeptide under biological conditions and for a period of time sufficient for antibody-polypeptide  
15 conjugate formation and the formed conjugates are detected.

#### Screening Assay for Polynucleotide That Encodes a *piwi* family Polypeptide of the Present Invention

A DNA molecule and, particularly a probe molecule, can be used for hybridizing as an oligonucleotide probe to a DNA source suspected of  
20 encoding a *piwi* family polypeptide of the present invention. Preferably the *piwi* family polypeptide possesses a biological activity in accordance with the present invention. The probing is usually accomplished by hybridizing the oligonucleotide to a DNA source suspected of possessing a *piwi* family gene. In some cases, the probes constitute only a single probe, and in others, the  
25 probes constitute a collection of probes based on a certain amino acid sequence or sequences of the polypeptide and account in their diversity for the redundancy inherent in the genetic code.

A suitable source of DNA for probing in this manner is capable of expressing a polypeptide of the present invention and can be a genomic library  
30 of a cell line of interest. Alternatively, a source of DNA can include total DNA

-70-

from the cell line of interest. Once the hybridization method of the invention has identified a candidate DNA segment, one confirms that a positive clone has been obtained by further hybridization, restriction enzyme mapping, sequencing and/or expression and testing.

5           Alternatively, such DNA molecules can be used in a number of techniques including their use as: (1) diagnostic tools to detect normal and abnormal DNA sequences in DNA derived from patient's cells; (2) reagents for detecting and isolating other members of the polypeptide family and related polypeptides from a DNA library potentially containing such sequences; (3)  
10          primers for hybridizing to related sequences for the purpose of amplifying those sequences; (4) primers for altering native *piwi* family DNA sequences; as well as other techniques which rely on the similarity of the DNA sequences to those of the DNA segments herein disclosed.

          As set forth above, in certain aspects, DNA sequence information  
15          provided by the invention allows for the preparation of relatively short DNA (or RNA) sequences (e.g., probes) that specifically hybridize to encoding sequences of a selected *piwi* family gene. In these aspects, nucleic acid probes of an appropriate length are prepared based on a consideration of the encoding sequence for a polypeptide of this invention. The ability of such  
20          nucleic acid probes to specifically hybridize to other encoding sequences lend them particular utility in a variety of embodiments. Most importantly, the probes can be used in a variety of assays for detecting the presence of complementary sequences in a given sample. However, other uses are envisioned, including the use of the sequence information for the preparation of mutant species  
25          primers, or primers for use in preparing other genetic constructions.

          To provide certain of the advantages in accordance with the invention, a preferred nucleic acid sequence employed for hybridization studies or assays includes probe sequences that are complementary to at least a 14 to 40 or so long nucleotide stretch of a nucleic acid sequence of the present invention,  
30          such as a sequence shown in any of SEQ ID NOs:1, 3 and 5. A size of at least 14 nucleotides in length helps to ensure that the fragment is of sufficient length to form a duplex molecule that is both stable and selective. Molecules having

complementary sequences over stretches greater than 14 bases in length are generally preferred, though, to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having  
5 gene-complementary stretches of 14 to 20 nucleotides, or even longer where desired. Such fragments can be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR technology of U.S. Pat. No. 4,683,202, herein incorporated by reference, or by introducing selected  
10 sequences into recombinant vectors for recombinant production.

Accordingly, a nucleotide sequence of the present invention can be used for its ability to selectively form duplex molecules with complementary stretches of the gene. Depending on the application envisioned, one employs varying conditions of hybridization to achieve varying degrees of selectivity of the probe  
15 toward the target sequence. For applications requiring a high degree of selectivity, one typically employs relatively stringent conditions to form the hybrids. For example, one selects relatively low salt and/or high temperature conditions, such as provided by 0.02M-0.15M NaCl at temperatures of 50°C to 70°C. Such conditions are particularly selective, and tolerate little, if any,  
20 mismatch between the probe and the template or target strand.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template or where one seeks to isolate polypeptide coding sequences from related species, functional equivalents, or the like, less stringent hybridization  
25 conditions are typically needed to allow formation of the heteroduplex. Under such circumstances, one employs conditions such as 0.15M-0.9M salt, at temperatures ranging from 20°C to 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions  
30 can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily

-72-

manipulated, and thus will generally be a method of choice depending on the desired results.

5 In certain embodiments, it is advantageous to employ a nucleic acid sequence of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal. In preferred embodiments, one likely employs an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other  
10 environmentally undesirable reagents. In the case of enzyme tags, calorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

In general, it is envisioned that the hybridization probes described herein  
15 are useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the sample containing test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The  
20 selected conditions depend *inter alia* on the particular circumstances based on the particular criteria required (depending, for example, on the G+ C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface so as to remove nonspecifically bound probe molecules, specific hybridization is detected, or  
25 even quantified, by means of the label.

#### Assay Kits

In another aspect, the present invention contemplates assay kits for detecting the presence of a polypeptide of the present invention in biological samples, where the kits comprise a first container containing a first antibody  
30 capable of immunoreacting with the polypeptide, with the first antibody present in an amount sufficient to perform at least one assay. Preferably, the assay kits

-73-

of the invention further comprise a second container containing a second antibody that immunoreacts with the first antibody. More preferably, the antibodies used in the assay kits of the present invention are monoclonal antibodies. Even more preferably, the first antibody is affixed to a solid support. More preferably still, the first and second antibodies comprise an indicator, and, preferably, the indicator is a radioactive label or an enzyme.

The present invention also contemplates a kit for screening agents. Such a kit can contain a polypeptide of the present invention. The kit can contain reagents for detecting an interaction between an agent and a receptor of the present invention. The provided reagent can be radiolabeled. The kit can contain a known radiolabelled agent capable of binding or interacting with a receptor of the present invention.

In an alternative aspect, the present invention provides assay kits for detecting the presence, in biological samples, of a polynucleotide that encodes a polypeptide of the present invention, the kits comprising a first container that contains a second polynucleotide identical or complementary to a segment of at least 10 contiguous nucleotide bases of, as a preferred example, SEQ ID NOs:1, 3 and 5.

In another embodiment, the present invention contemplates assay kits for detecting the presence, in a biological sample, of antibodies immunoreactive with a polypeptide of the present invention, the kits comprising a first container containing a *piwi* family polypeptide, that immunoreacts with the antibodies, with the polypeptide present in an amount sufficient to perform at least one assay. Preferably, the *piwi* family polypeptide has a biological activity in accordance with the present invention. The reagents of the kit can be provided as a liquid solution, attached to a solid support or as a dried powder. Preferably, when the reagent is provided in a liquid solution, the liquid solution is an aqueous solution. Preferably, when the reagent provided is attached to a solid support, the solid support can be chromatograph media or a microscope slide. When the reagent provided is a dry powder, the powder can be reconstituted by the addition of a suitable solvent. The solvent can be provided.

### EXAMPLES

The following examples have been included to illustrate preferred modes of the invention. Certain aspects of the following examples are described in terms of techniques and procedures found or contemplated by the present  
5 inventors to work well in the practice of the invention. These examples are exemplified through the use of standard laboratory practices of the inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following examples are intended to be exemplary only and that numerous changes, modifications and alterations can be  
10 employed without departing from the spirit and scope of the invention.

In exploring stem cell renewal mechanisms in the germline, the *piwi* gene is disclosed herein to be essential for GSC maintenance in *Drosophila*. The role of the *piwi* gene is characterized herein by recessive mutations that cause failure in GSC maintenance in both females and males. *piwi* mutant  
15 gonads contain a normal number of GSCs at the onset of gametogenesis. However, mutant adult gonads are devoid of GSCs and contain only a very small number of gametes that is approximately equal to or less than the wild-type number of GSCs. These observations reveal that *piwi* is essential for GSC maintenance in both males and females.

#### Summary of Observations in Examples

  
20

The purification and isolation of cDNAs representing *piwi* family genes from human, mouse, *Drosophila* are disclosed in the Examples, along with the primary structure of the PIWI proteins in human, mouse and *Drosophila* as deduced from the cDNA sequences. Additionally, the essential function of *piwi*  
25 in *Drosophila* germline stem cell growth, proliferation and self-renewal and in embryonic development is also disclosed.

Further, the identification of *piwi* homologous genes, *prg-1* and *prg-2* in *C. elegans* and the demonstration of the important function of *prg-1* and *prg-2* in *C. elegans* germline self-renewal similar to that of *piwi* in *Drosophila* is described in the Examples. The identification of two *piwi* family-like genes in  
30 *Arabidopsis*, *Zwille* and *argonaute(ago)*, that are known to be required for meristem cell divisions is also described.



The growth, proliferation and self-renewing division modulating biological activity of human and murine *piwi* genes (named *hiwi* and *miwi*, respectively) in germline stem cell renewal, proliferation of primordial germ cells and in other developmental processes is characterized in the Examples based on the following data and reasoning: (i) *hiwi* and *miwi* are more homologous to *piwi* than *prg-I*, *prg-II*, *Zwille* and *ago* to *piwi*; (ii) human and murine germline stem cells are much more similar to *Drosophila* germline cells than to the *C. elegans* germline or *Arabidopsis* meristem cells; (iii) the function of *piwi* family genes are well conserved among *Drosophila*, *C. elegans*, and *Arabidopsis*, which are evolutionarily more diverse than between *Drosophila* and human/mammals; and (iv) *hiwi* and *miwi* is indeed specifically expressed in the adult human and murine testis, respectively, but not in the adult human or murine ovary which does not contain germline stem cells. *miwi* is further shown to be expressed specifically in the germline stem cell region in the mouse testis. Therefore, *hiwi*, *miwi*, and other mammalian *piwi* family genes are shown to play an important role in germline stem cell division and other stem cell-related processes.

The specific expression pattern of *hiwi* and *miwi* in the adult human and murine testis, respectively, but not in the adult human or murine ovary which do not contain germline stem cells is also demonstrated in the Examples. *miwi* is further shown to be expressed in the germline stem cell region in the mouse testis. The discovery of a highly conserved protein signature motif of 43-amino acid residues, the PIWI box, that exists in the *piwi* family genes as well as in a broader class of novel genes which may be structurally and functionally defined by the PIWI box is also described in the Examples. The demonstration that the PIWI protein and, thus, the PRG-1, PRG-2, MIWI, HIWI, Zwille, and AGO proteins are nuclear proteins is also disclosed.

#### Example 1

##### Isolation and Purification of *piwi*

The cloning and characterization of the *Drosophila piwi* gene is disclosed in this Example. Germline stem cells (GSCs) serve as the source for gametogenesis in diverse organisms. The *piwi* gene product is required for the

asymmetric division of GSC to produce and maintain a daughter GSC but is not essential for the further differentiation of the committed daughter cell. Genetic mosaic and RNA *in situ* analyses indicate that *piwi* expression in adjacent somatic cells regulates GSC division.

5           *piwi* encodes a highly basic novel protein well conserved during evolution. This Example also describes the isolation of *piwi* family homologs in *C. elegans* and human. This Example further describes the identification of *Arabidopsis piwi* family-like genes known to be required for meristem cell maintenance. Decreasing *C. elegans piwi* expression reduces the proliferation  
10 of GSC-equivalent cells. Thus, *piwi* represents a novel class of genes required for GSC division in diverse organisms.

*Drosophila* has been used in the art as a model for studying mechanisms that are conserved among diverse developmental systems. As show herein, this is also the case for the study of stem cells. In *Drosophila*,  
15 stem cells exist in the germline at the apical tip of the ovariole, the functional unit of the ovary. In the ovariole, germline stem cells (GSCs) are located in a specialized structure called the germarium, as first proposed by Brown and King (1962, 1964). The existence of GSCs was strongly supported by germline clonal analysis (Schüpbach et al., 1978; Wieschaus and Szabad, 1979) and  
20 directly verified by laser ablation (Lin and Spradling, 1993). In each germarium, 2-3 GSCs contact the somatic basal terminal filament cells. GSCs undergo oriented asymmetric divisions to produce a daughter stem cell which remains associated with the terminal filament and a differentiated daughter, the cystoblast, that becomes displaced one cell away from the terminal filament  
25 (Lin and Spradling, 1997; Deng and Lin, 1997). The germline cyst then becomes enveloped by follicle cells produced by somatic stem cells (Margolis and Spradling, 1995) to form an egg chamber, which buds off the germarium, joins pre-existing egg chambers in a linear array to form an ovariole, and eventually develops into a mature egg (reviewed in King, 1970; Spradling,  
30 1993). This assembly-line organization, with each egg chamber representing a differentiated stem cell product whose position along the ovariole

-77-

corresponds to its birth order, provides a unique opportunity to study stem cell division.

To investigate the nature of the *piwi*-mediated mechanism, this Example reports that *piwi* mediates a somatic signaling mechanism essential for the division and maintenance of GSCs in *Drosophila*. Moreover, *piwi* encodes a novel basic protein well conserved in *C. elegans* and humans, and also conserved in *Arabidopsis*, where two *piwi* family-like genes are known to be required for meristem cell maintenance. It is also demonstrated that the *C. elegans piwi* family homolog is also required for germline proliferation and maintenance. Thus, *piwi* family genes represent essential stem cell genes existing in diverse organisms.

*Drosophila* strains and culture. All strains were grown at 25°C on yeast-containing molasses/agar medium. The *piwi*<sup>1</sup>, *piwi*<sup>3</sup> and *piwi*<sup>4</sup> mutations are single PZ insertional mutations reported by Lin and Spradling (1997) while the *piwi*<sup>2</sup> mutation is a single P-ry<sup>11</sup> transposable insertion. *Oregon R* (*Ore-R*) serves as the wildtype strain for all experiments.

Phenotypic analysis of *piwi* mutants. *Piwi* mutations were balanced over CyO-y<sup>+</sup> and introduced into the y/y genetic background. The homozygous and heterozygous larvae were separated at the late third instar stage by scoring mouth hooks and denticle belts for y. They were then dissected to obtain the ovary immediately or were aged at 25°C to desired pupal stages before dissection. Dissected ovaries were analyzed by immunofluorescence microscopy for defects in ovary differentiation and GSC division.

Immunocytochemistry and immunofluorescence microscopy. Wild type and mutant ovaries from larval, pupal, or adult stages were dissected, fixed and stained as described by Lin et al. (1994). For immunofluorescence staining, anti-VASA antibodies (Hay et al., 1990) were used to specifically mark germ cells at 1:2000 dilution. Anti- $\alpha$ -spectrin antibodies (Byers et al., 1987) were used to outline somatic cells and to mark spectrosomes and fusomes (Lin and Spradling, 1995) at 1:200 dilution. The monoclonal anti-MYC epitope antibody 1-9E10.2 was described by Evan et al. (1985) and was used at 1:2 dilution. All the fluorescence-conjugated secondary antibodies were from Jackson

ImmunoResearch Laboratory Inc., Westgrove, Pennsylvania, and were used at 1:200 dilution.

Immunofluorescently labeled samples were also counter-stained with the DNA specific dye DAPI as described in Lin and Spradling (1993). The immunologically labeled samples were examined using Nomarski and epifluorescence microscopy under a Zeiss AXIOPLAN® microscope (Zeiss, Oberkochen, Germany) equipped with a STAR-1™ cooled CCD camera (Photometrics, Tucson, Arizona). Selected samples were further analyzed by confocal microscopy using a Zeiss LSM410™ confocal microscope mounted on an AXIOVERT® 100. Images from the Zeiss AXIOPLAN® were collected using IP Lab software and confocal images were processed using the LSM410 software. All images were processed using the Adobe Photoshop™ program (Adobe Systems, Inc., San Jose, California).

Cloning of *piwi* and mapping of its mutations. *piwi* maps to the left arm of the second chromosome within polytene band 32C, as defined by insertions of single transposable elements (Lin and Spradling, 1997). DNA fragments flanking the *piwi*<sup>1</sup>, *piwi*<sup>3</sup>, and *piwi*<sup>4</sup> insertions were recovered by a plasmid rescue method (Wilson *et al.*, 1989). Genomic DNA in the rescued plasmid was used to isolate additional genomic clones from a λ genomic DNA library (Maniatis *et al.*, 1978) to constitute a 36 kb region of overlapping walk clones (Figure 2). The insertion sites for *piwi*<sup>1</sup>, *piwi*<sup>3</sup>, and *piwi*<sup>4</sup> were first mapped by Southern blots of EcoRI digested walk clones, and then precisely determined by DNA sequencing. The site of the *piwi*<sup>2</sup> insertion was determined by sequencing its flanking DNA fragments isolated by inverse PCR of *piwi*<sup>2</sup> genomic DNA using primers specific to the P-element termini (Ochman *et al.*, 1990).

Genomic DNA fragments derived from the *piwi* locus were used to probe Northern blots of poly (A)+ RNA from wild-type male and female flies. Three non-overlapping transcripts, α (1.1 kb), β (0.64 kb), and c12 (3.1 kb) were identified in the region and only c12 was interrupted by *piwi* mutations. 9.36 kb of genomic DNA that encompasses the c12 transcription unit was sequenced either using a Sequenase kit (U.S. Biochemical) or an ABI 377

Prism DNA Sequencer (Perkin-Elmer, Applied Biosystems Inc). All sequence data was analyzed using the DNASTAR software package (DNASTAR, Madison, WI). Two additional transcripts, LD08487 (1.43 kb) and LD13681, were identified on the right side of the P-insertions by BLAST analysis  
5 (Altschul, et al., 1990) of genomic sequence.

Two overlapping cDNA clones which together represent the 3.1 kb full length c12 mRNA and the LD08487 cDNA were sequenced. Comparison between the genomic and the cDNA sequences precisely determined the intron-exon organization of these two transcription units. The LD13681  
10 transcription unit were also mapped by partial sequencing. Standard molecular biology techniques were carried out according to Sambrook et al. (1989).

Transgenic rescue. The 6.8 kb *HindIII*/*EcoRV* (pRc12; *piwi*) and 3.9 kb *PstI* (pRLD; LD08487) genomic fragments were subcloned into the P element transformation vector pCaSpeR4 (Pirrotta, 1988). Transgenic flies were  
15 produced according to Spradling and Rubin (1982), using *w; Δ2-3 Sb e/TM6 e* (Robertson et al., 1988) embryos as recipients. Transgenes were then separated from the Δ2-3 transposase and introduced into the homozygous *piwi*<sup>1</sup> background for fertility tests by genetic crosses. Six independent pRc12 inserts and eight independent pRLD inserts were recovered. Rescue crosses  
20 were carried out at 25°C.

Northern blot analysis and *piwi* cDNA isolation. Poly (A)+ mRNA isolation, Northern blot preparation, and <sup>32</sup>P-labeled probe preparation by random-hexamer extension were according to Sambrook et al. (1989). For Fig. 2B, the probe was made from a 5.4 kb *HindIII* genomic fragment encompassing  
25 the *piwi* transcription unit. The same probe was used to isolate a 2.1 kb partial cDNA from the pNB40 third instar library of Brown and Kafatos, 1989. Using the sites within the polylinker (*HindIII* at 5' end and *NotI* at 3' end), the 2.1 kb cDNA was subcloned into pBlueScript KS(+) (Stratagene), resulting in a construct denoted pDC1. A primer, pDC1 5'REV, 5'-  
30 ACGATAAGTTCTGTTAT-3' (SEQ ID NO:11) was designed downstream of the 5' end of pDC1 and was used in combination with library specific primers to screen the Tulle Hazelrigg ovarian cDNA library (Friedman et al., 1990). A

partially overlapping 500 bp PCR product was isolated, cloned into the pGEM-T vector (Promega, Madison, Wisconsin), and used to probe the same library. An overlapping 1 kb cDNA clone was isolated and subcloned into the *Sall* site of pDC1 to produce a full length 3.1 kb *piwi* cDNA construct denoted pDC2.

5        Characterization of *piwi* homologs from *C. elegans* and *Homo sapiens*.

The BLAST algorithm (Altschul et al., 1990) was used to search the non-redundant databases at the National Center for Biotechnology Information (NCBI) at the National Library of Medicine. The Prosite Protein Motif Database (DNASTar, Madison, WI) was also searched to identify domains shared  
10        between *piwi* and other known proteins. The PIWI ORF was used to query the SWISS-Prot database by BLAST for homologous proteins. Significantly, the search identified two *C. elegans* predicted proteins of unknown function. Expressed sequence tags (ESTs) corresponding to these two gene products were then identified as D2030.6 (*prg-1*; GenBank accession No. Z73906) and  
15        C01G5.2 (*prg-2*; GenBank accession NoU50068) from GenBank. Dr. Yuji Kohara (National Institute of Genetics, Japan) kindly provided  $\lambda$  ZAPII phagemid clones corresponding to *prg-1* and *prg-2*.

The *piwi* cDNA was further used to query the NCBI dbEST database and identified an EST, zw68h01.r1, isolated from a human testes cDNA library,  
20        GenBank accession number AA430311. This 0.9 kb EST clone was sequenced and used to screen an oligo-(dT) primed human testis cDNA library (Clontech, Palo Alto, California). A 2.3 kb cDNA clone corresponding to *hiwi* was isolated and sequenced.

Whole-mount tissue *in situ* hybridization. Ovarian whole-mount tissue  
25        *in situ* hybridization was performed as described in Yue and Spradling (1992) with DIG-labeled (Genius Kit, Boehringer Mannheim) full length *piwi* cDNA from pDC2 as a probe. For detecting RNA in surface cells, ovaries were digested 5 minutes with 50  $\mu$ g/ml proteinase K. Under this condition, only terminal filament cells and anterior sheath cells, but not any other surface cells, were  
30        stained with the *piwi* cDNA probe. The pBST control probe did not show any significant signal. For detecting RNA in inner germarial cells, the digestion was 7-10 minutes. Under this condition, the *piwi* probe revealed a hybridization

pattern as shown in Results, the pBST control probe did not show any significant signal, while the positive control *oskar* probe showed specific staining in presumptive oocytes (Ephrussi et al., 1991). Staging of egg chambers is according to King (1970).

- 5        Genetic clonal analyses and germarial transplantation. The *piwi*<sup>1</sup> and *piwi*<sup>2</sup> germline clones were generated with the FLP-DFS technique as described in Chou and Perrimon (1996). *y, w P[hsFLP]12; P[ovoD1]2L, FRT40A/CyO* males were crossed to *w, piwi*<sup>1</sup>, *FRT40A/CyO* virgin females to produce *y, w P[hsFLP]12; P[ovoD1]2L, FRT40A/piwi*<sup>1</sup>, *FRT40A* progeny.
- 10       Identical crosses were performed with *w; piwi*<sup>2</sup>, *FRT40A/CyO* virgin females. The genotype of the flies were verified both by Southern analysis for the presence of *piwi* P insertion and the FRT as well as by sterility tests by backcrossing to the original *piwi* allele. Crosses were carried out for two days to produce transheterozygous progeny. After 2 days, adults were transferred
- 15       to fresh vials. Larvae were heat shocked on days 3 and 4 for one hour in a 37°C water bath to induce mitotic recombination. The heat-shocked females with germline clones were crossed to *Ore-R* males for fertility tests and their ovarian phenotype examined by immunofluorescence microscopy.

- 20       To generate somatic clones of *piwi*<sup>1</sup> and *piwi*<sup>2</sup> the above described *piwi*<sup>1</sup>, *FRT40A/CyO* and *piwi*<sup>2</sup>, *FRT40A/CyO* strains were crossed to *w; P[hsFLP]<sup>9F</sup>; P[w<sup>+</sup>; hs-NM], FRT40A/CyO* males as described in Xu and Rubin (1993). Females of the genotype *w, P[hsFLP]<sup>9F</sup>; P[w<sup>+</sup>; hs-NM], FRT40A/piwi, FRT40A* were crossed to *Ore-R* males for fertility tests. Clonal induction was carried out as described above except that females of the appropriate genotype
- 25       were subjected to an additional 20-minute heat shock at 37°C 90 minutes prior to dissection to induce the expression of the myc tag. Germarial transplantation was carried out as described by Lin and Spradling (1993).

- 30       RNA-mediated interference (RNAi). Templates for *in vitro* transcription were cloned into pBluescript KS (+) and transcribed using either T7 or T3 RNA polymerases according to the manufacturer's protocol (Megascript T7 and T3 kits, Ambion). *prg-1* cDNA served as the experimental RNA for injection while pBluescript KS(+) RNA was used as a negative control. RNA integrity was

determined by gel electrophoresis; concentration was determined by a combination of UV spectrophotometry and ethidium bromide staining. Injections used an equimolar mixture of uncapped sense and antisense RNA at a concentration of 10 mg/ml. Gonadal injections of wild type N2 Bristol hermaphrodites was done as described in Mello and Fire (1995).

After recovery and transfer to standard solid media, injected animals were transferred to fresh culture plates at 24 hours intervals to facilitate the identification of phenotypic differences. Germlines of progeny produced between 6 and 48 hours after injection were examined for gamete differentiation either by DAPI staining or fertility. For DAPI analysis, adult hermaphrodites displaying RNAi induced phenotypes were fixed overnight in Carnoy's solution (60% ethanol; 30% acetic acid; 10% chloroform; Sulston and Hodgkin, 1988). The mitotic index is defined as the ratio between the number of prophase, metaphase, anaphase, and telophase nuclei and the total number of nuclei in the MPZ.

Piwi mutations eliminate the growth, proliferation and self-renewing division of germline stem cells. *piwi*<sup>1</sup> mutant ovaries contain a normal number of mispositioned GSCs at the onset of oogenesis at the late third instar larval stage, which, however, leads to an equal or somewhat smaller number of gametes in the adult gonads that no longer contain GSCs (Lin and Spradling, 1997). This failure of germline maintenance could be due to: (1) the differentiation of GSCs without growth, proliferation and self-renewing divisions; (2) a defect in the asymmetry of GSC division, producing aberrant germ cells that eventually degenerate; and/or (3) a secondary defect influenced by abnormal ovary differentiation.

To examine whether the failure of germline maintenance is indeed a secondary defect due to abnormal ovary development, the ovarian morphology of *piwi*<sup>2</sup> and *piwi*<sup>3</sup> mutants which also fail to maintain GSCs was examined. The examination relied on Nomarski optics as well as markers that specifically identify germ cells, somatic cells, and spectrosomes/fusomes, germline specific organelles that indicate individual stages of germ cell development (Lin et al., 1994; Lin and Spradling, 1995). These mutant ovaries show normal



morphology at the third instar larval stage. Their germline cells are normal in number and are correctly positioned along the medial plane of the ovary. Moreover, the expected number of terminal filaments are forming, so that at the pupal stage, the ovary differentiates normally, partitioning GSCs and their daughter cells correctly into individual germaria and ovarioles. GSCs are able to divide several times to provide a normal complement of germ cells to the germarium. Yet, GSCs subsequently fail to continue self-renewing divisions, and the existing germline cysts often degenerate during the late pupal stage so that the adult ovarioles contain germlineless germaria and fewer egg chambers than expected. These observations indicate that the failure of GSC maintenance in *piwi* mutants is not a secondary defect due to abnormal ovary development.

To examine whether the failure of GSC maintenance is due to differentiation without self-renewing divisions or due to aberrant divisions followed by degeneration, the ovarian development of the *piwi*<sup>1</sup> mutant was examined more closely. The *piwi*<sup>1</sup> third instar larval ovaries contain a normal number of 50-70 presumed GSCs that are mis-positioned. However, these GSCs still seem to, and indeed must have, partitioned during subsequent pupal development, since the number of ovarioles formed in most adult ovaries is within the normal range ( $13 \pm 3$  in mutant vs.  $15 \pm 3$  in wildtype). Hence, the effect of *piwi*<sup>1</sup> on GSC mis-positioning is not essential for oogenesis.

The main oogenic defect of the *piwi*<sup>1</sup> mutant is the differentiation of GSCs without self-renewing divisions immediately following the initiation of oogenesis. At this stage in wildtype ovaries, GSCs in 16-23 newly formed germaria have initiated asymmetric divisions to generate multiple developing germline cysts. However, in mutant ovaries, GSCs and their immediate differentiated daughters, cystoblasts, are undetectable, as indicated by the absence of spectrosome-containing germ cells. Instead, most ovaries contain differentiated germline cysts whose number approximately equals that of GSCs. These cysts are much larger in size and contain 2- to multi-cell stage fusomes, indicating their differentiating state. By the adult stage, most ovarioles contain only two normal or abnormal egg chambers derived from

these cysts, but no other germline cells. This defect contrasts the development of wildtype ovaries, in which ovarioles contain a fully developed germarium and a stage 1 egg chamber by the 48-hour pupal stage, and have produced multiple egg chambers by adult stage. This observation indicates that the mutant GSCs have differentiated into germline cysts without self-renewing divisions. The abnormal fusome morphology often seen in cysts suggest that they contain more or less than the normal number of 16 cells, which indeed was seen in adult egg chambers.

Thus, *piwi* is required for the self-renewing division of GSCs during oogenesis in *Drosophila*. Confocal images showing third instar larval ovaries from wild-type, *piwi*<sup>2</sup>, and *piwi*<sup>1</sup> mutant flies, respectively, were prepared and stained with a germline specific marker VASA in green and spectrin in red to mark somatic cells and spectrosomes/fusomes. GSCs were positioned medially along the anterioposterior axis in the wild-type and *piwi*<sup>2</sup> ovary; however, GSCs are mispositioned in the *piwi*<sup>1</sup> mutant ovary. Spectrosomes (Sp) appear as red dots in germ cells. A 50µm measurement bar was used in the analysis of the confocal images.

Confocal images of 24-hour pupal ovaries from wild-type and *piwi*<sup>1</sup> mutant flies, respectively, were prepared, with wild type stained solely for VASA while *piwi*<sup>1</sup> mutant was stained for both VASA in green and spectrin in red. At this stage, the wild-type ovary has partitioned into individual germaria (Ge), which contain GSCs and early germline cysts. In *piwi*<sup>1</sup> mutant ovaries germ cells still appear to have been partitioned, although the partition is distorted by the highly differentiated large germline cysts containing elaborate fusomes (Fu). The number of cysts did not exceed the number of GSCs.

Confocal images of 48-hour pupal ovaries from wild-type, *piwi*<sup>2</sup> and *piwi*<sup>1</sup> mutant flies, respectively, were prepared and stained with VASA in green and spectrin in red. By this stage, in both wild-type and *piwi*<sup>2</sup> mutant ovaries, germaria have fully developed and stage 1 egg chambers (S1) have budded off the germarium in synchrony due to continued GSC division. However, in *piwi*<sup>1</sup> mutant ovaries, the number of germline cysts remained unchanged, despite their continued differentiation.

A confocal image of a 72-hour pupal ovary from *piwi*<sup>2</sup> mutant flies was prepared and stained with VASA in green and spectrin stained in red. At this stage, GSCs fail to self-renew and some existing germline cysts start to degenerate. DAPI images of 0-1 day old adult ovarioles from wild-type, *piwi*<sup>2</sup> and *piwi*<sup>1</sup> mutant flies, respectively, were also prepared. Both *piwi*<sup>1</sup> (L) and *piwi*<sup>2</sup> (H) mutant ovarioles typically contain two normal or abnormal egg chambers connected to a germlineless germaria (Ge). In contrast, wild-type ovarioles contain a long string of developing egg chambers produced continuously by the germarium. *piwi*<sup>3</sup> phenotype is indistinguishable from that of *piwi*<sup>2</sup>.

Molecular cloning of *Drosophila piwi*. To study the molecular nature of the *piwi*-mediated mechanism, a 15 kb genomic region flanking the *piwi* insertions was cloned. Candidate transcripts in the region were identified, and a 6.8 kb genomic fragment (pRc12) containing a 3.1 kb transcript interrupted by *piwi* mutations (transcript c12) was able to rescue the *piwi* phenotype completely (Fig. 1). An overlapping 3.9 kb genomic fragment (pRLD) containing a 1.43 kb transcript immediately adjacent to the *piwi* mutations fails to rescue the *piwi* phenotype (Fig. 1). Therefore, the c12 transcript is the *piwi* mRNA.

*Drosophila* PIWI represents a novel class of conserved proteins. To study the structure of the *piwi* gene, two overlapping cDNA clones which together represent the 3.1 kb full length c12 mRNA were isolated and sequenced. The c12 cDNA sequence contains a large open reading frame (ORF) starting at +84 bp and encoding a protein of 843 amino acid residues with a predicted molecular weight of 97.2 kD (SEQ ID NOs:1 and 2). Multiple stop codons in all three frames are present upstream of the putative start codon. Downstream of the ORF is a 432 bp 3' untranslated region (UTR) followed by a 55-bp poly(A) tail not encoded in the genomic sequence. Thus, *piwi* RNA is present in *piwi*<sup>1</sup>/CyO adult males and females. Northern blots including female and male lanes containing approximately 10 and 1.5 mg of polyA<sup>+</sup> RNA, respectively, were prepared. They were exposed for 3.5 and 12 hours, respectively, and a band was observed at 3.1 kb in each lane.

The PIWI protein is a highly basic (pI 9.6) novel protein with no obvious similarity to other known proteins or functional motifs in the databases. It is characterized by alternating basic and acidic regions and is particularly basic over the C-terminal 100 amino acid residues. Hydropathy analysis indicates that the PIWI protein contains no significant local hydrophobic regions that could be potential signal peptide or transmembrane domains. PSORT analysis (Nakai and Kanehisa, 1992) predicts nuclear localization of the PIWI protein. The protein has 21 conserved protein kinase C phosphorylation sites, 14 casein kinase 2 phosphorylation sites, and 4 tyrosine phosphorylation sites, indicating its potential as a phosphorylation target.

To determine whether the PIWI protein is conserved during evolution, applicant searched for its homologous sequences at the protein level and identified two ORFs of unknown function from *C. elegans* and an expressed sequence tag (EST, AA430311) from a human testis cDNA library. Applicant isolated and sequenced cDNAs for the two *C. elegans* genes, herein named *prg-1* and *prg-2* (*prg* for *piwi*-related gene) to verify their homology to *Drosophila piwi*. The *prg-1* and *prg-2* genes share 40.1% and 38.5% amino acid identity to *piwi*, respectively, over their entire length. In the C-terminal 104 amino acid region, the homology increases to 55.8% and 56.7%, respectively. Moreover, *prg-1* and *prg-2* are 90% identical to each other over their full length and 98% identical at the C-terminus. This high degree of homology suggests that *prg-1* and *prg-2* may represent a gene duplication event. The two clones differ primarily in that *prg-1* is 60 amino acids longer at the N-terminus than *prg-2*. Using ACeDB (Thierry-Mieg and Durbin, 1992), *prg-1* was mapped to chromosome I between *unc-15* and *gld-1* in cosmid D2030 and *prg-2* was mapped to chromosome IV, between *unc-44* and *smg-7* on cosmid CO1G5.

To isolate human *piwi* homologs, the human EST (0.9 kb) clone was sequenced and used to screen a human testis cDNA library. A resulting 2.3 kb partial cDNA, herein named *hiwi* (for human *piwi*), shows 47.1% identical amino acid sequence to the *Drosophila piwi* over its full length, with 58.7% identity at the C-terminus. No *piwi*-related sequences were found from bacteria or yeast genomes whose entire sequences are known. This is consistent with

the stem cell-related function of *piwi* and indicative of *piwi* family-like genes specific for multicellular organisms.

In addition to the above *piwi* family homologs, a large number of putative and known proteins were identified from various animals and plants which share significant homology with *piwi* solely at their respective C-termini. This indicates that the *piwi* family is a large novel gene family. Within this family are 13 additional putative *C. elegans* proteins and three *A. thaliana* proteins, two of which are required for meristem cell divisions (Moussian, et al., 1998; Bohmert, et al., 1998). Particularly, between *piwi* and the three *Arabidopsis* genes, *ZWILLE* (*ZLL*) *argonaute* (*ago*), and *argonaute-like* (Moussian et al., 1998; Bohmert et al., 1998), an overall homology of approximately 20% amino acid identity was observed. The homology increases to 32% to 52% identity in four regions, 30-100 amino acid residues each, located throughout the length of the PIWI protein, including the highly conserved C-terminal region. Given the role of *ZLL* and *ago* in meristem cell division (Moussian et al., 1998; Bohmert et al., 1998), this homology may have important implications for a conserved stem cell mechanism.

PIWI, PRG-1, PRG-2, and HIWI differ from *ZLL* and *AGO* proteins, and especially from the 13 additional putative *C. elegans* proteins, predominantly at the N-terminus, suggesting that this region may be involved in *piwi*-specific function. The C-terminal conservation suggests that this region of PIWI may contain a novel functional domain that plays an important role for the general activity of these proteins in diverse biochemical processes, with the N-terminus rendering the specificity of the activity.

To examine the C-terminal region of homology more closely, the sequences were aligned using Block Maker™, which reveals characteristic regions of protein families (Henikoff et al., 1995) (Figure 2). Block Maker™ analysis identified a 43 amino acid domain conserved among all 22 proteins, within which five residues are absolutely conserved with defined spacing. Eight more residues are also conserved with defined spacing among all known genes across the phyla except for several *C. elegans* ORFs with unknown function. This region is referred to herein as the PIWI box and represents a

novel conserved functional motif. PIWI, that is the *piwi* family of gene products, thus represents a novel class of evolutionarily conserved proteins with conserved functionality, as described herein below.

5 *Drosophila piwi* mRNA is present in both the germline and soma during oogenesis. To investigate in which cells *piwi* is expressed to regulate GSC division, the expression pattern of *piwi* during oogenesis was examined by *in situ* hybridization of whole mount *Drosophila* ovaries with DIG-labeled DNA probes prepared from the *piwi* cDNA clone. *piwi* mRNA is detected specifically in the somatic terminal filament cells apical to GSCs in the germarium and  
10 anterior sheath cells as well as in the germline. In the germline, it is first abundantly expressed in region 2 of the germarium where 16-cell germline cysts are formed, persists at a lower level through stages 1-6 of oogenesis, is at its lowest level between stage 7-9, becomes strongly expressed again at stage 10, and eventually accumulates in early embryos (for staging, see King,  
15 1970). Given that removing sheath cells does not affect oogenesis whereas the terminal filament cells play a role in regulating GSC division (Lin and Spradling, 1993), it is likely that the somatic expression in the terminal filament is responsible for *piwi* function in regulating GSC division.

Thus, *piwi* mRNA expression in *Drosophila* ovaries was characterized.  
20 A complete *Ore-R* ovariole was studied and showed germline *piwi* expression in region II of the germarium (Gell) and in early stage egg chambers up to stage 10 (S10) was studied. In the germarium, the *piwi* RNA was also detected in the terminal filament cells (TF) and epithelial sheath cells (ES) apical to GSCs. *piwi* RNA was also observed to be uniformly present in early embryos.  
25 The aforementioned structures were reviewed on slides, and the slides included bars denoting 50  $\mu$ m, 10  $\mu$ m and 50  $\mu$ m for ovariole, germarium and early embryos, respectively, to facilitate review.

Piwi expression in apical somatic cells regulates GSC division while its expression in the germline provides a maternal component for embryogenesis.  
30 To examine the roles of somatic and germline *piwi* expression, genetic clonal analyses on *piwi*<sup>1</sup> and *piwi*<sup>2</sup> mutations was conducted. First, the germline requirement of *piwi* was tested by germline clonal analysis using the FLP-DFS

technique (Chou and Perrimon, 1996). The *ovo<sup>D1</sup>* dominant mutation blocks oogenesis at the very beginning stage in a cell-autonomous manner, so that *piwi<sup>+</sup> ovo<sup>D1</sup>* females contain germ cells that never differentiate beyond the germarium. In this *ovo<sup>D1</sup>* background, applicant generated germline cells homozygous for either the *piwi<sup>1</sup>* or *piwi<sup>2</sup>* mutation by applying a heatshock treatment at the second and early third instar larval stage. The resulting adult females developed some completely normal ovarioles in which germline cells at all stages of oogenesis were observed, and mature eggs were continuously being produced (see Table 3).

This result demonstrates that removing the *piwi<sup>+</sup> ovo<sup>D1</sup>* chromosome from the germline allows oogenesis, including GSC division, to occur normally. Thus, the requirement of *piwi* for GSC division does not reside in the germline but in somatic cells.

Eggs produced from homozygous *piwi<sup>1</sup>* or *piwi<sup>2</sup>* GSC clones are arrested in embryogenesis, not rescuable by the paternal *piwi<sup>+</sup>* gene (see Table 3). Approximately 30% of the arrested embryos show severe mitotic defects during cleavage stage. The remaining embryos show various morphological defects during late embryogenesis, including a high frequency of severe deformation of the head region. These defects demonstrate that *piwi* expression in the germline provides an essential maternal contribution for embryogenesis.

To determine whether *piwi* is required in somatic cells outside the ovary for GSC maintenance, wildtype germaria were transplanted into the abdominal cavity of homozygous *piwi<sup>2</sup>* and wildtype females, which produced  $17 \pm 0$  egg chambers ( $n=13$ ) after 7 days of incubation in the host. Parallel transplantation into wildtype host yielded  $16 \pm 2$  egg chambers ( $n=5$ ), indicating that the wildtype germaria continued oogenesis at a normal rate in the *piwi<sup>2</sup>* females. Hence, *piwi* is not required in extra-ovarian cells for GSC maintenance.

To determine in which group of ovarian somatic cells *piwi* is required for GSC maintenance, applicant used a similar FRT-mediated technique for somatic clonal analysis of *piwi<sup>1</sup>* and *piwi<sup>2</sup>*, marking the *piwi<sup>+</sup>* chromosome with a transgenic myc tag so that homozygous *piwi<sup>-</sup>* somatic cells are identified by

-90-

their lack of myc epitope expression (Xu and Rubin, 1993). By inducing mitotic recombination at the second and third instar larval stages, *piwi*<sup>-</sup> somatic clones were generated throughout ovarioles, with some egg chambers completely covered by *piwi* mutant follicle cells. These egg chambers develop normally, indicating that *piwi* function is not required in follicle cells for egg chamber development. Since follicle cells are derived from their precursor cells in region II of the germarium (Margolis and Spradling, 1995), this suggests that *piwi* is not required in somatic cells from germarial region II on for GSC division and ovarian development. These results, together with the *piwi* expression pattern *in situ*, suggest that *piwi* is required in somatic cells in the anterior-most tip of the germarium to regulate GSC division.

Thus, *piwi* function is dispensable in the germline and differentiated follicle cells for GSC division. A pair of ovaries containing ovarioles with homozygous *piwi*<sup>-</sup> germline clones and ovarioles with *piwi*<sup>+</sup> *ovo*<sup>D1</sup> germline stained for DAPI to mark DNA and for VASA to mark germ cells for observation via confocal microscopy. The *piwi*<sup>+</sup> *ovo*<sup>D1</sup> germline cells were arrested at the beginning of oogenesis in the germarium due to the *ovo*<sup>D1</sup> mutation. By contrast, in ovarioles in the left ovary containing *piwi*<sup>-</sup> germline clones, GSCs divided normally, giving rise to a progression of morphologically wild-type egg chambers which eventually develop into mature eggs. This indicates that *piwi* is not required in the germline for GSC division and subsequent steps of oogenesis. To facilitate confocal microscopy, bars denoting 100 µm were employed in each slide.

Confocal microscopy was also employed to show that *piwi*<sup>-</sup> clones in differentiated follicle cells do not effect normal GSC division and egg chamber development. Egg chambers were stained with DAPI and a monoclonal anti-MYC antibody. Absence of MYC staining was indicative of homozygous *piwi*<sup>-</sup> clones. Induction of somatic clones around an entire early stage egg chamber had no effect on GSC division and oogenesis. Similarly, removing *piwi* function from some follicle cells of later stage egg chambers also had no effect on oogenesis. Therefore, *piwi* function is dispensable in differentiated follicle cells



for oogenesis including GSC division. To facilitate confocal microscopy, bars denoting 50  $\mu$ m were employed in each slide.

*piwi*-like genes in *C. elegans* are also required for germline self-renewal.

The high degree of sequence homology between *piwi* and its homologs in other organisms suggests a potential functional conservation. This hypothesis was tested in *C. elegans*. Guo and Kemphues (1995) have shown that the injection of specific antisense RNA into the germline syncytium of *C. elegans* eliminates maternal and zygotic gene activity, producing a gene-specific loss-of-function effect that may persist through several generations. This technique, as refined by Fire et al. (1998) and termed RNA-mediated interference (RNAi), was used to assess the function of *prg-1* and *prg-2*. Given the extremely high homology between *prg-1* and *prg-2*, an anti-*prg-1* RNA was used for injection to interfere with the function of both genes. The F1 progeny of the injected worms were designated as *prg-RNAi* worms for simplicity.

In wild-type *C. elegans*, two germline precursor cells, Z2 and Z3, give rise to approximately 2000 germ cells in the adult hermaphrodite. Germline proliferation occurs throughout most of larval development (L1-L4) and continues in the adult. This proliferation and maintenance of the germline requires signals from the DTC at the tip of each gonadal arm. During gonadal development, DTC migration results in the formation of two U-shaped gonadal arms by the L4 stage. Germline proliferation is limited to the distal end of each arm, forming a mitotic proliferation zone (MPZ) which serves as the GSC equivalent in *C. elegans*. Moving proximally, near the U turn of the gonad, germ cells enter meiotic prophase and then further differentiate into gametes at the proximal half of each arm, producing sperm in L4 and then oocytes in young adults.

The phenotype of *prg-RNAi* worms was examined both by quantitating their fertility and by assessing their gonadal and germline development via DAPI staining and Nomarski optics. As controls for RNA injection, worms were injected with BlueScript plasmid RNA sequences.

The *prg-RNAi* worms show three major aspects of germline defects. First, as indicated by the distribution of the number of progeny per F1 animal

-92-

(Fig. 3), the fertility difference between the *prg-RNAi* and control worms is highly significant ( $t$  value=7.93,  $p<0.0001$ ). On average, *prg-RNAi* worms produced  $92\pm 53$  progeny ( $n=99$ ), with 75.5% of *prg-RNAi* worms giving rise to fewer than 125 progeny. By contrast, control RNAi animals on average produced  $191\pm 40$  progeny ( $n=20$ ), with 90% of these animals giving rise to greater than 125 progeny. The significant reduction of the fertility, as well as other defects described below, may still only reflect a partial loss of *prg-1* and *prg-2* function, since the RNAi technique is known to phenocopy partial rather than complete loss-of-function mutants (Kuwabara, 1996).

Second, DAPI staining reveals a dramatic shortening of MPZ in *prg-RNAi* worms. On average, adult *prg-RNAi* worms exhibited a 50% reduction in the number of mitotic nuclei as compared to control animals. Associated with the reduction of the mitotic zone is a gonadal shortening. 57% of *prg-RNAi* worms ( $n=287$ ) exhibited a moderate to severe shortening. In the most severe case, the gonadal arm never made the U-turn. The number of sperm produced in these worms is greatly reduced as well. By contrast, only 7% of the BlueScript-RNA-injected control animals ( $n=548$ ) exhibited a mild gonadal shortening. The above observed gonadal defects in *prg-RNAi* worms indicate that *prg-1* and *prg-2* are essential for germline proliferation and maintenance. Since the gonadal shortening may be due to a defect in DTC migration, it is also possible that *prg-1* and *prg-2* play a role in proper gonadogenesis.

Thus, reducing *prg* activity results in reductions in both the MPZ and the mitotic index. Variable defects in both the size of the MPZ and the mitotic index were observed by DAPI staining and preparation of photomicrographs of same. The MPZ in each micrograph was denoted in white brackets. In moderate to severely defective animals, a 50% reduction in the number of mitotic nuclei and a concomitant five-fold reduction in the mitotic index were typically observed. A measurement bar was included in the wildtype photomicrograph and denoted 100  $\mu\text{m}$  for all panels.

In addition to the MPZ shortening, the mitotic index in the remaining mitotic zone is further reduced by 5.5 fold from  $(7.1\pm 2.2)\%$  ( $n=1,339$  nuclei,  $n_s=10$  worms) in the control RNAi injected worms to  $(1.3\pm 0.8)\%$  ( $n=1,409$

nuclei,  $n_s=10$  worms) in *prg-RNAi* worms with mildly to moderately shortened gonads. This indicates the important role of *prg-1* and *prg-2* in maintaining the mitotic ability of the germline stem cell nuclei.

*Drosophila piwi* is required for the self-renewing divisions of stem cells in the germline. The above experimentation demonstrates that *piwi* provides for female and male GSC maintenance predominantly by promoting the self-renewing division of GSCs. In a germarium, it normally takes at least 10 hours for a GSC division to occur and 5 days for a cystoblast to develop into a stage one egg chamber (King, 1970; Lin and Spradling, 1993). Necrosis and apoptosis during oogenesis are also easily detectable. Thus, examination of the *piwi* mutant phenotype at 24-hour intervals immediately prior to the onset of oogenesis is sufficient to monitor every major event in germline proliferation, differentiation, or cell death. Under these conditions, GSC divisions would have been detected as an increased number of germline cysts, whereas cell death process would have been easily detected by looking for pycnotic nuclei and necrotic bodies via DAPI staining and Nomarski optics (Lin and Spradling, 1993; Forbes et al., 1996a, b; Lin and Spradling, 1997). Numerous cases of GSC divisions and cell death in the germline during *Drosophila* oogenesis have been detected using these criteria (Lin and Spradling, 1993; Forbes et al., 1996a, b; Lin and Spradling, 1997).

Despite their high sensitivity, the techniques followed in this Example, even though more systematic, did not detect either GSC division or cell death in *piwi* mutants. Instead, immediately following the onset of oogenesis, only differentiating cysts were detected in *piwi*<sup>1</sup> mutant ovaries, with the cyst number generally corresponding to the number of GSCs. Although this does not rule out the possibility that infrequent GSC divisions or cell death might have been missed, which might account for the smaller-than-expected number of gametes sometimes observed in adult *piwi* mutants, these factors do not weaken the conclusion that the predominant defect of *piwi* mutants is the differentiation of GSCs without accompanying self-renewing division.

A number of elegant studies have identified genes that regulate germline proliferation. In mammalian systems, mechanisms mediated by paracrine

factors such as the *Steel* factor (the ligand of the *c-Kit* receptor tyrosine kinase), leukemia inhibitory factor (LIF), and basic fibroblast growth factor (bFGF), control the proliferation and survival of primordial germ cells, i.e., the precursors of GSCs (reviewed in Lin, 1997). In *C. elegans*, the LAG-2/GLP-1 pathway is essential for the self-renewal of a stem-cell equivalent population of germline nuclei in the gonad (reviewed in Kimble and Simpson, 1997). In the *Drosophila* ovary and testis, the BAM-mediated mechanism is involved in the further development of the differentiated GSC daughter (McKearin and Ohlstein, 1995); the *dpp* pathway plays a similar role in testis (Matunis et al. 1997). More recently, this pathway has been shown to be essential for GSC division and maintenance in the ovary (Xie and Spradling, 1998). Among these discoveries, *piwi* is the first gene known to mediate a somatic signaling mechanism to regulate the division and maintenance of GSCs in *Drosophila*. It therefore provides an important entry point for studying the somatic control of stem cell division in the germline.

The *piwi* gene family and the conservation of a stem cell self-renewing mechanism. The identification of *prg-1* and *prg-2* in *C. elegans* and *hiwi* in human suggest that *piwi* represents a novel class of evolutionarily conserved genes (described herein as the "*piwi* family") with potentially important functions in GSC self-renewal. Among this class of genes, the significantly higher homology between *piwi* and *hiwi* as compared to that between *piwi* and *prg-1/prg-2* suggests that *hiwi* function is closer to *piwi*. Consistent with this, GSC division and gametogenesis in humans are much more similar to that in *Drosophila* than that in *C. elegans* whose gonads contain syncytial mitotic germline nuclei which divide symmetrically and are capable of self-renewing only as a population. The RNAi experiments described herein, which likely interfered with the activity of both *prg-1* and *prg-2* due to their extremely high homology, caused germline depletion similar to that in *piwi* mutants. This suggests that the *piwi*-mediated mechanism in germline self-renewal is conserved even in this evolutionarily distant organism without stereotypic GSCs.

The conservation of the *piwi*-mediated mechanism appears to extend to the plant kingdom as well. A level of homology between PIWI and ZLL and AGO was observed. Intriguingly, ZLL is essential for maintaining stem cells of the shoot meristem in an undifferentiated state during the transition from embryo-specific development to repetitive organ formation through the self-perpetuating shoot meristem divisions (Moussian et al., 1998). AGO also plays an important role in maintaining normal apical shoot meristem function (Bohmert et al., 1998). Thus, the homology between *piwi* and ZLL and *ago* further suggests the existence of a family of novel genes essential for stem cell division in diverse organisms.

The conserved *piwi* mechanism may mediate cell-cell interactions. In *Drosophila*, genetic mosaic and *piwi* expression analyses together suggest that *piwi* function is required in the apical non-mitotic somatic cells to control GSC division. Similarly, in *A. thaliana*, it is thought that ZLL is required to maintain the undifferentiated state of shoot meristem stem cells by relaying positional information, possibly by mediating cell-cell interactions within the center of the shoot meristem (Moussian et al., 1998).

Stem cells are characterized by two common properties that extend across diverse species: the capacity for self-renewal and the ability to give rise to numerous progeny that are fated for further differentiation (for review see Lin, 1997; Morrison et al., 1997). Although significant progress has been made in identifying genes important for stem cell function, no common molecular mechanism shared by diverse stem cell types in diverse organisms has been characterized with respect to those two basic stem cell properties. The *piwi* gene family represents the first class of such genes. The analysis of the *piwi* gene family, therefore, provides an important first step towards the elucidation of molecular mechanisms underlying stem cell divisions.

The analyses of this Example were extended to homologs in *C. elegans*, an isolated human homolog (*hiwi*), and identified two *piwi*-like genes in *Arabidopsis* which are known to maintain meristem cells. This work reveals a new class of genes that play an essential role in stem cell division in multicellular organisms ranging from invertebrates to humans and plants.

-96-

Table 2

*piwi*<sup>1</sup> rescue results by pRc12 and pRLD<sup>a,b</sup>

	<i>piwi</i> <sup>1</sup> / <i>piwi</i> <sup>1</sup>	<i>piwi</i> <sup>1</sup> /CyO	<i>pRc12; piwi</i> <sup>1</sup> / <i>piwi</i> <sup>1</sup>	<i>pRLD; piwi</i> <sup>1</sup> / <i>piwi</i> <sup>1</sup>	
5	females	0 (136)	100 (45)	100 (39)	0 (81)
	males	0 (119)	97.8 (47)	88.4 (43)	0 (64)

<sup>a</sup>The percentage of fertile flies for each genotype and sex are indicated. The number of individuals tested for fertility (n) is in parentheses.

<sup>b</sup>Data are pooled from 6 and 4 independent insertion lines on the X and 3rd chromosomes for pRLD and pRc12, respectively. Not included are two other pRc12 rescue lines which showed sex-specific restoration of fertility, presumably due to position effects stemming from the insertion site.

Table 3

*piwi* function in GSC division is soma-dependent, while its function in embryogenesis is germline dependent\*

15	FLP/FRT <i>ovo</i> <sup>D1</sup> -induced germline clones	Heatshock	N	Avg. # eggs
	% embryos	laid/female	hatched	
	(a) <i>piwi</i> <sup>1</sup> , FRT/ <i>ovo</i> <sup>D1</sup> , FRT x <i>Oregon</i> <sup>R</sup> males +	37	50.4	0
	(b) <i>piwi</i> <sup>2</sup> , FRT/ <i>ovo</i> <sup>D1</sup> , FRT x <i>Oregon</i> <sup>R</sup> males +	26	66.7	0
20	(c) <i>piwi</i> <sup>1</sup> , FRT/ <i>ovo</i> <sup>D1</sup> , FRT x <i>Oregon</i> <sup>R</sup> males -	44	0	na
	(d) <i>piwi</i> <sup>2</sup> , FRT/ <i>ovo</i> <sup>D1</sup> , FRT x <i>Oregon</i> <sup>R</sup> males -	26	0	na
	(e) <i>ovo</i> <sup>D1</sup> , FRT/CyO x <i>Oregon</i> <sup>R</sup> males +	20	0	na
	(f) <i>ovo</i> <sup>D1</sup> , FRT/CyO x <i>Oregon</i> <sup>R</sup> males -	10	0	na

25 \* In all tester and control crosses, a number (N) of newly eclosed females were allowed to lay eggs at 25°C for 2 days. In both *piwi*<sup>1</sup> and *piwi*<sup>2</sup> testers, germline develops beyond that of *ovo*<sup>D1</sup> mutant ovarioles only following heat shock, giving rise to numerous eggs. This indicates the generation of *piwi* germline clones and the dispensability of *piwi* function in the germline for  
30 normal GSC division. However, none of the eggs develop beyond

-97-

embryogenesis, indicating the germline *piwi* expression is required as a maternal component for embryogenesis. The *ovo<sup>D1</sup>*, FRT control females lay no eggs either with or without heatshock. na=not applicable.

### Example 2

5

#### Molecular Cloning and Expression Analysis of *Hiwi*,

#### A Human Homolog of the *Drosophila Piwi* Gene Essential for Germline Stem Cell Division and Embryogenesis

*piwi* is a novel gene first identified in *Drosophila* and was demonstrated to be essential for germline stem cell development in Example 1. In this  
10 Example the cloning of a 3.47 kb human *piwi* homolog that includes the whole open reading frame through cDNA library screening and 5' RACE is described. Sequence analysis showed high identity of HIWI to *Drosophila* PIWI, especially in the C-terminal domain of the protein. Chromosome mapping showed located  
15 *hiwi* to Chromosome 12q 24. 33, approximately 130kb from the AFM 295 ye5 marker. Northern blot analysis revealed that *hiwi* is only expressed in the testis among human adult tissues. The sequence and expression homology between human and *Drosophila piwi* genes suggested that *piwi* is conserved during evolution and plays an important role during early stages of spermatogenesis in human.

20

Human spermatogenesis followed a precise and coordinated manner in the seminiferous epithelium of testis (reviewed in Bellve, 1979; Thomas et al., 1989; Hoog, 1995). During this period the germ cells undergo a series of stage-specific morphological transitions, beginning with the proliferation and renewal of spermatogonia, followed by meiosis of spermatocytes, and finished by  
25 differentiation of spermatids during spermiogenesis (Oakberg, 1956a; Nebel et al., 1961; Bellve et al., 1977; Russel et al., 1990). Closing to the basal membrane, type A spermatogonia are stem cells (Bartmanska and Clermont, 1983; De Rooij, 1988), undergoing a series of mitoses to give rise to more type A cells or produce type B spermatogonia which passes through a mitotic  
30 division to differentiate into spermatocytes.

-98-

Spermatocytes need to undergo a final round of DNA replication before entering meiosis. During meiosis, the synaptonemal complex and the recombination nodule become associated with chromosomes, which was thought to be important for two basic tasks in meiosis, the reduction of ploidy level and generation of new combinations of genes (reviewed in von Wettstein et al., 1984). The most radical morphological changes occurred during spermiogenesis (Oakberg, 1956b). Based on acrosome formation and nuclear condensation, the round spermid differentiated into mature spermatozoa which released into the lumen indicating the end of the spermatogenesis (reviewed in Bellve and O'Brien, 1983).

The proliferation and differentiation of germ cells in the seminiferous tubule has been demonstrated to be associated with adjacent somatic cells, the Sertoli cells (reviewed in Russel and Griswold, 1993; Griswold, 1995; Bitgood et al., 1996; de Miguel et al., 1997). The tubule of human testis is composed of germ cells in all stages of spermatogenesis. From basal membrane to lumen are cells ranging from stem cell to differentiated cell state and from proliferation to differentiation stage. Particular cell at particular developmental stage is associated with others at given sites in the tubule, the least mature stem cells are located furthest outside, while the most mature spermatozoa are located inside the seminiferous epithelium. The specific tubule organization and cellular association thus provide a good model system to study germ cell development.

Genes expressed in male germ cells had been identified in high mammals (Kramer and Erickson, 1982; Gold et al., 1983; Thomas et al., 1989; Wolgemuth and Watrin, 1991; Hoog, 1995). Some of these genes were expressed exclusively during spermatogenesis (reviewed in Willison and Ashworth, 1987; Erickson, 1990; Sandlow et al., 1997; van Roijen et al., 1998), while others were expressed only in the later stages of spermatogenesis (Shankar et al., 1998; Zhu and Naz, 1998). However, very few genes had been demonstrated that was expressed specifically in the early stage of spermatogenesis, in the stem cells (Menke et al., 1997).



To study the mechanisms of *piwi* family function in germline stem cells in various organisms during evolution and especially its role in human beings, molecular cloning and expression analysis of human *piwi* family homolog was performed.

5        5'-RACE. A 2.3kb partial human *piwi* family cDNA clone was first isolated from adult human testis cDNA library through library screening. To obtain the 5' end of this gene, a cDNA synthesis primer and a gene specific primer has been designed. Adult human testis Poly A+ RNA was purchased from Clontech, Palo Alto, California. First-strand cDNA was obtained by using  
10       the above cDNA synthesis primer and AMV reverse transcriptase (Clontech, Palo Alto, California). Second-strand synthesis cDNA synthesis was performed with second-strand enzymes bought from Clontech, Palo Alto, California subsequently. Using the above gene specific primer and an adaptor primer obtained from Clontech, Palo Alto, California, an 1.4kb fragment has been  
15       obtained through 5'-RACE PCR by using Marathon™ cDNA Amplification Kit (Clontech, Palo Alto, California) and has been cloned into a pGEM-T Easy vector (Promega, Madison, Wisconsin) subsequently.

Construction of a full length human *piwi* homolog and its sequence analysis. The fully-length *hiwi* cDNA was generated in a modified pGEM-T  
20       Easy vector (Promega, Madison, Wisconsin) by partial digestion of above two overlapping cDNA fragments with *SacI* and subsequent ligation with T<sub>4</sub> DNA ligase (Gibco). The full length human *piwi* family homolog was sequenced fully on both strands using an ABI 377 Prism™ DNA Sequencer (Perkin-Elmer, Applied Biosystems) and analyzed using the DNASTar™ sequence analysis  
25       package (DNASTAR, Madison, Wisconsin). Homologous comparison between *hiwi* and its homologs was carried out using the Megalign™ program from the DNASTar™ package.

Chromosome mapping. Radiation Hybrid mapping against Stanford G3 Human Hamster panel was used for chromosome mapping for *hiwi*.

30       Northern Blot Analysis. A 0.9kb EST fragment used for Northern blot analysis was purchased from ATCC (American Type Culture Collection) and was subcloned into a pBlueScript KS(+) vector (Stratagene) with *EcoRI* and

-100-

*HindIII*. The 3.47kb plasmid DNA obtained from 5'RACE was used to make sense and antisense RNA probes for *in situ* hybridization. The above plasmid DNA were linearized with appropriate restriction enzymes. Using these linearized template DNA, sense and antisense RNA probes for Northern blot analysis and *in situ* hybridization were transcribed from the T7 and SP6 promoters with appropriate T7 and SP6 RNA polymerase (Gibco), following the protocols suggested by manufacturers. Probes used for Northern blot analysis were labeled by <sup>32</sup>P-UTP (Amersham).

Premade Northern blot of high-quality poly A+ RNA from different human tissues (Human Multiple Tissue Northern Blot II) was purchased from Clontech, Palo Alto, California. Human  $\beta$ -actin cDNA probe (Clontech, Palo Alto, California) was used as a positive control. ExpressHyb™ Hybridization Solution (Clontech, Palo Alto, California) was used as hybridization buffer for Northern analysis. The hybridization for both sample blot and positive control was performed under 68°C for 2 hours followed by 2 washes in 2x SSC, 0.05% SDS for 50 minutes at room temperature, and another 2 washes in 0.1x SSC, 0.1% SDS for 40 minutes at 50°C. The sample blot was exposed at -80°C for 10 hours while the positive control was exposed for 2 hours at the same temperature.

Cloning of full-length human *piwi* cDNA clone. An isolated 2.3 kb partial human *piwi* cDNA clone from a human testis library by library screening is described in Example 1. To obtain the 5' end of this gene, by using a gene-specific primer, a 1.4 kb cDNA fragment containing overlapping sequence was obtained through 5'RACE and subcloned. To obtain a full length human *piwi* family clone, the above overlapping cDNA clones were partially digested. Fragments of the correct sizes were subsequently ligated and subcloned into a pGEM-T Easy vector (Figure 4) to generate the 3472 bp full-length human *piwi* family (*hiwi*) that includes an open reading frame (ORF) encoding a protein of 861 amino acids, with a predicted molecular weight of 94.71kDa (Fig. 7 and Fig. 8). The ORF starts at 167bp and stops at 2749bp. Upstream of the start codon is a 166bp 5'untranslated region (5'UTR). Downstream of the stop codon is a 723bp 3'untranslated region (3'UTR).

-101-

Protein sequence analysis showed that HIWI is 36.6% identical to *Drosophila* PIWI at amino acid level over its full length and 58.7% identical at the C terminal 104 amino acid residues. HIWI also shares 33.4% and 33.1% identity with two *C. elegans* PIWI family homologs PRG-1 and PRG-2 over its full length while the percentage increased to 57.7% and 58.7% at the C-terminals, suggesting *piwi* family genes and gene products are conserved during evolution. In addition, the higher degree of sequence homology between the C terminals suggests a conserved role of the C-terminal domain of PIWI in protein function.

10        Chromosomal mapping of *hiwi*. By using Radiation Hybrid mapping method against the Stanford G3 panel, human *piwi* was mapped to chromosome 12q 24. 33, approximately 130kb from the AFM 295 ye5 marker.

15        Tissue distribution of *hiwi* in adult human. Northern blot analysis were performed to study the tissue distribution of *hiwi* in adult human tissues. A variety of human tissues were examined, including spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte. Among them, two transcripts were detected in testis: a more abundant 3.6kb band and a less abundant band of 8.1kb. No expression was found in other analyzed tissues, consistent with the known functions of *hiwi* in GSC division.

20        An autoradiograph of Northern blot analysis of *hiwi* mRNA in adult human and mouse tissues was thus prepared. The expression of *hiwi* mRNA in different tissues: spleen; thymus; prostate; testis; ovary; small intestine; colon; peripheral blood leukocyte. Two *hiwi* transcripts of 3.6kb and 8.1kb are visible in testis. Human  $\beta$ -actin cDNA probe was used as a positive control for the Northern blot with above tissues.

25        The specific expression of *hiwi* in the testis is contemplated to modulate the mechanism of some human genetic diseases related to testis malignancy and/or infertility. *hiwi* and other mammalian *piwi* family genes play an important role in germline stem cell division and other stem cell-related processes and are thus contemplated to be useful in the therapeutic methods, the screening methods, and the diagnostic and prognostic methods of the present invention set forth herein.

30

-102-

Example 3Molecular Cloning and Expression Analysis of *miwi*,a Murine Homolog of the *Drosophila piwi* Gene

SEQ ID NOs:3 and 4 depict the cDNA and protein sequences of *miwi*,  
5 the murine homolog of the *piwi* gene in the *piwi* family. These sequences were  
purified and isolated as described in Examples 1 and 2 using a murine testis  
cDNA library and murine testis mRNA as starting materials. The genomic locus  
of *miwi* is depicted schematically in Figure 5. Additionally, homology alignment  
between the PIWI, HIWI, MIWI, PRG-1 and PRG-2 proteins is analyzed in  
10 Figure 6.

RNA *in situ* hybridization of a *miwi* probe to sections of wildtype mouse  
testis was also performed. *miwi* is expressed specifically in the germline stem  
cell region in the mouse testis at specific stages of the seminiferous tubule  
cycle. Color photographs of RNA *in situ* hybridization of a *miwi* probe to  
15 sectioned wildtype mouse testis were prepared. A measurement bar denoting  
40µm was employed in each photograph.

The murine *piwi* family gene and gene product (*miwi*) thus also plays a  
role in germline stem cell renewal and in other developmental processes based  
on the following important data and reasoning. First, *miwi* is more homologous  
20 to *piwi* than *prg-I*, *prg-II*, *Zwille* and *ago* to *piwi* (see Example 1 and Figure 6).  
Next, murine germline stem cells are much more similar to *Drosophila* germline  
cells than to the *C. elegans* germline or *Arabidopsis* meristem cells. Further,  
the function of *piwi* family genes are well conserved among *Drosophila*, *C.*  
*elegans*, and *Arabidopsis*, which are evolutionarily more diverse than between  
25 *Drosophila* and human/mammals. *miwi* is further shown to be expressed  
specifically in the germline stem cell region in the mouse testis. Finally, the  
specific expression pattern of *miwi* in the adult is in the murine testis, but not  
in the adult murine ovary which do not contain germline stem cells.

Therefore, *miwi*, as well as *hiwi* and other mammalian *piwi* family genes,  
30 play an essential role in germline stem cell division and other stem cell-related  
processes and are thus contemplated to be useful in the therapeutic methods,

the screening methods, and the diagnostic and prognostic methods of the present invention set forth herein.

#### Example 4

##### PIWI Family Proteins are Nuclear Proteins Whose Level

##### Determines the Number of Stem Cells In the Germline

Two immunofluorescence micrographs were prepared and showed germline cells (marked in green) in the *Drosophila* germarium in the background of normal and elevated level of PIWI. The ectopically elevated expression of *piwi* causes an increase in the number of stem cells and/or their immediate daughter cells (cystoblasts) from normally 2-3 to approximately 15, with 7 of which were shown in the focal plan of micrograph of elevated PIWI levels. Stem cells were marked by the spectrosome (Sp), an organelle specific to these cells. The differentiating germline cyst contains fusome (F), an organelle specific to mitotic stage of cyst development. Thus, over-expression of *piwi* increases the number of germline stem cells/cystoblasts.

Immunofluorescence micrographs of detection of a myc-tagged PIWI protein (with and without myc as a control) in *Drosophila* ovariole, *Drosophila* terminal filament, basal cells and GSC in *Drosophila* germarium, apical polar cells (APC) in *Drosophila* egg chambers, and hub cells in *Drosophila* testis were also prepared. These micrographs showed that PIWI is a nuclear protein present in both the germline and in somatic cells at different stages of oogenesis and spermatogenesis. myc-PIWI was shown to completely rescue the defects caused by loss of *piwi* function, thus demonstrating a therapeutic method of the present invention. PIWI is demonstrated to be a nuclear protein at certain development stages. MIWI and HIWI proteins are thus also contemplated to be nuclear proteins at certain development stages.

Additionally, as disclosed below, the PIWI protein can localize either in the nucleoplasm or cytoplasm, the dose of the PIWI protein determines both the number and the mitotic rate of germline stem cells, and the PIWI protein is localized in the germplasm (the cytoplasm of future germ cells) and plays a key role in determining the initial number of germ cells in during embryogenesis.

-104-

The mouse PIWI protein (i.e., MIWI protein) has also been observed in the cytoplasm via antibody screening and is thus also envisioned to be a cytoplasmic factor with very similar functions in germ cell and stem cell determination. Thus, the HIWI protein is thus also envisioned to be a cytoplasmic protein at certain development stages.

### Example 5

#### *piwi* Encodes a Nucleoplasmic Factor Whose Activity Modulates the Number and Division Rate of Germline Stem Cells

As disclosed above, *piwi* represents the first class of genes known to be required for stem cell self-renewal in diverse organisms. In the *Drosophila* ovary, *piwi* is required in somatic signaling cells to maintain germline stem cells. In this Example it is shown that that *piwi* encodes a novel nucleoplasmic protein present in both somatic and germline cells, with the highly conserved C-terminal region essential for its function. Removing PIWI protein from single germline stem cells significantly decreases the rate of their division. This is indicative of a second role for PIWI as a cell-autonomous promoter of germline stem cell division. Consistent with its dual function, over-expression of *piwi* in somatic cells causes an increase both in the number of germline stem cells and the rate of their division. Thus, PIWI is a key regulator of stem cell division—its somatic expression modulates the number of germline stem cells and the rate of their division while its germline expression also contributes to promote stem cell division in a cell-autonomous manner.

### Materials and Methods

*Drosophila* strains and culture. All *Drosophila* strains were grown at 25°C on yeast-containing molasses/agar medium. The following fly strains were used in this study: *piwi*<sup>1</sup> and *piwi*<sup>2</sup> mutant chromosomes, generated in different genetic screens (Lin and Spradling, 1997), were dominantly marked with *Irregular facets* (*If*) (Lindsley and Zimm, 1992); *ep(2)1024* is an EP element insertion (Rorth, 1996; Rorth et al., 1998) in the *piwi* 5' UTR; *piwi*<sup>1</sup>FRT40A/CyO and *piwi*<sup>2</sup>FRT40A/CyO; hsFlp; + FRT40A/CyO (Xu and

Rubin, 1993); *hsFlp*; *armadillo-lacZ* FRT40A (*armlacZ* FRT40A, Lecuit and Cohen, 1997); *hsGal4* (Brand and Perrimon, 1993) are as described herein above.

Generation of mutant germline stem cell clones. *piwi* mutant GSC clones were generated by Flp-mediated recombination as described by Xu and Rubin (1993). To generate wild-type and mutant GSC clones for analyses, *piwi*<sup>+</sup> FRT40A/CyO, *piwi*<sup>1</sup>FRT40A/CyO and *piwi*<sup>2</sup>FRT40A/CyO males were mated to *w* *hsFlp1*; *armlacZ* FRT40A virgin females, respectively, to produce *w* *hsFlp1*/+; *piwi*\* FRT40A/ *armlacZ* FRT40A progeny, where \* denotes the wildtype or mutant alleles. The parental adults were transferred to fresh vials after 2 days. Larvae from the original vials were heat-shocked once daily for 1 hour in a 37°C water bath on days 3 and 4 to induce mitotic recombination immediately prior to the onset of oogenesis at the late third instar stage as described herein above. After eclosion, adult *w* *hsFlp1*/+; *piwi*\* FRT40A/*armlacZ* FRT40A females were transferred to fresh food at room temperature and ovaries were removed 1 week, 2 weeks, and 3 weeks after the last heat shock treatment and processed for anti-lacZ antibody staining to look for lacZ-negative clones.

Heat-shock induced PIWI overexpression. To construct a *piwi*-overexpressing stock, *ep(2)1024*/CyO virgin females were crossed to males homozygous for a *hsGal4* transgene on chromosome 3. Females carrying both the *ep(2)1024* chromosome and the *hsGal4* transgene were heat shocked at 37°C for 1 hour each time with an interval of 12 hours for 3-4 days. At the end of the heat shock regime, ovaries were dissected and processed for antibody staining.

To analyze the functionality of the PIWI protein produced by *hsGal4*-induced overexpression of *ep(2)1024*, *ep(2)1024*/CyO; *hsGal4*/*hsGal4* virgin females were crossed to *piwi*<sup>1</sup>*lf*/CyO; +/+ males to produce the *ep(2)1024*/*piwi*<sup>1</sup>*lf*; *hsGal4*/+ transheterozygous progeny. After 2 days, parental adults were transferred to fresh vials. Larvae were heat shocked daily for 1 hour at 37°C starting at day 3 and continued to 3 days after eclosion. The transheterozygous progeny were subsequently dissected and processed for

antibody staining. The transheterozygous progeny which were not subjected to the heat shock regime served as controls.

Immunofluorescence microscopy and BrdU labeling. Ovaries and testes were dissected, fixed and stained as described by Lin et al. (1994). For immunofluorescence staining the following antisera were used: polyclonal anti-Vasa antibody (1:2000; Hay et al., (1990)), monoclonal anti-Hts antibody 1B1 (1:1; Zaccai and Lipshitz, (1996)), polyclonal anti- $\alpha$ -spectrin antibody (1:200; Byer et al., (1987)), monoclonal anti-myc epitope antibody 1-9E10.2 (1:50; Evan et al., 1985), monoclonal anti-BamC antibody (1:1000; McKearin and Ohlstein, 1995), polyclonal anti- $\beta$ -galactosidase antibody (1:600; Cappel, Costa Mesa, California), monoclonal anti-BrdU antibody (1:50; Becton-Dickinson, Franklin Lakes, New Jersey). All the fluorescence-conjugated secondary antibodies were from Jackson Immunoresearch Laboratory (Westgrove, Pennsylvania) and were used at 1:200 dilution.

Immuno-fluorescently labeled samples were also counter-stained with DAPI as described previously (Lin and Spradling, 1993). Micrographs were taken using either a Zeiss AXIOPLAN® microscope or a Zeiss LSM410™ confocal microscope (Zeiss, Oberkochen, Germany) as described herein above. BrdU labeling was performed essentially as described in Gonczy and DiNardo (1996). Briefly, on day 3 of the heat shock regime, *ep(2)1024*; *hsGAL4* females were transferred to an Eppendorf tube that was held horizontally and contained 100  $\mu$ l of 100 mM BrdU in grape juice. The flies were fed (pulse) with BrdU for 1 hour at room temperature. After the pulse, flies were returned to fresh vials without BrdU for 12 hours at room temperature (chase). These females were subsequently dissected and fixed for immunofluorescence labeling with anti-BrdU and anti- $\alpha$ -spectrin antibodies.

Construction of transgenes encoding N- and C-terminal-tagged PIWI proteins. Synthetic oligonucleotides (Gibco BRL) encoding a myc-epitope were cloned into unique sites at the N- and C-terminus of the *piwi* ORF in a 6.8 kb *piwi* genomic construct (pRc12) that fully rescues the *piwi* activity (Examples 1-4 above and Cox et al., 1998) as follows: For the N-terminal myc insertion, the following primers were used: *Bcl*/*myc*: 5'-GAT CAT ATG GAG CAA AAG



-107-

CTT ATT AGC GAG GAA GAT CTG AAT-3' (SEQ ID NO:7) and *Bcl/antisense myc*: 5'-GAT CAT TCA GAT CTT CCT CGC TAA TAA GCT TTT GCT CCA TAT-3' (SEQ ID NO:8). The primers were annealed according to the manufacturer's recommendations and cloned into a unique *Bcl* recognition site in a Bluescript clone containing *piwi* genomic DNA.

The resulting recombinant *myc-piwi* gene was cloned into pCasper 4 (Pirrotta, 1988) to produce the plasmid pPMB1-6 in which the *myc* sequence is inserted between PIWI amino acid residues 3 and 4. For the C-terminal *myc* insertion, the following primers were used: *Nhe/myc*: 5'-CTA GCA TAT GAG CAA AAG CTT ATT AGC GAG GAA GAT CTG AAT AAG-3' (SEQ ID NO:9) and *Nhe/antisense myc*: 5'-CTA GCT TAT TCA GAT CTT CCT CGC TAA TAA GCT TTT GCT CAT ATG-3' (SEQ ID NO:10). Primers were annealed as described above and cloned into a unique *Nhe* recognition site in a Bluescript clone containing part of *piwi* genomic DNA. The recombinant insert was cloned into pCasper 4 (Pirrotta, 1988) to produce the plasmid pPMN in which *myc* is inserted between PIWI amino acid residues 795 and 796. The insertions were confirmed by DNA sequencing.

P-element mediated germline transformation. Transgenic flies were produced according to Spradling and Rubin, 1982, using *w; 2-3 Sb e/TM6 e* (Robertson et al., 1988) embryos as recipients. Eight independent pPMB1-6 lines and twelve independent pPMN lines were recovered. The *myc*-tagged transgenes were then separated from the 2-3 transposase and introduced into the homozygous *piwi*<sup>1</sup> background for fertility tests by genetic crosses. Rescue crosses were carried out at 25°C. Each transgene was further tested for Myc expression by whole-mount immunofluorescence.

Immunoblotting analysis and *in vitro* translation. To prepare total protein extracts from pPMB1-6 transgenic flies, ovaries were dissected in 1X EBR (130 mM NaCl; 5 mM KCl; 2 mM CaCl<sub>2</sub>; 10 mM Hepes pH 6.9) and homogenized in 1X sample buffer (5% 2-mercaptoethanol, 3% SDS, 10% glycerol, 62.5 mM TrisCl pH 6.8, 0.1% bromophenol blue). Protein samples were boiled 5 minutes at 95°C and then loaded on 10% SDS-PAGE gels. After electrophoresis, gels were electro-transferred to Genescreen (NEN Research

-108-

Products, DuPont, Wilmington, Delaware) in a TRANS-BLOT® apparatus (Bio-Rad Laboratories, Inc., Hercules, California). Blots were blocked for 1 hour in Blotto (5% non-fat dry milk in 1X PBS) and primary antibodies were subsequently diluted in Blotto followed by an incubation overnight at 4°C. The monoclonal 9E10 anti-myc antibody (Evan et al., (1985)) was used at a dilution of 1:50. HRP-conjugated anti-mouse IgG secondary antibody (Jackson Immunoresearch Laboratory, Westgrove, Pennsylvania) was used at 1:4000. Blots were washed and processed for detection using enhanced chemiluminescent (ECL) reagents as recommended by the manufacturer (Amersham, Buckinghamshire, England). *In vitro* translation analysis was performed on the plasmid pDC2 to produce <sup>35</sup>S-labeled PIWI protein according to the manufacturer's recommendations (Promega, Madison, Wisconsin). The translation products were separated on a 10% SDS-PAGE gel and images were collected by exposing the gel to X-ray film.

Quantitation of germline stem cell division rate. Relative division rate of *piwi* GSCs was determined as follows: The number of marked *piwi* cysts in 30 germaria was counted to obtain the average number of the *piwi* cysts per germarium. This number is then divided by the average number of marked wild-type cysts per germarium as obtained from counting 20 germaria. The relative division rate of GSCs in the *piwi*-overexpressing germaria and that in the wild-type and un-induced *ep(2)1024* control germaria was determined by counting the frequency of telophase spectroosomes contacting the cap cells in the 2-3 GSCs in the most apical region of the germarium.

### Results

PIWI is a nuclear protein present in both the soma and germline in both sexes. Examples 1-4 above demonstrate that *piwi* encodes a 97.2 kDa novel protein required for the self-renewing division of GSCs in both males and females. To elucidate further the function of *piwi* in regulating GSC division, the expression and subcellular behavior of the PIWI protein was studied *in vivo*. The PIWI protein was tagged by inserting a sequence encoding a myc epitope (Evan et al., (1985)) into the *piwi* gene, at the 5' end of the *piwi* open reading

-109-

frame (Figure 2). The p[5'-myc-piwi] transgene (denoted as *myc-piwi*) was introduced into *Drosophila* via P-element mediated germline transformation (Spradling and Rubin, (1982)). *myc-piwi* fully restores the fertility and gametogenesis of *piwi*<sup>1</sup> mutant males and females (Table 4). Thus, the myc-PIWI protein confers wild-type PIWI function. In contrast, a p[*piwi*-3'-myc] transgene (denoted as *piwi-myc*) with the *myc* sequence inserted in the highly conserved C-terminal region (Fig. 7) fails to rescue any *piwi* mutant phenotype (Table 4). The PIWI-myc protein was not detectable either by Western blotting analysis or by immunostaining of the transgenic ovaries (Table 4), indicating that this region is essential at least for the stability of the PIWI protein.

Table 4  
Rescue of the *piwi1* phenotype and myc expression by myc-PIWI and PIWI-myc<sup>1</sup>

# of independent transgenic lines	Staining for myc	rescue of <i>piwi</i> <sup>1</sup> fertility <sup>2</sup>						
		female			male			
		<i>piwi</i> <sup>1</sup>	<i>myc;piwi</i> <sup>1</sup>	<i>piwi</i> <sup>1</sup> /CyO	<i>piwi</i> <sup>1</sup>	<i>myc;piwi</i> <sup>1</sup>	<i>piwi</i> <sup>1</sup> /CyO	
myc-PIWI	8	100% (8)	0	34.9±6.8	30.9±8.7	0	49.8±6.7	49.8±0.6
PIWI-myc	12	0% (7)	0	0	30.9±8.7	0	0	49.8±0.6

- 1 - The number of independent transformant lines tested for myc staining and for fertility is indicated in parentheses.
- 2 - The fertility rescue is measured by counting the number of F1 adult eclosed from the tester or control parents. The data presented in the table is a summarized from three independent transgenic lines of myc-PIWI and two independent transgenic lines of PIWI-myc. *piwi1* denotes homozygous *piwi1*, *myc;piwi1* denotes either *myc-piwi*; *piwi1/piwi1* or *piwi-myc; piwi1/piwi1* transgenic lines. Homozygous *piwi1* females not only show zero fertility as indicated, but also fail to lay eggs. The small number of eggs produced by these females are retained in the ovary and eventually undergo atrophy.

-111-

The expression of myc-PIWI was confirmed by immunoblot analysis using a monoclonal anti-myc antibody as a probe, which reveals a single 97.5 kDa band in the ovarian extract of *myc-piwi* flies. This agrees well with both the 97.2 kDa predicted size of PIWI and the 97.1 kDa observed size of PIWI when a full-length *piwi* cDNA was translated *in vitro*. Furthermore, eight independent *myc-piwi* transgenic lines share the identical subcellular localization pattern throughout gametogenesis. Thus, the myc-PIWI protein reflects the function and distribution of endogenous PIWI.

The expression and localization pattern of myc-PIWI during gametogenesis was also examined by immunofluorescence microscopy. Whole mount ovaries and testes isolated from wild-type flies carrying a *myc-piwi* transgene were stained with the anti-myc antibody to visualize myc-PIWI; this antibody did not detect any signal above the background in ovaries and testes from siblings without *myc-piwi*. The samples were also stained with anti-VASA antibody to highlight germ cells and DAPI to label nuclear DNA. In the third instar larval ovary, where GSCs begin their asymmetric divisions, myc-PIWI was found in the nucleus of all germ cells of the ovary. In addition, myc-PIWI was also present in the nuclei of the forming terminal filament cells. In adult ovaries, myc-PIWI is present in the nuclei of both the somatic and germline cells, as predicted by *piwi* RNA *in situ* analyses described in Examples 1-4. Specifically, in the germarium, myc-PIWI is expressed in all the somatic cells, including the main terminal filament cells, the cap cells and the inner sheath cells, consistent with the genetic clonal analyses presented herein above which indicated that *piwi* is required in these cells to maintain GSCs. PIWI is also expressed in somatic stem cells and the follicle cells in the germarium.

In the germline, myc-PIWI shows a dynamic nuclear expression pattern: it is present abundantly in GSCs, but is down-regulated in cystoblasts and developing cysts. In 16-cell cysts in regions 2 and 3, the myc-PIWI regains its high level expression, and remains so in nurse cells and oocytes in post-germarial egg chambers throughout oogenesis. This expression is consistent with the clonal and RNA *in situ* analyses presented herein above which indicate

-112-

that PIWI is also loaded in eggs as a maternal component essential for embryogenesis. In all post-germarial egg chambers, myc-PIWI is also specifically expressed in the anterior polar follicle cells. The consistent nuclear localization of myc-PIWI in various types of somatic and germline cells during oogenesis indicates that PIWI is a nuclear protein.

Therefore, PIWI is a nuclear protein present in the soma and germline of both sexes. In the third instar larval ovaries, PIWI is present in the nucleus of all germline cells (GSC) as well as in forming terminal filament cells (TFC) as revealed by myc-PIWI in red and by VASA, a germline-specific marker, in green. PIWI is expressed in a dynamic pattern in the adult germarium (Ge), while being weakly expressed in main terminal filament cells and strongly expressed in cap cells (CpC). In the soma, PIWI is strongly expressed in the cap cells, inner sheath cells (ISC), somatic stem cells (SSC), and follicle cells (FC). In the germline, PIWI is expressed in germline stem cells (GSC) and is downregulated in cystoblasts (Cb) and early mitotic cysts. PIWI regains its high level expression in differentiating 16-cell cysts (DC) in regions 2b and 3.

In post-germarial egg chambers, PIWI is expressed strongly in all nurse cell nuclei (NCN) as well as in the nucleus (germinal vesicle, GV) of the developing oocyte. In the somatic follicle cell layer around each egg chamber, PIWI is expressed in anterior polar follicle cells (APC). The sharp down regulation of PIWI in cystoblast is also evident in the germarium, in which the three PIWI-bright small nuclei at the germarial apex are cap cell nuclei. The two larger nuclei in the next layer are GSC nuclei. Other small PIWI-bright nuclei in region 1 are inner sheath nuclei. The PIWI-negative region starts with a cystoblast positioned in the third layer.

In the third instar larval testis, PIWI, is present in the nuclei of both somatic and germline cells. In the soma, PIWI is expressed in the nuclei of hub cells (Hub) apical to GSCs and in cyst progenitor cells (CPC). In the germline, PIWI is present in the nuclei of GSCs and their immediate daughters. The apical region of the adult testis shows the same apical-distal organization as the third instar larval testis. PIWI expression pattern in the adult testis is identical to that in the third instar larval testis. PIWI is expressed in hub cells,

GSC, and CPC. Ovaries from sibling females which do not carry the *myc-piwi* transgene show no specific staining with the anti-Myc antibody.

PIWI is also expressed as a nuclear protein during spermatogenesis.

In the third instar larval testes which contain mostly premeiotic germ cells, myc-PIWI is localized to the nuclei of apical somatic cells, including the hub cells, which are the testicular equivalent of terminal filament cells. myc-PIWI is also present in somatic stem cells and their progeny, the cyst progenitor. At the apical germline, PIWI is present in the nuclei of GSCs and their immediate daughter cells. In newly formed 16-cell cysts of primary spermatocytes somewhat away from the apex, the myc-PIWI staining is sharply reduced in the germline. The staining is only present in the cyst progenitor cells, which are equivalent to follicle cells in the ovary. Once the developing cyst enters the spermatocyte growth phase, myc-PIWI expression is completely undetectable. This pattern of expression is maintained in the adult testis which displays the same apical-distal organization but now contains more differentiated post-meiotic germ cells in the basal region of the testis. Given the role of *piwi* in testicular germline stem cell maintenance described herein above, the nuclear localization of PIWI in the testis is envisioned to be of functional importance.

PIWI is localized in the nucleoplasm. To further investigate the role of PIWI in the nucleus, the subnuclear localization of the myc-PIWI protein was examined. In interphase GSCs, myc-PIWI is present in subnuclear areas where DNA staining is the weakest. The myc-PIWI staining appears as numerous bright foci in DNA-deficient areas that are sometimes connected into a network, complementing the DNA staining pattern. The DNA-bright area is completely devoid of myc-PIWI. In interphase cap cells, myc-PIWI shows a similar staining pattern. This staining pattern suggests that, in interphase somatic and germline nuclei, myc-PIWI is not associated with the chromatin or the nuclear envelope, but is localized in the nucleoplasm.

The nucleoplasmic localization of myc-PIWI is even more evident during GSC division. At metaphase, myc-PIWI is not associated with mitotic chromosomes or the nuclear envelope area, but becomes scattered throughout the cytoplasm, forming concentrated foci at the cell cortex. The localization

pattern remains so throughout anaphase. This dynamic localization pattern of myc-PIWI verifies that PIWI is not associated with chromosomes or the nuclear envelope, but is a nucleoplasmic factor that is dispersed into the cytoplasm during mitosis.

5           The myc-PIWI protein also shows clear nucleoplasmic localization in the nuclei of nurse cells, oocytes, and follicle cells in developing egg chambers. In nurse cell nuclei, myc-PIWI is accumulated in subnuclear areas devoid of DNA staining, complementing the DNA localization pattern. This complementary relationship is most clearly illustrated in the oocyte nucleus  
10 (germinal vesicle), in which chromatin forms a discrete subnuclear structure called the karyosome that occupies a spherical area in the nucleus (King, 1970). The myc-PIWI staining is not detectable in the karyosome, but is conspicuously present in the nucleoplasm that surrounds the karyosome. In follicle cells, myc-PIWI is also localized in the nucleoplasm in a punctate  
15 fashion. Thus, PIWI is a nucleoplasmic factor in all types of ovarian cells.

          Therefore, PIWI is localized in the nucleoplasm. In the interphase germline stem cell nucleus, myc-PIWI mostly accumulates as bright foci in DNA-deficient areas within the nucleus. DNA-bright spots were observed to be are completely devoid of myc-PIWI. This complementary staining pattern  
20 is also observed in cap cells (CpC).

          In metaphase and anaphase germline stem cells, the myc-PIWI staining is dispersed throughout the cytoplasm, forming numerous foci at the cortical region of the cell. In a stage 4 egg chamber (for staging, see King, 1970), myc-PIWI is accumulated in regions of nurse cell nuclei (NCN) and follicle cell nuclei  
25 (FCN) devoid of DNA staining. In the germinal vesicle (GV), the myc-PIWI staining is absent from the karyosome (K) but present in the nucleoplasm that surrounds it. The oocyte region of a stage 6 egg chamber showing the complementary myc-PIWI and DNA staining in the germinal vesicle (GV) and follicle cell nuclei (FCN). A magnified view of a nurse cell nuclei (NCN) in a  
30 stage 6 egg chamber, showing the largely non-overlapping staining pattern of myc-PIWI and DNA.



PIWI is cell-autonomously required in germline stem cells to promote their division. The above-presented clonal analyses indicated that *piwi* functions in the apical somatic cells of the germarium to regulate GSC maintenance. However, as PIWI is also present in the nuclei of GSCs, the function of PIWI in GSCs was evaluated by removing PIWI from a single stem cell using the FLP/FRT-mediated clonal technique (Xu and Rubin, 1993). *piwi*<sup>1</sup> and *piwi*<sup>2</sup> mutations were used for generating *piwi*<sup>-</sup> deficient clones because they are both strong mutations, as described in Examples 1-4. The *piwi*<sup>-</sup> stem cell clones were induced in *piwi* FRT/*amrlacZ* FRT transheterozygous flies.

The *amrlacZ* transgene (Lecuit and Cohen, 1997) is expressed in all somatic and germline cells in the germarium. *piwi* deficient clones created by a mitotic recombination no longer contain the *amrlacZ* gene and can thus be identified by the absence of the lacZ protein. The control lacZ-negative *piwi*<sup>+</sup> germline clones were induced in *piwi*<sup>+</sup> FRT/*amrlacZ* FRT transheterozygous flies for comparison. Since it takes four days for a cystoblast to develop into an egg chamber that buds off the germarium (Margolis and Spradling, (1995)), among *piwi*-deficient clones, only GSC clones can persist over more than five days (Figure 5B). If no *piwi*<sup>-</sup> GSC is observed five days after induced mitotic recombination, this would clearly indicate the failure of *piwi*<sup>-</sup> stem cells to maintain themselves.

Because recombination events can only occur in mitotically active cells yet all somatic signaling cells are postmitotic, this approach allows the analysis of the cell-autonomous function of *piwi* in single GSCs without the complication of generating mutant clones in the signaling cells. However, even if any somatic clones are induced, they can be readily identified. Furthermore, by marking individual mutant and wild-type GSCs, the relative division rate and maintenance ability of each stem cell can be determined by counting the number of its cyst progeny within the germarium (also see Xie and Spradling, 1998). Finally, the cell-autonomous function of *piwi* in the germline can be assessed at all stages of oogenesis by examining the development of the individually marked *piwi*<sup>-</sup> germline cysts and egg chambers.

Mitotic recombination was induced immediately prior to oogenesis and looked for *piwi*<sup>-</sup> GSC clones one week, two weeks, and three weeks following oogenesis. *piwi*<sup>-</sup> GSCs were present even three weeks following oogenesis, consistent with the above-presented observation that PIWI in GSCs is not required for their maintenance.

The number of marked *piwi*<sup>-</sup> and *piwi*<sup>+</sup> germline cysts was then examined in tester and control germaria to compare the division rate between the *piwi*<sup>-</sup> and *piwi*<sup>+</sup> GSCs within the germarium. For accurate comparison, germaria that contain only two GSCs, one marked and one unmarked, were always examined. In wild-type control germaria, marked wild-type stem cells gave rise to approximately 50% of the cysts present within the germarium. This indicated that the *lacZ*-marked and unmarked wild-type stem cells divide at the same rate (Figure 5). However, in tester germaria, the number of the marked *piwi*<sup>-</sup> germline cysts is consistently only 25% of marked wild-type cysts (Figure 5). This analysis reveals that *piwi*<sup>-</sup> GSCs divided four-fold slower than wild-type GSCs. Thus, in addition to its somatic function, PIWI acts cell-autonomously in the stem cells to facilitate their division.

The *piwi*<sup>-</sup> cysts and postgermarial *piwi*<sup>-</sup> egg chambers were examined by DAPI staining and by Nomarski microscopy for potential developmental defects. They usually developed normally, suggesting that *piwi* does not play a cell-autonomous role in germline cyst development and subsequent stages of oogenesis.

Therefore, PIWI acts cell-autonomously in GSCs to promote their division. Germaria were labeled with anti-LacZ antibody for *piwi*<sup>+</sup> cells and anti-1B1 antibody for spectrosomes and fusomes. Marked stem cells and cysts developed from *piwi*<sup>-</sup> germline stem cells (GSCs) are recognized by the absence of *lacZ* expression. In a *piwi*<sup>-</sup> *lacZ*<sup>FRT</sup>/*piwi*<sup>+</sup> *lacZ*<sup>+</sup> FRT germarium in the absence of heat shock, no *piwi*<sup>-</sup> *lacZ*<sup>FRT</sup>/*piwi*<sup>-</sup> *lacZ*<sup>FRT</sup> clones were induced. GSCs are distinguished by the presence of the spectrosome (Sp) in direct contact with the terminal filament cells (TFC).

A *piwi*<sup>-</sup> *lacZ*<sup>FRT</sup>/*piwi*<sup>+</sup> *lacZ*<sup>+</sup> FRT germarium was stained one week after heat shock, and showed a wild-type GSC and a mutant GSC, as well as

-117-

three *piwi*<sup>-</sup> cysts derived from the mutant stem cell. The entire ovariole is enveloped by the epithelial sheath (ES), which is different from the inner sheath cells (IS). The graph of Figure 5 displays the relative division rates of wild-type and *piwi*<sup>-</sup> GSCs. The number of germaria counted is given in parentheses. Only germaria containing one marked and one unmarked GSC were examined.

Overexpression of PIWI increases the number of germline stem cells.

Examples 1-4 above establish that the somatic expression of PIWI is essential for GSC maintenance. This somatic induction can be achieved via a threshold mechanism, in which a certain level of somatic PIWI activity is required to establish or maintain the stem cell identity, but a higher level of somatic PIWI expression will not increase the number of GSCs. Alternatively, the PIWI-mediated somatic induction could act via a dosage-dependent mechanism, in which the somatic level of PIWI dictates the number of GSCs.

To test these possibilities, PIWI was overexpressed in the somatic cells of the adult ovary via heat shock induction using *hsp70-Gal4* (*hsGal4*) and *ep(2)1024*, an EP element inserted in the 5' UTR of the *piwi* locus. EP is a modified P element carrying an UAS<sub>t</sub> promoter oriented to transcribe the flanking genomic sequence upon the activation of the yeast Gal4 protein (Rorth, (1996)). Specifically, *ep(2)1024* in the 5'UTR of *piwi* is oriented in the same direction of *piwi* transcription so that it can produce a *piwi* mRNA containing the complete PIWI open reading frame. The UAS<sub>t</sub> promoter is active in the soma but not in the germline (Rorth, 1998), and its somatic specificity was confirmed by examining the ovarian expression of the UAS<sub>t</sub> - GFP reporter gene under experimental conditions. Because endogenous PIWI is expressed in all somatic cells in the germarium, by constructing a *Drosophila* strain that contains *hsGal4* and *ep(2)1024*, it was possible to over-express, but not ectopically express, *piwi* specifically in the somatic cells by heat shock induction.

To verify that *ep(2)1024* can express a functional PIWI protein, *ep(2)1024* was overexpressed by heat shocking *hsGal4* in an *ep(2)1024/piwi*<sup>1</sup> mutant background. Because *ep(2)1024* is a strong loss-of-function mutation

of *piwi*, *ep(2)1024/piwi<sup>1</sup>*; *hsGal4* females and males in the absence of heat shock display typical *piwi* phenotype. In contrast, the same mutants, after receiving daily heat shock treatment from the second instar larvae to three days after eclosion, produced significantly restored fertility in both

5 *ep(2)1024/piwi<sup>1</sup>* females and males. The morphology of both the ovaioles and testes in the heatshocked mutants are indistinguishable from their wild-type siblings. In addition, the fertility of the rescued mutants is comparable to their wild-type siblings. Heatshock starting at the pupal stage does not rescue the fertility. Therefore, *ep(2)1024* can produce a functional PIWI protein capable

10 of rescuing the *piwi* mutant phenotype when expressed in somatic cells.

*ep(2)1024* was then used to overexpress PIWI in wild-type adult females, and its effects on GSCs were analyzed. The females were heat-shocked at a 12-hour interval for three days and then dissected. The ovaries were stained with anti-VASA antibody (Hay et al., (1990)) to highlight germ

15 cells and anti-1B1 antibody (Zaccai and Lipshitz, (1996)) to outline somatic cells as well as to label spectroosomes and fusomes that mark individual stages of germline development in the germarium (Lin and Spradling, (1995)). Wild-type germaria typically have 2-3 spectrosome-containing cells, with one often being a cystoblast that is not associated with the terminal filament. This is also

20 the case for uninduced *ep(2)1024/+* germaria. Interestingly, the number of the spectrosome-containing germ cells increased to an average of 7.5 cells per *ep(2)1024/+* germarium following heat shock induction. In the most extreme case, up to 15 spectrosome-containing cells were observed in a single germarium. This increase is not due to the expression of *hsGal4* alone, since

25 ovaries from *hsGal4* females subjected to the same heat shock regime were indistinguishable from wild-type. Thus, overexpression of PIWI in the soma leads to a 3-4 fold increase in the number of GSCs and/or cystoblasts.

Thus, the observation that *EP(2)1024* expression rescues the *piwi<sup>1</sup>* mutant phenotype was shown via DAPI staining of the gonads from

30 *ep(2)1024/piwi<sup>1</sup>*; *hsGAL4* females and males either without or with heat shock. In the absence of the heat shock, the ovaries and testes display the typical *piwi<sup>1</sup>* mutant phenotype. Following *hsGal4*-induced over-expression of the

-119-

5 *ep(2)1024* in the soma, significant rescue of the mutant phenotype was observed in both females and males. Specifically, in females, germline stem cells are maintained and a string of developing egg chambers was observed. Similarly, in males, germline stem cells were also rescued, and spermatogenesis was fully restored.

10 To distinguish whether the spectrosome-containing cells are stem cells or cystoblasts, the germaria were stained with anti-cytoplasmic BAM (BAM-C) antibody, since BAM-C is only expressed in cystoblasts and early mitotic cysts but not in GSCs (McKearin and Ohlstein, (1995)). In *piwi*-overexpressed germaria, BAM-C staining is strongly present in early cysts. However, BAM-C staining is conspicuously absent from all the spectrosome-containing cells. This observation suggests that the ectopically induced spectrosome-containing cells are GSC-like cells.

15 The observation that somatic PIWI over-expression increases the number of germline stem cells was supported a confocal z-series analysis (10  $\mu$ m stacks) of wild-type germarium immunofluorescently labeled with anti-1B1 antibody. At the apical tip of region 1 in direct contact with the terminal filament, two germline stem cells containing spectrosomes (Sp) were observed. Posterior to germline stem cells, developing germline cysts containing  
20 branched fusomes (Fu) were observed. A germarium from a *ep(2)1024; hsGal4* female was observed to display many germline stem-like cells following 4 days of heat shock treatment, with 12 shown in this focal plan as indicated by spectrosomes (Sp; stained with anti-1B1 antibody) and the absence of the BAM-C protein. The stem-like cells were evenly distributed between regions  
25 1 and 2a. The BAM-C protein was only present in a cyst containing a branched fusome in region 2a.

30 A germarium containing ectopic stem-like cells was stained with anti-BrdU and anti- $\alpha$ -spectrin antibodies following BrdU incorporation as described above in the Materials and Methods. Some mitotically active germline cells which have incorporated BrdU in their nuclei were observed. A fusome-containing germline cyst (Fu) was present in region 1 but not in contact with somatic cells. A germarium from an *ep(2)1024; hsGal4* female subjected to 4

-120-

days of heat shock treatments followed by 4-5 days of culture at room temperature was also stained. The stainings indicated anti-VASA and anti-1B1 antibody signals, respectively. This germarium, like a typical wild-type germarium, contained two germline stem cells contacting the apical somatic cells and a cystoblast that is one cell away from the terminal filament. In addition, the number of fusome-containing cysts (Fu) have increased to a normal level.

Figure 7 depicts a graphical comparison of the number of spectroosomes present per wild-type germarium versus per *piwi*-overexpressed germarium. The number of germaria examined (n) is in parentheses. All germaria are oriented with anterior toward the left.

The ectopic GSC-like cells appear to be functional GSCs. First, they incorporate BrdU, an indicator of DNA replication, at a level similar to the wild-type GSCs. This suggests that they are not arrested in the cell cycle. Second, these GSC-like cells can all differentiate within four days following the withdrawal of heat shock; leaving the germaria with only 2-3 GSCs at their normal locale. No signs of cell death, such as pycnotic nuclei or apoptotic bodies, were detected by DAPI staining and Nomarski optics. This suggests that the GSC-like cells are capable of oogenesis. Thus, the dependence of GSC number on the PIWI level reveals that *piwi*-mediated somatic signaling controls the number of GSCs via a dosage dependent mechanism.

The ectopically induced GSCs show an even distribution pattern along the germarial axis. In wild-type germaria, spectroosome-containing cells are exclusively located in the apical area of region 1, either in direct contact with or one-cell away from the terminal filament (for stem cells and cystoblasts, respectively). However, following PIWI overexpression, spectroosome-containing cells were evenly expanded along the somatic germarial wall to both regions 1 and 2a. All the spectroosome-containing cells are in apparent contact with the somatic cells; there is no apparent gradient of the stem-like cell distribution towards the terminal filament. In wild-type germaria, inner sheath cells express as much PIWI as cap cells, and much more than the main terminal filament cells, yet there are no GSCs located near them in posterior

region 1 or region 2a. Therefore, the appearance of the ectopic stem-like cells in the entire regions 1 and 2a following *piwi*-overexpression suggests that a very high level of PIWI in the inner sheath cells expands the stem cell domain to region 2.

5        Over-expression of PIWI increases the rate of germline stem cell division. Since over-expression of *piwi* in somatic cells increases the number of GSCs, yet loss of *piwi* function from the soma and germline in *piwi* mutants abolishes stem cell division and thus their maintenance, one might expect that over-expression of *piwi* in the soma may also increase the rate of GSC division.

10      To address this possibility, the mitotic index of GSCs in *piwi*-overexpressed females was directly quantified. GSC division is unique in that it has an unusually long telophase-to-interphase period characterized by the presence of a dumb bell-shaped telophase spectroosome spanning the two daughter cells. Deng and Lin, (1997); de Cuevas and Spradling, (1998). The morphologically

15      distinctive telophase spectroosome provides an easy marker for the accurate measurement of the telophase/early interphase index, which is a direct quantitation of the frequency of GSC division.

To avoid a bias in quantifying the division frequency due to the presence of an increased number of GSC-like cells in *piwi*-overexpressed germaria, the

20      2-3 anterior-most GSCs that contact the terminal filament were quantified, and the same number of stem cells in the wild-type and uninduced *ep(2)1024* controls were quantified. In the wild-type and uninduced *ep(2)1024* controls, 20-25% of germaria contained a single GSC with a telophase spectroosome; only 2-3% of germaria contained two GSCs with telophase spectroosomes.

25      These frequencies are increased to 31% and 13% in *piwi*-overexpressed germaria. Moreover, 3% of the *piwi*-overexpressed germaria contain three GSCs with a telophase spectroosome, a situation that was not observed in the control germaria. These results indicate that in addition to an increase in the number of stem cells, *piwi* overexpression also increases the rate of GSC

30      division. Because the GSCs under examination are located in their normal niche, the increase in their mitotic frequency should be mostly, if not all, due to the increased PIWI expression in the terminal filament.

-122-

Four micrographic panels of anti-1B1 images of germaria containing 0, 1, 2, and 3 telophase spectrosome-containing germline stem cells were prepared and examined. The frequency of observing such germaria in the wild-type control, the uninduced *ep(2)1024* control, and the *piwi*-overexpressed germaria is presented in Table 5. The number of germaria counted for each genotype (n) is given in parentheses.

Table 5

		Percentage (%) of GSC in Telophase		
Telophase	GSCs	W. T.	EP (-) HS	EP (+) HS
		(n=100)	(n=100)	(n=100)
0		73	77	53
1		25	20	31
2		2	3	13
3		0	0	0

### Discussion

Stem cells are characterized by two common properties: the capacity for self-renewal and the ability to propagate numerous progeny fated for further differentiation (for review, see Morrison et al., 1997; Lin, 1997). The unique self-renewing division of stem cells is controlled by both intracellular and extrinsic signaling mechanisms (Knoblich, 1997; Lin, 1997). Example 5 shows that *piwi* encodes a novel nucleoplasmic protein present in both somatic and germline cells of both sexes. Moreover, the single stem cell clonal analyses and *piwi* overexpression experiments establish the important function of *piwi* in both the intracellular and the cell-cell signaling mechanisms. Example 5 thus reveals a novel nuclear factor whose activity modulates the number of GSCs and the rate of their division.

The role of PIWI as a nucleoplasmic factor in somatic signaling. The immunofluorescence analysis of the fully functional myc-PIWI protein reveals that PIWI is a nucleoplasmic protein. Consistent with RNA *in situ* analyses, PIWI is present in both the soma and the germline during oogenesis. In Example 5 the cell-autonomous function of PIWI as a mitotic promoter in GSCs



-123-

is revealed. PIWI is localized in the nucleoplasm in both the apical somatic cells and GSCs. Hence, the nucleoplasm is the likely site of PIWI function, and in accordance with one aspect of the present invention, PIWI is the first nucleoplasmic factor known to play a key role in controlling GSC division.

5       As a nucleoplasmic factor in the apical somatic cells, PIWI is expressed in three types of post-mitotic cells that form a somatic cap surrounding GSCs and their immediate daughter cells: the main terminal filament cells, the cap cells, and the inner sheath cells. Among these cell types, the main terminal filament cells express a very low level of PIWI while cap cells and inner sheath  
10       cells express a very high level of PIWI. Since cap cells are in direct contact with GSCs, it is envisioned that PIWI expression in cap cells plays a role in somatic signaling.

      Since PIWI is a nucleoplasmic protein, it is unlikely a somatic signal itself, but rather an essential component of the somatic signaling machinery  
15       responsible for producing the signal. Given its nucleoplasmic localization, PIWI might be involved in post-transcriptional mRNA processing in the nucleus or in nuclear functions indirectly related to gene expression. In either case, the somatic activity of PIWI acts via a dosage dependent mechanism to control the number of GSCs in the germline. Therefore, *piwi* can help to define a stem cell  
20       niche in the germarium for GSC maintenance, with the size of the niche corresponding to the level of PIWI activity.

      A number of genes, including *fs(1)Yb* (King and Lin, 1999) and *dpp* (Xie and Spradling, 1998), have recently been shown to play roles in the cell-cell signaling mechanism in maintaining GSCs. Among these genes, *dpp* is the  
25       only known signaling molecule. DPP over-expression dramatically expands the number of GSCs and prevents their differentiation, leading to tumorous germaria filled with undifferentiated GSC-like cells (Xie and Spradling, 1998). This overexpression phenotype, in sharp contrast to that of *piwi*, suggests that DPP is not the downstream signal of the *piwi*-mediated mechanism, even  
30       though it may be one of the signals. *fs(1)Yb*, on the other hand, shares a very similar loss-of-function phenotype with *piwi*. These two genes are more likely to be involved in the same somatic signaling pathway.

The role of PIWI as a nucleoplasmic factor in germline stem cells. PIWI is expressed dynamically in the germline of the germarium. In region 1, PIWI is present in the nucleus of GSCs at a high level but is sharply down regulated in cystoblasts and early mitotic cysts. This expression pattern correlates well with the mitosis-promoting function of PIWI in GSCs as revealed by single stem cell clonal analysis. The differential distribution of proteins between the stem cell and the cystoblast has also been observed for several other factors known to be important for GSC division or differentiation. For example, PUM is required for GSC maintenance (Lin and Spradling, 1997; Forbes and Lehmann, 1998) and is accumulated at a high level in GSCs but a low level in the cystoblasts (Forbes and Lehmann, 1998; Parisi and Lin, 1999). On the other hand, NOS and BAM-C are required for cystoblast development and are localized either preferentially or exclusively in the cystoblast.

All of these molecules, except for BAM-C, are known to play important roles in other developmental processes (Cox et al., 1998; Parisi and Lin, 1999). For example, the germline expression of PIWI during oogenesis also provides PIWI as a maternal component essential for embryogenesis (Cox et al., 1998). Therefore, the asymmetric fates between GSCs and cystoblasts might not be determined by unique "stem cell factors" or "cystoblast factors". It, instead, may be created by unique combinations of various regulatory molecules that are repeatedly used throughout development.

This pleiotropic function of stem cell genes is also manifested within the stem cell mechanisms, in which *piwi* is involved in both somatic signaling and in cell-autonomous mitotic functions. *piwi* thus acts in two distinct cell types and in two different mechanisms. Although applicant does not desire to be bound by any particular mechanism of action, it is contemplated that the PIWI protein directly or indirectly mediates gene expression in the nucleus either at the transcriptional or post-transcriptional level. The different *piwi* target genes or their products in different cell types then lead to the distinctively different cellular function of *piwi*.

-125-

Example 6PIWI is a Pole Plasm Component Required for  
Pole Cell Formation, Migration and Transcriptional Quiescence

5 This Example shows that PIWI is also a maternally deposited polar  
granule component that plays a key role in pole cell formation, migration, and  
transcriptional quiescence. However, unlike most other genes known to be  
required for pole cell formation, *piwi* is specifically required for pole cell  
formation with no effect on abdominal patterning. PIWI is dynamically  
10 expressed during germ plasm assembly and pole cell formation. The protein  
is first expressed in polar granules at the posterior end of the embryo and is  
subsequently expressed in the nuclei of all primordial germ cells throughout  
embryogenesis. Furthermore, the *piwi* gene product directs germ plasm  
assembly and controls the number of pole cells formed at the posterior pole of  
the *Drosophila* embryo. These results indicate that *piwi* has many of the  
15 properties of a germ cell-specific determinant.

Materials and Methods

Drosophila strains and culture. All strains were grown at 25°C on yeast-  
containing molasses/agar medium. The following fly strains were used in this  
study: *w*; *piwi*<sup>1</sup>, *FRT*<sup>40A</sup>/*CyO* and *w*; *piwi*<sup>2</sup>, *FRT*<sup>40A</sup>/*CyO* (as disclosed in  
20 Examples 1-4) were used to generate maternal clones; *y*, *w* *P[hsFLP]*<sup>12</sup>;  
*P[ovoD1]2L*, *FRT*<sup>40A</sup>/*CyO* (Chou and Perrimon, 1996); *P[myc-PIWI]* insertions  
on the second and X chromosomes were used to increase the *piwi* copy  
number as well as to visualize PIWI protein expression; 4X *oskar* flies bear two  
wild-type copies of *oskar* on the third chromosome and two transgenic rescue  
25 copies of *oskar* on the second chromosome (Ephrussi and Lehmann, 1992.  
*OregonR* (*Ore-R*) serves as the wild-type control in all experiments.

Immunohistochemistry. Ovaries were dissected, fixed and stained as  
described in Lin *et al.*, 1994. Embryos were collected, fixed and stained  
according procedure described by Patel *et al.* (1989). For immunofluorescence  
30 staining the following antisera were used: polyclonal anti-VASA antibody  
(1:2000; Hay *et al.*, 1990); monoclonal anti-MYC epitope antibody (1:50; Evan

*et al.*, 1985); monoclonal anti-SXL antibody (1:500; Bopp *et al.*, 1991). All the fluorescence-conjugated secondary antibodies were from Jackson Immunoresearch Laboratory, Westgrove, Pennsylvania and were used at 1:200 dilution. Immunofluorescently labeled samples were also counterstained with DAPI as described previously (Lin and Spradling, 1993). Micrographs were taken using either a Zeiss AXIOPLAN® microscope or a Zeiss LSM410™ confocal microscope (Zeiss, Oberkochen, Germany) as described herein above.

Maternal clones. To generate embryos maternally depleted for *piwi* the following fly strains were crossed: *y, w P[hsFLP]12; P[ovoD1]2L, FRT40A/CyO* males were crossed to *w; piwi1, FRT40A/CyO* virgin females to produce *y, w P[hsFLP]12; P[ovoD1]2L, FRT40A/piwi1, FRT40A* progeny. Identical crosses were performed with *w; piwi2, FRT40A/CyO* virgin females. Crosses were carried out for two days to produce transheterozygous progeny. After 2 days, adults were transferred to fresh vials. Larvae were heat shocked on days 3 and 4 for one hour in a 37°C water bath to induce mitotic recombination. The heat-shocked females with germline clones were crossed to *Ore-R* males or to *piwi2* mutant males. Embryos collected from these females were subsequently analyzed by immunofluorescence microscopy. Due to the presence of a copy of the *ovoD1* gene in these females, only *piwi*<sup>-</sup> germline clones can give rise to a mature egg.

Pole cell formation is dosage-dependent for *piwi*. Single copy embryos are from *piwi1/CyO* females and two copy embryos for both *piwi* and *oskar* are from *Ore-R* females. For the four-copy *piwi* embryos, a P[myc-PIWI] rescue transgene was homozygoused on a wild-type second chromosome; two such lines were examined for their effects on embryonic development. For the four-copy *osk* embryos, an *osk* rescue transgene was homozygoused on the second chromosome of an otherwise wild-type fly as described by Ephrussi and Lehmann, 1992. For the six-copy *piwi* embryos, P[myc-PIWI] transgenes on the X chromosome and second chromosome were homozygoused to generate four transgenic copies in addition to the two wild-type copies on the second chromosome. For maternally depleted embryos, germline clones were

-127-

produced as described above. Embryos from females carrying germline clones were collected and analyzed to examine the role of *piwi* in germline development. For pole cell counts, all embryos were stained with anti-VASA antibody and the pole cells of 50 embryos of each maternal genotype, described above, were counted in triplicate for each embryo. The pole cell count reflects the initial number of pole cells present shortly after budding at the posterior pole and prior to any amplification or migration. Embryo staging was performed as described in Zalokar and Erk (1976) according to the number of nuclei present.

### Results

PIWI encodes a polar granule component with a dynamic behavior during pole cell formation. As disclosed above, *piwi* is maternally required for embryogenesis. To examine *piwi* function in embryogenesis, PIWI protein expression in embryos was analyzed using a myc-tagged *piwi* transgene. Embryos were collected from females carrying a P[myc-PIWI] transgene and subsequently stained these embryos with antibodies against MYC to visualize P[myc-PIWI] protein expression and VASA, a polar granule component and pole cell-specific marker. Embryos were counterstained with DAPI to visualize nuclei and allow a stage-specific analysis of PIWI expression during embryogenesis (Zalokar and Erk, 1976).

PIWI is first expressed in a crescent at the posterior pole of the embryo during mitotic cycles 1-7, where it is co-localized with VASA during these cycles, including localization to polar granules of which VASA is a component. Thus, *piwi* encodes a polar granule component. During mitotic cycles 8-10, PIWI is dynamically expressed in the forming pole cells. At this stage in embryogenesis, nuclei have migrated from the center of the embryo and some of them enter the posterior pole plasm. These posterior nuclei become the first to cellularize as they bud off from the embryo to form pole cells. At the onset of pole cell formation, during mitotic cycles 8 and 9, PIWI is expressed cytoplasmically in an overlapping pattern with VASA in polar buds. However, at mitotic cycle 10 when pole cell formation and budding is complete PIWI completely translocates to the nucleus of all pole cells. PIWI is also zygotically

-128-

expressed in somatic cells at the stage. PIWI remains nuclear in pole cells throughout germ cell migration and finally gonad coalescence.

Maternal PIWI is required for pole cell formation. To analyze the potential requirement of *piwi* in embryogenesis embryos maternally depleted for *piwi* were generated. Females with *piwi*<sup>1</sup> germline stem cell clones were crossed to wild-type males and embryos from these females were collected. To assay germline formation and development, germ cells were visualized by staining with an anti-VASA antibody. In the absence of maternal *piwi* product, a dramatic reduction in the number of pole cells formed was observed. Maternally depleted *piwi* embryos contain on average  $7.5 \pm 5$  pole cells at mitotic cycle 10, the pole cell formation stage, in contrast to the  $24 \pm 5$  pole cells formed in wild-type embryos at the same stage. These results indicate that maternal *piwi* is required for pole cell formation as a wild-type paternal copy of *piwi*<sup>+</sup> is insufficient to rescue the pole cell formation defect.

Following pole cell formation there are typically one to two amplificatory mitoses in the pole cell population such that 30-40 pole cells are present prior to germ cell migration. There is no additional amplification of the pole cell population once germ cell migration has commenced (Williamson and Lehmann, 1996). To determine whether *piwi* is required for the amplification of the pole cell population, embryos lacking maternal *piwi* for the number of pole cells present before germ cell migration and after gonad coalescence were examined. There is no amplification of germ cells in the absence of maternal *piwi*; rather, a small decrease in the average number of germ cells present at gonad coalescence was observed. Prior to germ cell migration *piwi*<sup>-</sup> embryos contained  $7.5 \pm 5$  germ cells, however at germline coalescence the average number of germ cells dropped to  $4.5 \pm 3$  germ cells. Thus, in addition to its requirement for pole cell formation, maternally deposited *piwi* also plays an role pole cell amplification and survival.

The maternal effect of *piwi* on pole cell formation is similar to that observed with the posterior group genes which are also required for pole plasm assembly and pole cell formation. To examine whether maternally depleted *piwi* embryos have any abdominal defects, Nomarski optics were used to

examine the segmentation pattern of these embryos. There is no readily apparent defect in abdominal patterning. Thus, in contrast to the posterior group genes, *piwi* does not appear to be required for proper abdominal patterning of the embryo.

5        Maternal PIWI is required for pole cell migration. To analyze the effect of removing maternal *piwi* function on germ cell migration, embryos from females bearing *piwi* mutant germline stem cell clones were collected and stained for the germ cell specific marker VASA. In addition to its role for proper pole cell formation and proliferation, *piwi* activity also plays a role in successful  
10       germ cell migration. During pole cell migration in wild-type embryos, germ cells exit the posterior midgut and then actively migrate through the endoderm along its basal surface until making contact with the overlying mesodermal cells (Warrior, 1994). At late stage 10 to early stage 11 (for staging, see Zalokar and Erk, 1976), germ cells transfer from the endoderm into the mesoderm  
15       where they will associate with somatic gonadal precursor cells which give rise to the gonadal mesoderm. Finally, at stage 14 of embryogenesis, germ cells coalesce with somatic gonadal precursors in parasegment 10 to establish the primordial gonad.

         However, in embryos lacking maternal PIWI, defects in germ cell  
20       migration are seen from stage 10 onwards which marks the active phase of germ cell migration. As germ cells exit from the posterior midgut pocket, they fail to undergo directional migration over the surface of the endoderm. Rather, they are found migrating in a random fashion to many different sites within the embryo. In some cases highly aberrant germ cell migration into the anterior  
25       end of the embryo was observed. The random patterns of germ cell migration in these mutant embryos indicates a requirement for maternal PIWI in germ cell guidance. In addition to the defect in germ cell migration, defects in overall pole cell morphology were observed. In contrast to wild-type pole cells, pole cells maternally depleted of *piwi* are of variable size and shape and display  
30       unusual blebbing and aberrant pseudopodia. This indicates that maternal *piwi* also plays a role in proper pole cell morphology which might be essential for proper pole cell migration.

-130-

Previously, it has been demonstrated that signals produced by surrounding somatic tissues act to guide germ cells by both attractive and repulsive forces (Jaglarz and Howard, 1994; 1995; Zhang *et al.*, 1997; Van Doren *et al.*, 1998). However, few genes have been identified that control germ cell migration and are expressed in germ cells themselves. The expression of *piwi* in pole cells during migration suggests that *piwi* function is cell-autonomous. This is similar to *nanos* and *pgc-1* both of which are expressed in germ cells and are required for normal germ cell migration (Forbes and Lehmann, 1998; Kobayashi *et al.*, 1996). These data indicate that germ cell migration is controlled by both instructive signaling mechanisms as well as by cell-autonomous mechanisms within migrating germ cells.

Maternal PIWI plays a role in the transcriptional quiescence of pole cells. Transcriptional repression in germ cells has been implicated as a key mechanism in the establishment and maintenance of the germ cell fate (for review, see Seydoux and Strome, 1999). In *Drosophila*, zygotic transcription in the soma is detectable as early as one hour after egg laying (AEL; Pritchard and Schubiger, 1996). In the germline, however, general RNA synthesis is not detected until 3.5 hours AEL at embryonic stage 8 (Zalokar, 1976) and poly (A) containing mRNA transcripts are not observed in early germ cell nuclei (Lamb and Laird, 1976). Few genes have been shown to be specifically transcribed in pole cells and among the known genes, *vasa* is the earliest gene at embryonic stage 9-10 (Hay *et al.*, 1988b). Transcription of all other genes to be expressed in pole cells is not observed until the primordial gonad reinitiates proliferation at embryonic stage 16-18 (Mevel-Ninio *et al.*, 1995). Transcription is reinitiated in pole cells just before they migrate through the midgut epithelium approximately 3.5 hours AEL (Zalokar, 1976).

To analyze the potential role of *piwi* in the regulation of transcriptional quiescence in early germ cells, embryos maternally depleted of *piwi* were double-labeled with VASA, a germ cell specific marker, and SXL, a somatic sex-specific marker which is normally absent in pole cells. Ectopic expression of SXL protein in pole cells prior to embryonic stage 9 was observed. This



-131-

indicates that the mechanism which normally maintains transcriptional quiescence in pole cells is dependent on proper *piwi* function.

*piwi* Dose Determines the Initial Number of Pole Cells. Given the critical role of *piwi* in pole cell formation and development, the role of *piwi* in germ plasm assembly was further evaluated by examining the relationship between *piwi* gene dosage and the number of pole cells formed, which is also a reflection of the amount of pole plasm formed at the posterior end of the egg. The *piwi* copy number was increased in females from one to four and collected embryos from these females to examine the number of pole cells formed. In identically staged samples, embryos with one or two copies of the *piwi* gene contained on average  $24 \pm 5$  pole cells. However, a two-fold increase in *piwi* gene dosage over wild-type levels yields embryos containing on average  $50 \pm 7$  pole cells at the same developmental stage. This phenotype is strikingly similar to the phenotype displayed when *oskar* gene dosage is increased from one to four copies (Ephrussi and Lehmann, 1992). Like *oskar*, a two-fold increase in *piwi* gene dosage leads to an increase in both the amounts of known pole plasm components, such as VASA, at the posterior pole of the embryo and the number of pole cells formed. However, in contrast to *oskar*, increasing *piwi* gene dosage does not cause defects in abdominal patterning or polarity (Ephrussi and Lehmann, 1992). In support of the apparent linear effect of *piwi* gene dosage on the number of pole cells formed, we found that a three-fold increase in *piwi* gene dosage results in embryos containing on average  $66 \pm 7.5$  pole cells, representing a three-fold increase over the number of pole cells in wild-type embryos at the same developmental stage.

## 25 Discussion

*piwi* plays a role in embryonic germline determination. *piwi* encodes a polar granule component which is maternally required for pole cell formation. However, unlike other posterior group genes which are also required for abdominal patterning, *piwi* is specifically involved in pole cell formation. This Example indicates that, unlike the posterior group genes, *piwi* does not appear to be required for the proper localization of the abdominal determinant, *nanos*.

At the molecular level, germ plasm assembly occurs in a stepwise

ordered fashion. The presence of the VASA protein in the small population of pole cells formed in embryos lacking maternal *piwi* indicates that *piwi* must act downstream of *vasa* and therefore *oskar* in pole cell formation (for review, see Rongo and Lehmann, 1996). In this hierarchy of gene activity, *oskar* is required for the localization of *vasa* and *tudor* to the pole plasm. In addition, all three gene products are polar granule components which like *piwi* are required for pole cell formation. However, *piwi* has a role in pole cell formation which is downstream of the requirements for germ plasm assembly. This requirement is very similar to that reported for other putative germ cell determinants including, *germ cell-less (gcl)* (Jongens *et al.*, 1992), *polar granule component-1 (pgc-1)* (Nakamura *et al.*, 1996), and *mtlr* RNA (Kobayashi *et al.*, 1993). All of these genes act downstream of *tud* and are required for pole cell formation, but not for abdominal segmentation. These results suggest *piwi* can act as a maternally deposited germ cell determinant downstream of *tud* as well.

Maternal PIWI level determines the initial number of pole cells. A direct relationship was observed between the dosage of the *piwi* gene and the concentration of other pole plasm components, such as VASA, at the posterior pole of the embryo. This phenotype is highly similar to that observed when *oskar* copy number is increased in embryos (Ephrussi and Lehmann, 1992). For both *piwi* and *oskar*, an increase in gene copy number leads to an accumulation of pole plasm components which is independent of the dosage of other component genes. Therefore, both *piwi* and *oskar* can modulate the number of pole cells formed through a gene dosage effect via regulating the amount of pole plasm. Pole cell formation involves a hierarchy of gene expression. It has been proposed that *oskar* acts as a limiting factor for all aspects of pole plasm function (Ephrussi and Lehmann, 1992). The highly similar phenotypes observed in embryos carrying four copies of either *piwi* or *oskar*, suggest that *osk* is not the only limiting factor for germ cell formation and that *piwi* might be a downstream target of *oskar* in determining pole cell formation. The presence of VASA protein in germ cells of embryos maternally

-133-

depleted for *piwi* also suggests that *piwi* is required downstream of *oskar* for pole cell formation (Ephrussi and Lehmann, 1992).

As disclosed herein, *piwi* is a member of a large class of evolutionarily conserved genes. Intriguingly, *piwi* is related to *aubergine*, a *Drosophila* gene required to promote *oskar* translation (Wilson *et al.*, 1996). *piwi*, however, is not likely to promote *oskar* translation since *piwi*-depleted embryos do not show *osk*-like defects. Alternatively, *piwi* may act downstream of *oskar*, but in a completely *oskar*-independent fashion.

Previous analyses have revealed that pole plasm assembly is a two-step process beginning in oogenesis. The first step is the localization of *oskar* mRNA to the posterior pole of the oocyte. The second step is the recruitment of *vasa* and *tudor* by *oskar*. Both *vasa* and *tudor* are required for pole plasm assembly. Downstream of *tudor* there is a bifurcation of the hierarchy leading to germ cell determination and the proper localization of the abdominal determinant *nanos*, respectively. In the germ cell determination branch are potential germ cell determinants which are required for pole plasm assembly and pole cell formation, but are not required for abdominal patterning. The data presented in the Examples suggests that *piwi* is likely to act downstream of *oskar* in the germ cell determination branch as a germ cell determinant.

*piwi*'s potential role as a germ cell determinant can be further addressed by ectopically expressing the *piwi* mRNA at the anterior end of the embryo to examine whether it can induce pole cell formation. This approach has been used in identifying molecules crucial to germ cell determination (Ephrussi and Lehmann, 1992; Jongens *et al.*, 1994).

Maternal PIWI is required for migration and transcriptional quiescence of germ cells. In addition to initial pole cell formation, *piwi* activity is required for successful germ cell migration. Maternal PIWI is nuclearly localized to all pole cells as they form and remains nuclear throughout germ cell migration and primordial gonad formation. In the absence of maternal PIWI, germ cells migrate in a highly randomized fashion with few germ cells actually reaching the gonadal mesoderm. Recent studies have identified several genes which

-134-

regulate germ cell migration (Moore *et al.*, 1998; Zhang *et al.*, 1996), however, unlike *piwi*, all of these genes appear to be required in the soma and none of these mutants result in such randomized migration of germ cells as that observed in *piwi* mutant germ cells. In addition to *piwi*, maternal NOS has also  
5 been shown to act cell-autonomously in germ cells to facilitate their migration (Forbes and Lehmann, 1998). Somatic signaling has been shown to exert both attractive and repulsive forces on germ cells in order to guide their migration (Zhang *et al.*, 1996; Van Doren *et al.*, 1998a). The aberrant germ cell migration observed in embryos lacking maternal PIWI could result from a failure to  
10 respond to these somatic guidance cues perhaps due to the absence of specific receptors for the cues on the surface of germ cells. In any case, these results indicate that soma-germline signaling is essential for proper germ cell migration and that maternally supplied products, such as PIWI and NOS, are required for successful germ cell migration.

15 The small decrease in the average number of germ cells after migration was initiated in *piwi*-depleted embryos indicates that maternal PIWI also plays a role in germ cell survival. Both *in vitro* and *in vivo* studies suggest that the mammalian stem cell genes *White (W)* and *Steel (Sl)* also function in the survival of primordial germ cells (Gomperts *et al.*, 1994). *Sl* mutants are sterile  
20 due to poor germ cell survival and improper migration (Witte, 1990). Therefore, PIWI and SL play a similar role in the proliferation and migration of primordial germ cells. However, the SL function is zygotically required, just as *nos* and *ovo* in *Drosophila*. *piwi* is the first clearly demonstrated case where a maternally provided product functions in the survival of pole cells during  
25 embryogenesis.

This Example further reveal that maternal PIWI is required for transcriptional repression in early germ cells. Transcriptional repression has been implicated as an essential mechanism in the establishment and maintenance of the germ cell fate (for review, see Seydoux and Strome, 1999).  
30 Previous studies indicate that the repression of RNAP II activity in early germ cells may be part of an evolutionarily conserved mechanism that distinguishes the germline from the soma during early embryogenesis (Seydoux and Dunn,

1997). Germ cells in both *Drosophila melanogaster* and *C. elegans* have been shown to lack a specific phosphoepitope of RNAP II until germ cells associate with the gut primordium during gastrulation (Seydoux and Dunn, 1997). The phosphorylation of RNAP II is a prerequisite for its transcriptional activity.  
5 Thus, the absence of the phosphoepitope suggests that RNAP II activity is inhibited in early embryonic germ cells (Seydoux and Dunn, 1997; Van Doren *et al.*, 1998).

While applicant does not wish to be bound by a particular mechanism of action, *piwi* could function to repress transcription in early germ cells by  
10 regulating the expression of this specific phosphoepitope of RNAP II. In *C. elegans*, the *pie-1* gene product has been shown to function in transcriptional repression of the germ cell lineage (Mello *et al.*, 1992). In *Drosophila*, *piwi* represents the first gene implicated in regulating transcriptional quiescence in germ cells. Prior to zygotic gene expression in the *Drosophila* embryo, germ  
15 cells undergo a wide range of morphological and cellular behaviors including precocious cellularization, translational regulation (Dalby and Glover, 1993), germ cell-specific cell cycle regulation (Sonnenblick, 1941) as well as the development of a migratory cellular morphology (Jaglarz and Howard, 1995).

Therefore, the germ plasm, which is maternally provided, must contain  
20 a combination of factors which controls these processes in early germ cells. Maternally provided factors in the germ plasm must function to repress germ cell gene expression as well as to activate specific gene expression in primordial germ cells at the appropriate time. Thus, the mechanisms for timing the onset of zygotic gene expression in the germline should be maternally  
25 provided as cell-autonomous factors to germ cells. PIWI is envisioned to represent such a factor to maintain transcriptional quiescence until the appropriate developmental timepoint. The loss of transcriptional repression in germ cells lacking maternal PIWI could result in the loss of normal germ cell properties due to differentiation, which could account for the defective pole cell  
30 migration.

PIWI as a factor for maintaining totipotency in germ cells. Primordial germ cells are the only population of cells in the organism that retain totipotent

-136-

potential. Based on studies of genes such as *pie-1*, transcriptional repression has emerged as a key mechanism that prevents germ cells from expressing genes that would cause them to enter other lineages and differentiate (Mello *et al.*, 1992; for review, see Seydoux and Strome, 1999). *piwi* is essential for the maintenance and proliferation of germline stem cells in both males and females. Germline stem cells, like primordial germ cells, should be pluripotent; the maintenance of their identity is vital for the propagation of the species. Furthermore, PIWI is specifically expressed in all pole cell nuclei and is required for proper germ cell formation and transcriptional repression. Particularly, *piwi* gene dosage is directly related to the number of pole cells formed. These data, taken together, suggest that *piwi* has many of the essential properties required for establishing and maintaining pluripotency during germline development.

#### REFERENCES

- 15 Adelman et al. (1983) *DNA* 2:183.  
Allioli, N. et al., *Dev. Biol.* 1994 Sep; 165(1): 30-7  
Altschul et al. (1990) *J. Mol. Biol.* 215:403-410.  
Ausubel et al. (1992) *Current Protocols in Molecular Biology*, (J. Wylie & Sons, N.Y.)
- 20 Barker, D. D., et al. (1992) *Genes Dev.* 6, 2312-2326.  
Bartmanska and Clermont (1983) *Cell Tiss. Kinet.* 16, 135-143.  
Bellve et al. (1977) *J. Cell Biol.* 74, 68-85.  
Bellve and O'Brien (1983) *The Mammalian Spermatozoon: Structure and Temporal Assembly*, in *Mechanisms and Control of Animal Fertilization* (Hartman, J. F. ed.), pp. 55-137, Academic Press, New York.
- 25 Bellve, A. R. (1979) *The Molecular Biology of Mammalian Spermatogenesis*, in *Oxford Review of Reproductive Biology* (eds), pp 159-261, Oxford University Clarendon Press, Oxford.  
Benfey, P.N. (1999) *Curr. Biol.* 9, 171-172.
- 30 Bitgood et al. (1996) *Curr. Biol.* 6, 298-304.

- Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition, 1976.
- Bohmert, K., et al. (1998) *EMBO J.* 17:170-180.
- Brand, A.H., and Perrimon, N. (1993) *Development* 118, 401-415.
- 5 Brown, E. H., and King, R. C. (1962) *Growth* 26, 53-70.
- Brown and Kafatos (1988) *J. Mol. Biol.* 203, 425-437.
- Brown, E. H., and King, R. C. (1964) *Growth* 28, 41-81.
- Byers et al. (1987) *J. Cell Biol.* 105, 2103-2110.
- Chang, I. K. et al., *Cell. Biol. Int.* 1997 Aug; 21(8): 495-9.
- 10 Chang, I. K. et al., *Cell. Biol. Int.* 1995 Feb; 19(2): 143-9.
- Chien et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:9578-9582.
- Chou and Perrimon (1996) *Genet.* 144, 1673-1679.
- Cox, D. N., et al., (1998) *Genes Dev.* 12, 3715-3727.
- Crea et al. (1978) *Proc. Natl. Acad. Sci. U.S.A.*, 75:5765.
- 15 de Miguel et al. (1997) *Virchows Arch.* 431(2):131-8.
- de Rooij D. G. (1988) *J. Cell Sci. Suppl.* 10:181-194.
- de Cuevas, M. and Spradling, A. C. (1998) *Development*, 125, 2781-2789.
- Deng and Lin (1997) *Dev. Biol.* 189, 79-94.
- Eichenlaub et al. (1979) *J. Bacteriol* 138:559-566.
- 20 Ephrussi et al. (1991) *Cell* 66, 37-50.
- Erickson, R. P. (1990) *Trends Genet.* 6, 264-269.
- Etches et al., in *Avian Incubation*, Chapter 22, Butterworth Publishers (1990)
- Etches et al., *Poultry Science* 72:882-887 (1993);
- Evan, G. I., et al. (1985) *Mol. Cell. Biol.* 5, 3610-3616.
- 25 Fields et al., *Int. J. Peptide Protein Res.*, 35:161-214, 1990
- Fire et al. (1998) *Nature* 391, 806-811.
- Forbes et al. (1996a) *Development* 122:1125-1135.

- Forbes and Spradling (1996b), *Development* 122:3283-3294
- Forbes and Lehmann (1998) *Development* 125:679-690.
- Friedman et al. (1990) *Screening Lambda Gt11 Libraries*, in *PCR Protocols: A Guide to Methods and Applications* (Innis et al. eds.), pp.253-260, Academic Press, San Diego, CA.
- 5 Fuller, M. (1993). *Spermatogenesis*. In *Drosophila Development*. (eds. M. Bate and A. Martinez Arias), pp. 71-148. Cold Spring Harbor Press, Cold Spring Harbor, NY.
- Gillmor et al. (1997) *Nature Struct. Biol.* 4:1003-1009.
- 10 Gold et al. (1983) *J. Exp. Zool.* 225:123-134.
- Gonczy, P. and DiNardo, S. (1996) *Development* 122, 2437-2447.
- Green et al. (1989) *J. Invest. Dermatol.* 93:486-491.
- Griswold, M. D. (1995) *Biol. Reprod.* 52:211-216.
- Guo and Kemphues (1995) *Cell* 81:611-620.
- 15 Guyomard et al., *Biochimie*, 71:857-863 (1989).
- Hay et al. (1990) *Development* 109:425-433.
- Henikoff et al. (1995) *Gene* 163:17-26.
- Hoog, C. (1995) *Int. J. Dev. Biol.* 39:719-726.
- Hopp, U.S. Patent No. 4,554,101.
- 20 Howell et al. (1988) *Antibodies A Laboratory Manual*, (Cold Spring Harbor Laboratory).
- Inoue et al., *Cell Differ. Dev.*, 29:123-128 (1990).
- Keski-Oja et al., *J. Cell Biochem.* 33:95 (1987).
- Ketterling et al. (1993) *Am J Hum Genet.* 52(1):152-66.
- 25 Kimble and Simpson (1997) *Ann. Rev. Cell Dev. Biol.* 13, 333-361.
- King, F. J., and Lin, H. (1999) *Development* 126, 1833-1844.
- King, R. C. (1970) *Ovarian Development in Drosophila melanogaster* Academic Press, New York.



- Knoblich, J. A. (1997) *Curr. Opin. Cell Biol.* 9, 833-841.
- Kramer and Erickson (1982), *J. Reprod. Fertil.* 64:139-144.
- Kuwabara, P. E. (1996) *Genet.* 144:597-607.
- Kyte et al. (1982) *J. Mol. Biol.* 157:105.
- 5 Lecuit, T., and Cohen, S.M. (1997) *Nature* 388, 139-145.
- Lee, S. J. (1990) *Mol. Cell. Biol.* 3239-3242.
- Lin, H. (1997) *Annu. Rev. Genet.* 31, 455-491.
- Lin and Schagat (1997) *Trends Genet.* 13:33-39.
- Lin, H. and Schagat, T. (1997) *Trends Genet.* 13, 33-39.
- 10 Lin and Spradling (1997) *Development* 124:2463-2476.
- Lin and Spradling (1995) *Dev. Genetics* 16:6-12.
- Lin et al. (1994) *Development* 120:947-956.
- Lin, H. (1998) *Curr. Opin. Cell Biol.* 10, 687-693.
- Lin and Spradling (1993) *Dev. Biol.* 159:140-152.
- 15 Lindsley, D.L. and Zimm, G.G. (1992). The genome of *Drosophila melanogaster*. Academic Press Inc., New York, NY.
- Lord and Dexter (1988) *J. Cell Sci. Suppl.* 10.
- Mahowald and Kambyzellis (1980) *Oogenesis*, in *Genetics and Biology of Drosophila*, pp 141-224. Academic Press, London.
- 20 Maniatis et al. (1978) *Cell* 15:687-701.
- Mar and Ordahl, *Proc. Natl. Acad. Sci. USA* 85, 6404-6408 (1988)
- Margolis and Spradling (1995) *Development* 121:3797-3807.
- Margolis, J. and Spradling, A. C. (1995) *Development* 121, 3797-3807.
- Matunis et al. (1997) *Development* 124:4383-4391.
- 25 McKearin and Ohlstein (1995) *Development* 121:2937-2947.
- McKearin, D. and Spradling, A.C. (1990) *Genes Dev.* 4, 2242-2251.
- McOmie, *Protective Groups in Organic Chemistry*, Plenum Press, New York, (1973)

- Meienhofer, *Hormonal Proteins and Peptides*, Vol. 2, p. 46, Academic Press, New York, (1983)
- Mello and Fire (1995), *Methods Cell Biol.* 48:451-482.
- Menke et al. (1997) *Am J Hum Genet.* 60:237-241.
- 5 Merrifield (1969) *Adv Enzymol* 32:221-96.
- Messing et al. (1981) *Third Cleveland Symposium on Macromolecules and Recombinant DNA*, Editor A. Walton, (Elsevier, Amsterdam).
- Morrison et al. (1997) *Cell* 88:287-298.
- Morrison, S. J., et al. (1997). *Cell* 88, 287-298.
- 10 Moussian et al. (1998) *EMBO J.* 17:1799-1809.
- Munier et al. (1998) *FEBS lett.* 4: 434(3): 289-94.
- Murata, Y. and Wharton, R. P. (1995) *Cell* 80: 747-756.
- Nakai and Kanehisa (1992) *Genomics* 14:897-911.
- Nebel et al. (1961) *Science* 134:832-833.
- 15 Needleman et al. (1970) *J. Mol. Biol.* 48:443.
- Oakberg (1956) *Am. J. Anat.* 99:507-516.
- Oakberg (1956) *Am. J. Anat.* 99:391-409.
- Ochman et al. (1990) *Amplification of flanking sequences by Inverse PCR*, in *PCR protocols: a Guide to Methods and Applications* (Innis et al., eds.), pp. 219-227. Academic Press, San Diego, California.
- 20 Ozato et al, *Cell Differ.*, 19:237-244 (1986).
- Parisi, M. J. and Lin, H. (1998) *Cell Res.* 8, 15-21.
- Parisi, M. J. and Lin, H. (1999) *Genetics*, 153, 235-250.
- Petitte et al., *Development* 108, 185-189 (1990)
- 25 Pirrotta (1988) *Vectors for P-element transformation in Drosophila*, in *Vectors. A Survey of Molecular Cloning Vectors and Their Uses.* (Rodriguez and Denhardt, eds.), pp. 437-456. Butterworths, London, England.
- Potten, C. S. (1997). *Stem cells*. Academic Press, London, England.

- Ravnik and Wolgemuth (1996) *Dev Biol.* 173, 69-78.
- Robertson, H.M., et al. (1988) *Genetics* 118, 461-470.
- Rokkones et al., *J. Comp. Physiol. B*, 158:751-758 (1989).
- Rorth, P. (1998). *Mech. Dev.* 78, 113-118.
- 5 Rorth, P. et al., (1998) *Development* 125, 1049-1057.
- Rorth, P. (1996) *Proc. Natl. Acad. Sci. USA* 93:12418-12422.
- Ruohola et al. (1991) *Cell* 66, 433-449.
- Russel and Griswold, (eds.) (1993) *The Sertoli Cell*, Cache River Press, Clearwater.
- 10 Russel et al. (1990). *Histological and Histopathological Evaluation of the Testis*, Cache River Press, Clearwater.
- Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- Sandlow et al. (1997) *Urology* 49(3), 494-500.
- 15 Schroder et al., "The Peptides", Vol. 1, Academic Press (New York) (1965).
- Schupbach, T., et al. (1978) *Willhelm Roux Arch.* 184: 41-56.
- Shankar et al. (1998) *Biochem Biophys Res Commun.* 13: 243(2): 561-5.
- Shimmin et al. (1993) *Nature* 22, 362(6422): 745-7.
- Smith, A. G. and Hooper, M. L., *Dev. Biol.* 1987 May; 121(1): 1-9
- 20 Smith et al., *Adv. Appl. Math.* 2:482 (1981).
- Spradling and Rubin (1982) *Science* 218:341-347.
- Spradling A. (1993) *Developmental Genetics of Oogenesis*, in *Drosophila Development*, (Bate and Martinez-Arias eds.), pp. 1-70, Cold Spring Harbor, NY.
- 25 Steward et al. (1969) *Solid Phase Peptide Synthesis*, W. H. Freeman Co., San Francisco.

-142-

Sulston and Hodgkin (1988) *Methods*, in *The Nematode Caenorhabditis elegans*, (ed. W. B. Wood), pp. 598-600. Cold Spring Harbor Press, Cold Spring Harbor, NY.

Thierry-Mieg and Durbin (1992) *Cahiers IMABIO* 5, 15-24.

5 Thomas et al. (1989) *Biol. Reprod.* 41, 729-739.

U. S. Patent No. 4,877,729

U. S. Patent No. 4,761,371

U. S. Patent No. 4,912,038

U.S. Patent No. 5,648,061

10 U.S. Patent No. 5,643,567

U.S. Patent No. 5,624,816

U.S. Patent No. 5,614,396

U.S. Patent No. 5,627,158

U.S. Patent No. 5,625,125

15 U.S. Patent No. 5,580,979

U.S. Patent No. 5,573,933

U.S. Patent No. 5,550,316

U.S. Patent No. 5,739,278

U.S. Patent No. 5,436,288

20 U.S. Patent No. 5,651,964

U.S. Patent No. 5,589,375

U.S. Patent No. 5,583,103

U.S. Patent No. 5,352,660

U.S. Patent No. 5,279,833

25 U.S. Patent No. 5,234,933

U.S. Patent No. 5,162,215

U.S. Patent No. 5,120,535

- U.S. Patent No. 4,736,866
- U.S. Patent No. 5,645,999
- U.S. Patent No. 5,837,479
- U.S. Patent No. 4,244,946
- 5 U.S. Patent No. 4,196,265
- U.S. Patent No. 3,095,355
- U.S. Patent No. 2,868,691
- U.S. Patent No. 5,786,152
- U.S. Patent No. 5,723,593
- 10 U.S. Patent No. 5,753,687
- U.S. Patent No. 5,770,609
- U.S. Patent No. 5,693,488
- U.S. Patent No. 5,646,008
- U.S. Patent No. 5,286,634
- 15 U.S. Patent No. 5,741,957
- U.S. Patent No. 5,326,902
- U.S. Patent No. 5,399,346
- U.S. Patent No. 5,776,902
- U.S. Patent No. 5,780,436
- 20 U.S. Patent No. 5,489,742
- U.S. Patent No. 4,769,331
- U.S. Patent No. 5,641,484
- U.S. Patent No. 4,686,283
- U.S. Patent No. 4,683,202
- 25 U.S. Patent No. 5,734,033
- van Roijen et al. (1998) *Hum Reprod.* 13(6): 1559-66.
- Vanfleteren et al. (1994) *Mol. Phylogenet. Evol.* 3:92-101.

-144-

- Verrinder Gibbins et al., *Fourth World Congress on Genetics Applied to Livestock Production*, Edinburgh, (1990);
- Von Wettstein et al. (1984) *Annu. Rev. Genet.* 18: 331-413.
- Wetmur & Davidson (1968) *J. Mol. Biol.* 31:349-370.
- 5 Wieschaus and Szabad (1979) *Dev. Biol.* 68:29-46.
- Willison and Ashworth (1987) *Trends Genet.* 3: 351-355.
- Wilson et al. (1989) *Genes Dev.* 3:1301-1313.
- WO 93/25521
- WO 96/40276
- 10 WO 99/06533
- Wolgemuth and Watrin (1991) *Mamm Genome* 1:283-288.
- Xie and Spradling (1998) *Cell* 94:251-260.
- Xu and Rubin (1993) *Development* 117:1223-37.
- Xu et al. (1992) *Development* 115:913-922.
- 15 Yue and Spradling (1992) *Genes Dev.* 6:2443-2454.
- Zaccai, M. and Lipshitz, H.D. (1996). *Zygote* 4, 159-166.
- Zhao et al. (1996) *Genes Dev.* 10:1657-1669.
- Zhu and Naz (1998) *Biochem Biophys Res Commun.* 10:249(1):56-60.
- Zimmer et al., *Peptides* 1992, pp. 393-394, ESCOM Science Publishers, B.
- 20 V. 1993.

It will be understood that various details of the invention may be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation--the invention being defined by the claims.

CLAIMS

What is claimed is:

1. An isolated and purified biologically active *piwi* family polypeptide comprising:
  - 5 (a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
  - (b) a polypeptide encoded by a nucleic acid having at least about 75% or greater homology to a DNA sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
  - 10 (c) a polypeptide encoded by a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a sequence or the complement of a sequence as set forth in any of SEQ ID NOs:1, 3 and 5;
  - (d) a polypeptide which is a biologically functional equivalent of a  
15 peptide as set forth in any of SEQ ID NOs:2, 4 and 6;
  - (e) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with peptides encoded by the nucleic acid sequences as set forth in any of SEQ ID NOs:2, 4 and 6;
  - 20 (f) a polypeptide encoded by a nucleic acid molecule capable of hybridizing to a nucleic acid molecule having the sequence of any of SEQ ID NOs:1, 3 and 5, or fragments or variants or complementary sequences thereof, under high stringency conditions; or
  - 25 (g) a polypeptide comprising a portion of a polypeptide of a), b), c), d), e), or f).
2. The polypeptide of claim 1, wherein the polypeptide comprises a vertebrate *piwi* family polypeptide.
3. The polypeptide of claim 2, wherein the polypeptide comprises  
30 a human *piwi* family polypeptide.

-146-

4. The polypeptide of claim 1, wherein the *piwi* family comprises an amino acid sequence as set forth in any of SEQ ID NOs:2, 4 and 6.
5. The polypeptide of claim 1, modified to be in detectably labeled form.
- 5 6. An isolated and purified antibody capable of specifically binding to the polypeptide of claim 1.
7. The antibody of claim 6 which is a monoclonal antibody.
8. The antibody of claim 6 which is a polyclonal antibody.
9. A hybridoma cell line which produces the monoclonal antibody of  
10 claim 8.
10. An isolated and purified antibody capable of neutralizing the biological activity of the polypeptide of claim 1.
11. The antibody of claim 10 which is a monoclonal antibody.
12. The antibody of claim 10 which is a polyclonal antibody.
- 15 13. A hybridoma cell line which produces the monoclonal antibody of claim 11.
14. An isolated and purified polynucleic acid encoding a biologically active *piwi* family polypeptide of claim 1.
15. The polynucleic acid of claim 14, wherein the encoded  
20 polypeptide comprises a vertebrate *piwi* family polypeptide.
16. The polynucleic acid of claim 15, wherein the encoded polypeptide comprises a mammalian *piwi* family polypeptide.
17. The polynucleic acid of claim 16, wherein the encoded polypeptide comprises a human *piwi* family polypeptide.
- 25 18. The polynucleic acid of claim 14, wherein the encoded polypeptide comprises an amino acid sequence as set forth in any of SEQ ID NOs:2, 4 and 6.



-147-

19. The polynucleic acid of claim 18, further comprising a *piwi* family-encoding polynucleic acid sequence as set forth in any of SEQ ID NOs:1, 3 and 5.

5 20. The polynucleic acid of claim 14, further defined as a DNA segment.

21. The polynucleic acid of claim 14, further defined as positioned under the control of a promoter.

22. The polynucleic acid of claim 14, further defined as a recombinant vector.

10 23. The polynucleic acid of claim 22, wherein the vector is a recombinant expression vector.

24. The polynucleic acid of claim 22, further defined as a nucleic acid fragment of up to 50,000 basepairs in length.

15 25. The polynucleic acid of claim 24, further defined as comprising at least a 1,000 nucleotide long contiguous stretch of a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

26. A recombinant host cell comprising the polynucleic acid of claim 14.

20 27. The recombinant host cell of claim 26, wherein the host cell is a procaryotic cell.

28. The recombinant host cell of claim 26, wherein the host cell is a eukaryotic cell.

25 29. A method of preparing a *piwi* family polypeptide, comprising: transforming a cell with the polynucleic acid of claim 14 to produce a *piwi* family under conditions suitable for the expression of said polypeptide.

30. A method of detecting in a sample an RNA that encodes the *piwi* family polypeptide encoded by the nucleic acid of claim 14, said method comprising the steps of:

30 (a) contacting said sample under hybridizing conditions with the polynucleic acid of claim 14 to form a duplex; and

-148-

(b) detecting the presence of said duplex.

31. A method of producing an antibody immunoreactive with a *piwi* family polypeptide, the method comprising steps of:

- 5           (a) transfecting a recombinant host cell with the a polynucleic acid of claim 14, which encodes a *piwi* family polypeptide;
- (b) culturing the host cell under conditions sufficient for expression of the polypeptide;
- (c) recovering the polypeptide; and
- (d) preparing the antibody to the polypeptide.

10          32. The method of claim 31, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

33. The method of claim 31, wherein the polynucleic acid comprises a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

15          34. An antibody produced by the method of claim 31.

35. A method of detecting a *piwi* family polypeptide, the method comprising immunoreacting the polypeptide with an antibody prepared according the method of claim 31 to form an antibody-polypeptide conjugate; and detecting the conjugate.

20          36. A method of detecting a messenger RNA transcript that encodes a *piwi* family polypeptide, the method comprising the steps of hybridizing the messenger RNA transcript with the polynucleic acid of claim 14 to form a duplex; and detecting the duplex.

25          37. A method of detecting a DNA molecule that encodes a *piwi* family polypeptide, the method comprising the steps of hybridizing DNA molecules with the polynucleic acid of claim 14 to form a duplex; and detecting the duplex.

38. An assay kit for detecting the presence of a *piwi* family polypeptide in a biological sample, the kit comprising a first container containing a first antibody capable of immunoreacting with a *piwi* family

-149-

polypeptide of claim 1, wherein the first antibody is present in an amount sufficient to perform at least one assay.

39. The assay kit of claim 38, further comprising a second container containing a second antibody that immunoreacts with the first antibody.

5           40. The assay kit of claim 39, wherein the first antibody and the second antibody comprise monoclonal antibodies.

41. The assay kit of claim 39, wherein the first antibody is affixed to a solid support.

10           42. The assay kit of claim 39, wherein the first and second antibodies each comprise an indicator.

43. The assay kit of claim 42, wherein the indicator is a radioactive label, a fluorescent label or an enzyme.

15           44. An assay kit for detecting the presence, in biological samples, of a *piwi* family polypeptide, the kit comprising a first container that contains a polynucleic acid identical or complimentary to a segment of at least ten contiguous nucleotide bases of the polynucleic acid of claim 14.

20           45. An assay kit for detecting the presence, in a biological sample, of an antibody immunoreactive with a *piwi* family polypeptide, the kit comprising a first container containing a *piwi* family polypeptide of claim 1 that immunoreacts with the antibody, with the polypeptide present in an amount sufficient to perform at least one assay.

46. A method of screening candidate substances for an ability to modulate *piwi* family biological activity, the method comprising the steps of:

- 25           (a) establishing replicate test and control samples that comprise a biologically active *piwi* family polypeptide;
- (b) administering a candidate substance to the test sample but not the control sample;
- (c) measuring *piwi* family biological activity in the test and the control samples; and

-150-

- 5 (d) determining that the candidate substance modulates *piwi* family biological activity if the *piwi* family biological activity measured for the test sample is greater or less than the *piwi* family biological activity measured for the control sample.

47. The method of claim 46, wherein the candidate substance is further characterized as a candidate polypeptide, and further comprising the step of purifying and isolating a gene encoding the candidate polypeptide.

- 10 48. The method of claim 46, wherein the replicate test and control samples further comprise a cell that expresses a biologically active vertebrate *piwi* family polypeptide.

49. A recombinant cell line suitable for use in the method of claim 46.

- 15 50. A method of modulating *piwi* family polypeptide activity in a subject, the method comprising the step of administering to the subject an effective amount of a substance capable of modulating the *piwi* family polypeptide activity in the subject, whereby modulation of the *piwi* family polypeptide activity is accomplished.

- 20 51. The method of claim 50, wherein the step of administering further comprises administering an effective amount of a substance that modulates expression of a *piwi* family-encoding polynucleic acid in the subject.

52. The method of claim 51, wherein the substance that modulates expression of a *piwi* family-encoding polynucleic acid comprises an antisense oligonucleotide.

- 25 53. The method of claim 50, where the substance that modulates the *piwi* family activity comprises an anti-*piwi* family antibody.

54. The method of claim 53, where the anti-*piwi* family antibody comprises a monoclonal antibody.

55. The method of claim 50, wherein the *piwi* family activity comprises modulating cell growth, proliferation, division and combinations thereof, and

wherein the step of administering comprises administering to the subject an effective *piwi* family-modulating amount of a *piwi* family-modulating substance.

56. The method of claim 50, wherein the subject is a vertebrate.

57. The method of claim 56, wherein the vertebrate is a warm-blooded vertebrate.

58. A method of treating a subject suffering from a disorder associated with *piwi* family biological activity, the method comprising: administering to the subject an effective amount of a *piwi* family biological activity-modulating substance, whereby treatment of the disorder is accomplished.

59. The method of claim 58, wherein the step of administering further comprises administering an effective amount of a substance that modulates expression of a *piwi* family-encoding polynucleic acid in the subject.

60. The method of claim 59, wherein the substance that modulates expression of a *piwi* family-encoding polynucleic acid comprises an antisense oligonucleotide.

61. The method of claim 58, wherein the substance capable of modulating *piwi* family activity in the subject comprises an anti-*piwi* family antibody.

62. The method of claim 61, wherein the anti-*piwi* family antibody comprises a monoclonal antibody.

63. A method of treating a subject suffering from a disorder associated with *piwi*-mediated biological activity, the method comprising administering to the subject a therapeutic composition which comprises a biologically active *piwi* family polypeptide, whereby treatment of disorder associated with *piwi*-mediated biological activity in the subject is accomplished.

64. The method of claim 63, wherein the therapeutic composition comprises a biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

-152-

65. The method of claim 63, wherein the *piwi*-mediated biological activity comprises modulation of stem cell growth, proliferation, division and combinations thereof, modulation of primordial germ cell proliferation, and combinations thereof; and the *piwi* family polypeptide is administered in an effective amount.

65. A method for modulating *piwi*-mediated biological activity in a cell, the method comprising:

- (a) delivering to the cell an effective amount of a DNA molecule comprising a polynucleotide that encodes a biologically active *piwi* family polypeptide; and
- (b) maintaining the cell under conditions sufficient for expression of said polypeptide.

66. The method of claim 65, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

67. The method of claim 66, wherein the polypeptide is encoded by a polynucleic acid as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

68. A method of culturing a primitive cell, the method comprising:

- (a) providing a culture comprising a primitive cell; and
- (b) delivering to the primitive cell a *piwi* family gene product, whereby growth of the primitive cell in a culture is accomplished.

69. The method of claim 68, wherein the primitive cell is maintained in the culture for a time sufficient to produce a sustained cell culture.

70. The method of claim 68, wherein the *piwi* family gene product is delivered to the primitive cell by delivering to the primitive cell an effective amount of a polynucleotide that encodes a biologically active *piwi* family polypeptide; and maintaining the primitive cell under conditions sufficient for expression of the polypeptide.

71. The method of claim 68, wherein the *piwi* family gene product is delivered to the cell by administration of a biologically active *piwi* family polypeptide to the culture.

-153-

72. The method of claim 68, further comprising:

- (a) collecting primitive cells;
- (b) depositing the primitive cells in contact with a feeder matrix, the feeder matrix comprising a *piwi* family gene product; and
- 5 (c) culturing the primitive cells on the feeder matrix in the presence of media for a time sufficient to produce a sustained primitive cell culture.

73. The method of claim 68, wherein the feeder matrix comprises a recombinant cell comprising a polynucleic acid encoding a biologically active  
10 *piwi* family polypeptide.

74. The method of claim 68, further comprising establishing a monolayer of cells in the feeder matrix.

75. A transgenic or chimeric non-human animal having incorporated into its genome a polynucleic acid encoding a biologically active *piwi* family  
15 polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the *piwi* family polypeptide.

76. The transgenic or chimeric non-human animal of claim 75, wherein said polynucleic acid comprises a human *piwi* family-encoding segment.

20 77. The transgenic or chimeric non-human animal of claim 75, wherein the expression of the *piwi* family polypeptide is conferred in reproductive tissue of the animal.

78. The transgenic or chimeric non-human animal of claim 75, wherein the expression of the *piwi* family polypeptide confers an increased  
25 number of germline stem cells or primordial germ cells in the animal as compared to a normal animal.

79. The transgenic or chimeric non-human animal of claim 75, further comprising an additional polynucleic acid encoding a predetermined biologically  
30 active polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the polypeptide.

-154-

80. A method of altering the phenotype of an embryonic animal, the method comprising:

- (a) providing a recombinant primitive cell comprising a polynucleic acid encoding a biologically active *piwi* family polypeptide;
- 5 (b) transfecting the recombinant primitive cell with a polynucleic acid encoding a predetermined biologically active polypeptide;
- (c) transferring the transfected primitive cells into an embryo to confer expression of the predetermined biologically active polypeptide animal of the polypeptide, whereby the phenotype of the embryo is altered.

10

81. The method of claim 80, wherein the animal is a bird, and the transfected primitive cell is transferred into an egg containing an embryonic bird.

82. The method of claim 80, wherein the altered phenotype comprises a change in protein expression, a change in growth rate, feed efficiency, a change in stem cell count, a change in primordial germ cell count, disease resistance, or a combination thereof.

15

83. The method of claim 80, wherein the embryonic animal is permitted to develop into a fetus or animal.

20

84. A method of recovering a protein from a transgenic or chimeric non-human animal, the method comprising:

25

- (a) providing a transgenic or chimeric non-human animal having incorporated into its genome a polynucleic acid encoding a biologically active *piwi* family polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the *piwi* family polypeptide; and
- (b) recovering the biologically active *piwi* family polypeptide from the animal provided in step (a).



-155-

85. The method of claim 84, wherein the transgenic or chimeric non-human animal provided in step (a) further comprises another polynucleic acid incorporated into its genome, the polynucleic acid encoding a predetermined biologically active polypeptide, the polynucleic acid being present in said genome in a copy number effective to confer expression in the animal of the predetermined polypeptide; and wherein the predetermined biologically active polypeptide is recovered in addition to or instead of the biologically active *piwi* family polypeptide.

85. The method of claim 84 or 85, wherein the transgenic or chimeric non-human animal provided in step (a) further comprises an avian, and the polypeptide is recovered from an egg produced by the avian.

86. A pharmaceutical composition comprising an isolated and purified biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

87. The pharmaceutical composition of claim 86, wherein the polypeptide comprises a polypeptide as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

88. The pharmaceutical composition of claim 86, wherein the polypeptide is encoded by a polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

89. The pharmaceutical composition of claim 86, further comprising a cell expressing the polypeptide.

90. A pharmaceutical composition comprising an isolated and purified polynucleic acid encoding a biologically active *piwi* family polypeptide and a pharmaceutically acceptable carrier.

91. The pharmaceutical composition of claim 90, wherein the encoded polypeptide comprises an amino acid sequence as essentially set forth in any of SEQ ID NOs:2, 4 and 6.

92. The pharmaceutical composition of claim 90, further comprising a *piwi* family-encoding polynucleic acid sequence as essentially set forth in any of SEQ ID NOs:1, 3 and 5.

-156-

93. The pharmaceutical composition of claim 90, wherein the polynucleic acid is a DNA segment.
94. The pharmaceutical composition of claim 90, wherein the polynucleic acid is positioned under the control of a promoter.
- 5 95. The pharmaceutical composition of claim 90, wherein the polynucleic acid further comprises a recombinant vector.
96. The pharmaceutical composition of claim 90, further comprising a cell expressing the encoded polypeptide.




FIG. 1

2/11

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIG. 2

3/11




FIG. 3




FIG. 4




FIG. 5A

*miwi*  
genomic  
locus

FIG. 5B



*miwi*  
cDNA  
(partial)

FIG. 5C

genomic  
clones

FIG. 5D

6/11

MA	DQ	GR	RR	RR	PL	NE	DO	SS	TS	RG	SG	GD	GP	RV	KV	FR	GS	SS	GD	PP	RA	DP	RI	EA	-S	RR	RR	-A	LE	EA	PR	RG	-	-	-	65																																		
MA	GS	GR	GR	GR	GS	GN	NS	-	-	-	-	-	GG	KD	QX	YL	GT	-	-	-	Q	DL	FI	RQ	QS	-K	TG	SS	GQ	PQ	K	-	-	-	52																																			
PRG-1	MA	GS	GR	GR	GR	GS	GN	NS	-	-	-	-	GG	KD	QX	YL	GT	-	-	-	Q	DL	FI	RQ	QS	-K	TG	SS	GQ	PQ	K	-	-	-	1																																			
PRG-2	MA	GS	GR	GR	GR	GS	GN	NS	-	-	-	-	GG	KD	QX	YL	GT	-	-	-	Q	DL	FI	RQ	QS	-K	TG	SS	GQ	PQ	K	-	-	-	1																																			
MI	T	GR	AR	AR	GR	AR	GR	QET	V	Q	H	VA	AA	SS	QQ	PG	YI	P	PR	P	Q	S	P	TE	GD	L	V	GR	GR	QR	GM	V	V	GA	T	SK	SQ	EL	Q	IS	69																													
MI	T	GR	AR	AR	GR	AR	GR	QET	V	Q	H	VA	AA	SS	QQ	PG	YI	P	PR	P	Q	S	P	TE	GD	L	V	GR	GR	QR	GM	V	V	GA	T	SK	SQ	EL	Q	IS	68																													
MI	T	GR	AR	AR	GR	AR	GR	QET	V	Q	H	VA	AA	SS	QQ	PG	YI	P	PR	P	Q	S	P	TE	GD	L	V	GR	GR	QR	GM	V	V	GA	T	SK	SQ	EL	Q	IS	68																													
PI	WI	-	-	-	-	-	-	-	-	-	-	-	SK	KG	TG	DG	V	P	V	M	L	Q	T	N	F	E	R	L	K	T	K	P	E	M	R	I	V	H	Y	H	V	E	F	V	P	123																								
PRG-1	PI	WI	-	-	-	-	-	-	-	-	-	-	SK	KG	TG	DG	V	P	V	M	L	Q	T	N	F	E	R	L	K	T	K	P	E	M	R	I	V	H	Y	H	V	E	F	V	P	123																								
PRG-2	PI	WI	-	-	-	-	-	-	-	-	-	-	SK	KG	TG	DG	V	P	V	M	L	Q	T	N	F	E	R	L	K	T	K	P	E	M	R	I	V	H	Y	H	V	E	F	V	P	123																								
MI	WI	A	G	F	E	L	S	A	E	R	G	G	R	R	D	F	H	D	L	G	V	N	T	R	Q	N	L	O	H	V	K	E	S	K	I	G	S	S	G	I	I	V	K	L	S	T	N	H	F	R	L	T	S	R	P	Q	W	A	L	Y	Q	Y	H	I	D	Y	N	P	139	
MI	WI	A	G	F	E	L	S	A	E	R	G	G	R	R	D	F	H	D	L	G	V	N	T	R	Q	N	L	O	H	V	K	E	S	K	I	G	S	S	G	I	I	V	K	L	S	T	N	H	F	R	L	T	S	R	P	Q	W	A	L	Y	Q	Y	H	I	D	Y	N	P	138	
PI	WI	T	I	E	N	P	R	V	R	M	G	V	L	S	N	H	A	-	N	L	G	S	G	Y	L	F	D	G	L	Q	L	F	T	T	R	K	F	E	Q	E	I	T	V	L	S	G	K	X	L	D	I	E	Y	K	I	S	I	K	F	V	G	F	I	S	C	A	E	P	191	
PRG-1	PI	WI	T	I	E	N	P	R	V	R	M	G	V	L	S	N	H	A	-	N	L	G	S	G	Y	L	F	D	G	L	Q	L	F	T	T	R	K	F	E	Q	E	I	T	V	L	S	G	K	X	L	D	I	E	Y	K	I	S	I	K	F	V	G	F	I	S	C	A	E	P	191
PRG-2	PI	WI	T	I	E	N	P	R	V	R	M	G	V	L	S	N	H	A	-	N	L	G	S	G	Y	L	F	D	G	L	Q	L	F	T	T	R	K	F	E	Q	E	I	T	V	L	S	G																							

FIG. 6A



7/11

PIWI	VEYYLT	KYNI	RIR	DHN	QPL	ISK	-NR	KA	LKT	NASE	LV	LI	PE	LC	RV	TGL	NA	EM	RS	NF	QL	MR	AM	SS	Y	TRM	393																																								
PRG-1	KEYF	KNQY	GI	EIT	VDD	QPI	ISE	-G	KPK	PG	-EP	PQ	VS	YV	PE	LC	FP	TGL	DE	MR	KD	EK	MM	KE	I	AK	H	TRM	352																																						
PRG-2	KEYF	KNQY	DI	DIT	DE	QFI	ISE	-G	KPK	QPG	-EP	PQ	VN	YV	PE	LC	FP	TGL	DE	MR	KD	EK	MM	KE	I	AK	H	TRM	250																																						
MIWI	LEYR	RKQY	QNI	EIT	DL	KQ	PVL	VS	QPK	RRR	GP	GT	LP	GP	AM	LI	PE	LC	YLT	G	LT	D	K	MR	ND	F	N	V	M	KD	L	AV	H	TR	L	413																															
HIWI	LEYR	RKQY	QNI	EIT	DL	KQ	PVL	VS	QPK	RRR	GP	GT	LP	GP	AM	LI	PE	LC	YLT	G	LT	D	K	MR	ND	F	N	V	M	KD	L	AV	H	TR	L	412																															
PIWI	NP	KQR	--	-T	DL	R	AF	NH	R	L	QMT	P	ES	V	KVL	--	-RD	WN	ME	LD	KN	VTE	VQ	GR	II	QQ	NI	V	F	HN	GK	V	P	--	-	AGE	454																														
PRG-1	SP	QQR	--	-I	VE	SR	KL	I	VD	LS	KN	E--	--	KV	ME	CF	XY	WG	IS	LG	QD	LAN	VQ	AR	VL	K	SE	PL	--	-	Q	G	K	T	Y	--	-	EGK	411																												
PRG-2	SP	QQR	--	-L	DE	TR	KL	I	IK	LS	KN	E--	--	TM	ME	CF	XY	WG	IS	LG	QD	LAN	VQ	AR	VL	K	SE	PL	--	-	Q	G	K	T	Y	--	-	EGK	309																												
MIWI	T	P	Q	R	Q	R	E	V	G	R	L	I	D	Y	I	H	K	D	N	V	Q--	-REL	--	-RD	WG	LS	F	D	SN	L	S	F	S	G	R	I	L	Q	SE	K	I	--	-	HQ	G	K	T	F	D	Y	N	P	Q	475													
HIWI	T	P	Q	R	Q	R	E	V	G	R	L	I	D	Y	I	H	K	D	N	V	Q--	-REL	--	-RD	WG	LS	F	D	SN	L	S	F	S	G	R	I	L	Q	SE	K	I	--	-	HQ	G	K	T	F	D	Y	N	P	Q	474													
PIWI	N	AD	W	Q	R	H	F	R	D	Q	R	M	L	T	P	S	D	G	L	D	R	WA	V	I	A	P	Q	R	N	S	HEL	--	-RT	L	D	S	L	Y	R	A	S	G	M	G	L	R	I	R	S	P	Q	E	F	I	Y	D	D	R	T	G	522						
PRG-1	Q	A	E	W	A	R	G	V	K	E	C	G	I	Y	R	G	S	N	--	-MT	NW	I	V	I	G	P	G	S	G	N	S	G	L	L	S	K	F	I	E	E	A	R	R	L	G	K	I	L	Q	V	Q	L	G	E	P	M	C	V	P	I	R	G	I	S	P	N	479
PRG-2	Q	A	E	W	A	R	G	V	K	E	C	G	I	Y	R	G	S	N	--	-MT	NW	I	V	I	G	P	G	S	G	N	S	G	L	L	S	K	F	I	E	E	A	R	N	L	G	R	T	L	Q	V	Q	L	G	E	P	M	C	V	K	I	N	G	I	S	P	N	377
MIWI	F	AD	W	S	K	E	T	R	G	A	P	L	I	S	V	K	P	--	-L	DN	WL	I	I	Y	T	R	R	N	Y	E	A	--	-NS	L	I	Q	N	L	F	K	V	T	P	A	M	G	I	Q	M	K	A	I	M	I	E	V	-D	D	R	T	E	540					
HIWI	F	AD	W	S	K	E	T	R	G	A	P	L	I	S	V	K	P	--	-L	DN	WL	I	I	Y	T	R	R	N	Y	E	A	--	-NS	L	I	Q	N	L	F	K	V	T	P	A	M	G	M	Q	M	R	K	A	I	M	I	E	V	-D	D	R	T	E	539				
PIWI	T																																																																		

FIG. 6B

8/11

[illegible]

FIG. 6C

9/11




FIG. 7

10/11




FIG. 8





FIG. 9

**FIG. 10**

-1-

## SEQUENCE LISTING

<110> Duke University  
Lin, Haifan

<120> PURIFIED AND ISOLATED *piwi* FAMILY GENES AND GENE  
5 PRODUCTS AND METHODS EMPLOYING SAME

<130> Attorney Docket No. 180-104 PCT

<140>

<141>

<150> 60/110,091

10 <151> 1998-12-04

<160> 11

<170> PatentIn Ver. 2.1

<210> 1

<211> 3047

15 <212> DNA

<213> *Drosophila* sp.

<220>

<221> CDS

<222> (84)..(2612)

20 <220>

<221> misc\_feature

<222> (120)

<223> n=a or c, Xaa=Leu or Ile

-2-

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (399)

&lt;223&gt; n=a or t, Xaa=Leu or Ile

5 &lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2436)

&lt;223&gt; n=a or c, Xaa=Leu or Ile

&lt;400&gt; 1

10 ctgagtccaa agcgtcggtt tcaaagtact ctttcagttt ccattgtgaa gttttaagtg 60

atcgcgagtg ccaaaaagta aca atg gct gat gat cag gga cgt gga cgc agg 113  
Met Ala Asp Asp Gln Gly Arg Gly Arg Arg  
1 5 10

15 cgt cca ntt aac gaa gat gat tcc tct act tcc cga ggt agt ggt gat 161  
Arg Pro Xaa Asn Glu Asp Asp Ser Ser Thr Ser Arg Gly Ser Gly Asp  
15 20 25

ggg ccg cgg gtg aaa gta ttc aga gga tct tca tca ggt gac ccg aga 209  
Gly Pro Arg Val Lys Val Phe Arg Gly Ser Ser Ser Gly Asp Pro Arg  
30 35 40

20 gcg gat cct cgt ata gag gct tca aga gag aga aga gct ctc gag gaa 257  
Ala Asp Pro Arg Ile Glu Ala Ser Arg Glu Arg Arg Ala Leu Glu Glu  
45 50 55

gct ccc agg cgt gaa ggt ggc ccg cca gag cga aag ccg tgg ggt gac 305  
Ala Pro Arg Arg Glu Gly Gly Pro Pro Glu Arg Lys Pro Trp Gly Asp  
25 60 65 70

caa tat gat tac ctg aat acc cgt ccg gtt gag ctg gta tcc aag aag 353  
Gln Tyr Asp Tyr Leu Asn Thr Arg Pro Val Glu Leu Val Ser Lys Lys  
75 80 85 90

30 gga acc gat ggc gtc ccg gtc atg ctg cag acg aac ttt ttt cga nta 401  
Gly Thr Asp Gly Val Pro Val Met Leu Gln Thr Asn Phe Phe Arg Xaa  
95 100 105

-3-

	aaa acc aag ccg gaa tgg cgg atc gtt cat tat cac gtg gag ttt gtg	449
	Lys Thr Lys Pro Glu Trp Arg Ile Val His Tyr His Val Glu Phe Val	
	110 115 120	
5	ccg acc atc gag aat cct cgt gtc cgt atg gga gtt ttg tcc aat cat	497
	Pro Thr Ile Glu Asn Pro Arg Val Arg Met Gly Val Leu Ser Asn His	
	125 130 135	
	gct aac ctt ctg gga tca ggc tat cta ttc gac gga ctg caa ctg ttc	545
	Ala Asn Leu Leu Gly Ser Gly Tyr Leu Phe Asp Gly Leu Gln Leu Phe	
	140 145 150	
10	acc acc agg aaa ttc gag cag gaa atc acg gtg ctc agc gga aag tcg	593
	Thr Thr Arg Lys Phe Glu Gln Glu Ile Thr Val Leu Ser Gly Lys Ser	
	155 160 165 170	
	aag ctg gac att gaa tac aag ata tcc ata aag ttc gtt gga ttc ata	641
15	Lys Leu Asp Ile Glu Tyr Lys Ile Ser Ile Lys Phe Val Gly Phe Ile	
	175 180 185	
	tcg tgt gct gag ccc cgc ttt ttg caa gtc tta aat cta ata ttg cgc	689
	Ser Cys Ala Glu Pro Arg Phe Leu Gln Val Leu Asn Leu Ile Leu Arg	
	190 195 200	
20	cgc tcg atg aag ggc cta aat ttg gaa tta gtt ggc cgt aat ctc ttt	737
	Arg Ser Met Lys Gly Leu Asn Leu Glu Leu Val Gly Arg Asn Leu Phe	
	205 210 215	
	gat ccc cga gct aag atc gaa ata agg gag ttc aaa atg gag cta tgg	785
	Asp Pro Arg Ala Lys Ile Glu Ile Arg Glu Phe Lys Met Glu Leu Trp	
	220 225 230	
25	ccg ggc tat gag aca tcg att cgt cag cac gaa aaa gat att tta ttg	833
	Pro Gly Tyr Glu Thr Ser Ile Arg Gln His Glu Lys Asp Ile Leu Leu	
	235 240 245 250	
	ggc acc gaa ata act cac aaa gtt atg cgc acc gag acg atc tac gac	881
30	Gly Thr Glu Ile Thr His Lys Val Met Arg Thr Glu Thr Ile Tyr Asp	
	255 260 265	
	ata atg cga cgt tgc tca cac aat ccg gct cgt cat cag gac gaa gta	929
	Ile Met Arg Arg Cys Ser His Asn Pro Ala Arg His Gln Asp Glu Val	
	270 275 280	
35	cgg gta aat gtt ttg gac ttg att gtc ctt acg gat tac aat aac aga	977
	Arg Val Asn Val Leu Asp Leu Ile Val Leu Thr Asp Tyr Asn Asn Arg	
	285 290 295	
	act tat cgt atc aat gat gtc gac ttt gga caa act ccg aaa tca aca	1025
	Thr Tyr Arg Ile Asn Asp Val Asp Phe Gly Gln Thr Pro Lys Ser Thr	
	300 305 310	



-4-

	ttc agt tgc aag ggt aga gat atc agt ttc gtg gaa tac tat ctc act	1073
	Phe Ser Cys Lys Gly Arg Asp Ile Ser Phe Val Glu Tyr Tyr Leu Thr	
	315 320 325 330	
5	aaa tat aat ata cgc att cgc gac cac aat cag ccg ctg ctg att tcc	1121
	Lys Tyr Asn Ile Arg Ile Arg Asp His Asn Gln Pro Leu Leu Ile Ser	
	335 340 345	
	aaa aat agg gac aag gct cta aaa act aac gct agc gaa tta gtg gta	1169
	Lys Asn Arg Asp Lys Ala Leu Lys Thr Asn Ala Ser Glu Leu Val Val	
	350 355 360	
10	cta att cct gag ctc tgc cga gtg act ggg ctc aat gcc gag atg cgc	1217
	Leu Ile Pro Glu Leu Cys Arg Val Thr Gly Leu Asn Ala Glu Met Arg	
	365 370 375	
	tca aac ttt cag ctt atg cgt gcc atg agc agt tat acg cga atg aac	1265
15	Ser Asn Phe Gln Leu Met Arg Ala Met Ser Ser Tyr Thr Arg Met Asn	
	380 385 390	
	ccc aaa caa cgc act gat cga ttg cgc gct ttt aac cac cgt tta caa	1313
	Pro Lys Gln Arg Thr Asp Arg Leu Arg Ala Phe Asn His Arg Leu Gln	
	395 400 405 410	
20	aac act cca gaa agt gtg aag gtc ttg aga gac tgg aac atg gaa ctg	1361
	Asn Thr Pro Glu Ser Val Lys Val Leu Arg Asp Trp Asn Met Glu Leu	
	415 420 425	
	gac aag aac gtc aca gaa gta caa ggc cgg ata att gga cag cag aac	1409
	Asp Lys Asn Val Thr Glu Val Gln Gly Arg Ile Ile Gly Gln Gln Asn	
	430 435 440	
25	atc gtg ttt cat aat gga aag gtt cct gct gga gaa aac gct gat tgg	1457
	Ile Val Phe His Asn Gly Lys Val Pro Ala Gly Glu Asn Ala Asp Trp	
	445 450 455	
	caa agg cac ttc aga gac caa agg atg ctt acc act ccg agc gat ggc	1505
30	Gln Arg His Phe Arg Asp Gln Arg Met Leu Thr Thr Pro Ser Asp Gly	
	460 465 470	
	ctc gat cgt tgg gct gtc atc gcg ccg caa agg aat tcc cat gaa ctc	1553
	Leu Asp Arg Trp Ala Val Ile Ala Pro Gln Arg Asn Ser His Glu Leu	
	475 480 485 490	
35	cga act cta ctt gac tct ttg tat aga gca gct agt gga atg ggt ctt	1601
	Arg Thr Leu Leu Asp Ser Leu Tyr Arg Ala Ala Ser Gly Met Gly Leu	
	495 500 505	
	aga att cga agc ccc cag gaa ttc ata att tat gat gat cgc act gga	1649
	Arg Ile Arg Ser Pro Gln Glu Phe Ile Ile Tyr Asp Asp Arg Thr Gly	
	510 515 520	

-5-

	act tat gtg aga gca atg gat gat tgt gtg cgc tca gat ccc aaa ctt	1697
	Thr Tyr Val Arg Ala Met Asp Asp Cys Val Arg Ser Asp Pro Lys Leu	
	525 530 535	
5	ata tta tgc ctc gta ccc aat gat aac gcc gaa aga tac tca tca atc	1745
	Ile Leu Cys Leu Val Pro Asn Asp Asn Ala Glu Arg Tyr Ser Ser Ile	
	540 545 550	
	aaa aag aga gga tac gtt gac agg gcg gtg cca act caa gtt gtg acc	1793
	Lys Lys Arg Gly Tyr Val Asp Arg Ala Val Pro Thr Gln Val Val Thr	
	555 560 565 570	
10	ctt aaa acg acc aag aac cgt agc ctt atg agc att gcc acc aaa ata	1841
	Leu Lys Thr Thr Lys Asn Arg Ser Leu Met Ser Ile Ala Thr Lys Ile	
	575 580 585	
	gca atc caa ctg aat tgc aag ttg gga tat aca ccc tgg atg atc gaa	1889
15	Ala Ile Gln Leu Asn Cys Lys Leu Gly Tyr Thr Pro Trp Met Ile Glu	
	590 595 600	
	cta ccc ttg tcc gga ctg atg aca att ggc ttt gac att gcg aag agc	1937
	Leu Pro Leu Ser Gly Leu Met Thr Ile Gly Phe Asp Ile Ala Lys Ser	
	605 610 615	
	aca cga gat cgg aag agg gcc tac gga gca ttg att gcc tca atg gat	1985
20	Thr Arg Asp Arg Lys Arg Ala Tyr Gly Ala Leu Ile Ala Ser Met Asp	
	620 625 630	
	cta cag caa aac tcc acg tac ttc agc aca gtc acg gag tgc agc gcc	2033
	Leu Gln Gln Asn Ser Thr Tyr Phe Ser Thr Val Thr Glu Cys Ser Ala	
	635 640 645 650	
25	ttt gat gtg ctc gct aac acc ctt tgg ccg atg ata gca aag gcc ctg	2081
	Phe Asp Val Leu Ala Asn Thr Leu Trp Pro Met Ile Ala Lys Ala Leu	
	655 660 665	
	cgc caa tat caa cat gag cat agg aag ctg cca tct cga atc gta ttt	2129
30	Arg Gln Tyr Gln His Glu His Arg Lys Leu Pro Ser Arg Ile Val Phe	
	670 675 680	
	tat cga gac ggt gtg agc tcc ggc tct cta aag cag ctt ttt gaa ttt	2177
	Tyr Arg Asp Gly Val Ser Ser Gly Ser Leu Lys Gln Leu Phe Glu Phe	
	685 690 695	
	gaa gtc aag gac atc att gag aag ttg aaa act gaa tac gcc cgc gtc	2225
35	Glu Val Lys Asp Ile Ile Glu Lys Leu Lys Thr Glu Tyr Ala Arg Val	
	700 705 710	
	cag cta agc cca ccg caa tta gct tat att gtg gta acc aga tcc atg	2273
	Gln Leu Ser Pro Pro Gln Leu Ala Tyr Ile Val Val Thr Arg Ser Met	
	715 720 725 730	

-6-

aac acg cgc ttc ttc ctc aac gga caa aat cct ccg cct ggt act ata 2321  
 Asn Thr Arg Phe Phe Leu Asn Gly Gln Asn Pro Pro Pro Gly Thr Ile  
 735 740 745

5 gtt gat gac gtt ata act ctg ccc gag aga tac gac ttt tat ctg gtc 2369  
 Val Asp Asp Val Ile Thr Leu Pro Glu Arg Tyr Asp Phe Tyr Leu Val  
 750 755 760

tcg caa caa gtt cgt cag ggt aca gtg tcg ccg acc agc tac aat gtt 2417  
 Ser Gln Gln Val Arg Gln Gly Thr Val Ser Pro Thr Ser Tyr Asn Val  
 765 770 775

10 ctt tat agc agc atg ggt ntc tca ccg gag aaa atg caa aaa ctt acg 2465  
 Leu Tyr Ser Ser Met Gly Xaa Ser Pro Glu Lys Met Gln Lys Leu Thr  
 780 785 790

tac aag atg tgc cac ttg tac tac aat tgg tcg ggc acc aca cga gtg 2513  
 Tyr Lys Met Cys His Leu Tyr Tyr Asn Trp Ser Gly Thr Thr Arg Val  
 15 795 800 805 810

cca gca gtt tgc cag tac gct aag aag cta gct acc ctc gtg ggt acg 2561  
 Pro Ala Val Cys Gln Tyr Ala Lys Lys Leu Ala Thr Leu Val Gly Thr  
 815 820 825

20 aac ttg cac tct att ccg caa aac gcg ctc gaa aag aag ttt tat tat 2609  
 Asn Leu His Ser Ile Pro Gln Asn Ala Leu Glu Lys Lys Phe Tyr Tyr  
 830 835 840

cta taattggata taatttagaa tggagtatta atccttacta agaggccata 2662  
 Leu

tatgaaacta gccagacat ttatactttt tcaatacttc cttacttttg ctaagcactt 2722

25 cagcatttat gactaaatat ttgtatttg aaatgcatta ctgctctttt ttcaaacaaa 2782

agcaaaattg aggattaaga ttctggtatt taagcataag accagaggaa attcccaaac 2842

aaacatttaa agttatctat caagacatgt tcattaattt ggaatataat tactttattt 2902

ttattgtat attttagttt atgtaaagaa aaattacata catccatgtt tgcttactta 2962

accacacatt catggctgct tatattcgtg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3022

30 aaaaaaaaaa aaaaaaaaaa aaaaaa 3047

&lt;210&gt; 2

&lt;211&gt; 843

-7-

&lt;212&gt; PRT

<213> *Drosophila* sp.

&lt;400&gt; 2

5 Met Ala Asp Asp Gln Gly Arg Gly Arg Arg Arg Pro Xaa Asn Glu Asp  
 1 5 10 15  
 Asp Ser Ser Thr Ser Arg Gly Ser Gly Asp Gly Pro Arg Val Lys Val  
 20 25 30  
 Phe Arg Gly Ser Ser Ser Gly Asp Pro Arg Ala Asp Pro Arg Ile Glu  
 35 40 45  
 10 Ala Ser Arg Glu Arg Arg Ala Leu Glu Glu Ala Pro Arg Arg Glu Gly  
 50 55 60  
 Gly Pro Pro Glu Arg Lys Pro Trp Gly Asp Gln Tyr Asp Tyr Leu Asn  
 65 70 75 80  
 15 Thr Arg Pro Val Glu Leu Val Ser Lys Lys Gly Thr Asp Gly Val Pro  
 85 90 95  
 Val Met Leu Gln Thr Asn Phe Phe Arg Xaa Lys Thr Lys Pro Glu Trp  
 100 105 110  
 Arg Ile Val His Tyr His Val Glu Phe Val Pro Thr Ile Glu Asn Pro  
 115 120 125  
 20 Arg Val Arg Met Gly Val Leu Ser Asn His Ala Asn Leu Leu Gly Ser  
 130 135 140  
 Gly Tyr Leu Phe Asp Gly Leu Gln Leu Phe Thr Thr Arg Lys Phe Glu  
 145 150 155 160  
 25 Gln Glu Ile Thr Val Leu Ser Gly Lys Ser Lys Leu Asp Ile Glu Tyr  
 165 170 175  
 Lys Ile Ser Ile Lys Phe Val Gly Phe Ile Ser Cys Ala Glu Pro Arg  
 180 185 190  
 Phe Leu Gln Val Leu Asn Leu Ile Leu Arg Arg Ser Met Lys Gly Leu  
 195 200 205  
 30 Asn Leu Glu Leu Val Gly Arg Asn Leu Phe Asp Pro Arg Ala Lys Ile  
 210 215 220  
 Glu Ile Arg Glu Phe Lys Met Glu Leu Trp Pro Gly Tyr Glu Thr Ser

-8-

	225	230	235	240
	Ile Arg Gln His Glu Lys Asp Ile Leu Leu Gly Thr Glu Ile Thr His			
	245	250	255	
5	Lys Val Met Arg Thr Glu Thr Ile Tyr Asp Ile Met Arg Arg Cys Ser			
	260	265	270	
	His Asn Pro Ala Arg His Gln Asp Glu Val Arg Val Asn Val Leu Asp			
	275	280	285	
	Leu Ile Val Leu Thr Asp Tyr Asn Asn Arg Thr Tyr Arg Ile Asn Asp			
	290	295	300	
10	Val Asp Phe Gly Gln Thr Pro Lys Ser Thr Phe Ser Cys Lys Gly Arg			
	305	310	315	320
	Asp Ile Ser Phe Val Glu Tyr Tyr Leu Thr Lys Tyr Asn Ile Arg Ile			
	325	330	335	
15	Arg Asp His Asn Gln Pro Leu Leu Ile Ser Lys Asn Arg Asp Lys Ala			
	340	345	350	
	Leu Lys Thr Asn Ala Ser Glu Leu Val Val Leu Ile Pro Glu Leu Cys			
	355	360	365	
	Arg Val Thr Gly Leu Asn Ala Glu Met Arg Ser Asn Phe Gln Leu Met			
	370	375	380	
20	Arg Ala Met Ser Ser Tyr Thr Arg Met Asn Pro Lys Gln Arg Thr Asp			
	385	390	395	400
	Arg Leu Arg Ala Phe Asn His Arg Leu Gln Asn Thr Pro Glu Ser Val			
	405	410	415	
25	Lys Val Leu Arg Asp Trp Asn Met Glu Leu Asp Lys Asn Val Thr Glu			
	420	425	430	
	Val Gln Gly Arg Ile Ile Gly Gln Gln Asn Ile Val Phe His Asn Gly			
	435	440	445	
	Lys Val Pro Ala Gly Glu Asn Ala Asp Trp Gln Arg His Phe Arg Asp			
	450	455	460	
30	Gln Arg Met Leu Thr Thr Pro Ser Asp Gly Leu Asp Arg Trp Ala Val			
	465	470	475	480
	Ile Ala Pro Gln Arg Asn Ser His Glu Leu Arg Thr Leu Leu Asp Ser			
	485	490	495	
	Leu Tyr Arg Ala Ala Ser Gly Met Gly Leu Arg Ile Arg Ser Pro Gln			

-9-

	500	505	510
	Glu Phe Ile Ile Tyr Asp Asp Arg Thr Gly Thr Tyr Val Arg Ala Met		
	515	520	525
5	Asp Asp Cys Val Arg Ser Asp Pro Lys Leu Ile Leu Cys Leu Val Pro		
	530	535	540
	Asn Asp Asn Ala Glu Arg Tyr Ser Ser Ile Lys Lys Arg Gly Tyr Val		
	545	550	555 560
	Asp Arg Ala Val Pro Thr Gln Val Val Thr Leu Lys Thr Thr Lys Asn		
	565	570	575
10	Arg Ser Leu Met Ser Ile Ala Thr Lys Ile Ala Ile Gln Leu Asn Cys		
	580	585	590
	Lys Leu Gly Tyr Thr Pro Trp Met Ile Glu Leu Pro Leu Ser Gly Leu		
	595	600	605
15	Met Thr Ile Gly Phe Asp Ile Ala Lys Ser Thr Arg Asp Arg Lys Arg		
	610	615	620
	Ala Tyr Gly Ala Leu Ile Ala Ser Met Asp Leu Gln Gln Asn Ser Thr		
	625	630	635 640
	Tyr Phe Ser Thr Val Thr Glu Cys Ser Ala Phe Asp Val Leu Ala Asn		
	645	650	655
20	Thr Leu Trp Pro Met Ile Ala Lys Ala Leu Arg Gln Tyr Gln His Glu		
	660	665	670
	His Arg Lys Leu Pro Ser Arg Ile Val Phe Tyr Arg Asp Gly Val Ser		
	675	680	685
25	Ser Gly Ser Leu Lys Gln Leu Phe Glu Phe Glu Val Lys Asp Ile Ile		
	690	695	700
	Glu Lys Leu Lys Thr Glu Tyr Ala Arg Val Gln Leu Ser Pro Pro Gln		
	705	710	715 720
	Leu Ala Tyr Ile Val Val Thr Arg Ser Met Asn Thr Arg Phe Phe Leu		
	725	730	735
30	Asn Gly Gln Asn Pro Pro Pro Gly Thr Ile Val Asp Asp Val Ile Thr		
	740	745	750
	Leu Pro Glu Arg Tyr Asp Phe Tyr Leu Val Ser Gln Gln Val Arg Gln		
	755	760	765
	Gly Thr Val Ser Pro Thr Ser Tyr Asn Val Leu Tyr Ser Ser Met Gly		

-10-

	770	775	780
	Xaa Ser Pro Glu Lys Met Gln Lys Leu Thr Tyr Lys Met Cys His Leu		
	785	790	800
5	Tyr Tyr Asn Trp Ser Gly Thr Thr Arg Val Pro Ala Val Cys Gln Tyr		
	805	810	815
	Ala Lys Lys Leu Ala Thr Leu Val Gly Thr Asn Leu His Ser Ile Pro		
	820	825	830
	Gln Asn Ala Leu Glu Lys Lys Phe Tyr Tyr Leu		
	835	840	

10 <210> 3

<211> 4064

<212> DNA

<213> *Mus sp.*

<220>

15 <221> CDS

<222> (191)..(2776)

<220>

<221> misc\_feature

<222> (450)

20 <223> n=a or c, Xaa=Leu or Ile

<220>

<221> misc\_feature

<222> (1337)

<223> n=a or c, Xaa=Leu or Ile

25 <220>

-11-

&lt;221&gt; misc\_feature

&lt;222&gt; (2636)

&lt;223&gt; n=a or c, Xaa=Leu or Ile

&lt;400&gt; 3

5      agaagcctgc tacagggggt ggcgtgagga gcctcaagga ctgcggacct aagcgtgcta 60  
       agcacggggc caggatagga ctggacgctg ctggaccacg acgatcaggg agtgaccccc 120  
       accagcatcc agcctgcggc agttgtagga ctggaaggag gccaaactga acacctgagc 180  
       tgactggaaa atg act ggc cga gcc cga gct cgg gcc cgc ggc agg gca   229  
           Met Thr Gly Arg Ala Arg Ala Arg Ala Arg Gly Arg Ala  
10               1               5               10  
       cga ggt cag gag acg gtg cag cat gtt ggg gct gct gcg agc cag caa   277  
       Arg Gly Gln Glu Thr Val Gln His Val Gly Ala Ala Ala Ser Gln Gln  
           15               20               25  
       cct ggg tac atc cca ccg aga cct caa cag tcc ccc aca gag ggg gac   325  
15       Pro Gly Tyr Ile Pro Pro Arg Pro Gln Gln Ser Pro Thr Glu Gly Asp  
           30               35               40               45  
       ttg gtt ggc cga gga cga cag agg ggg atg gta gtc gga gcc aca tcc   373  
       Leu Val Gly Arg Gly Arg Gln Arg Gly Met Val Val Gly Ala Thr Ser  
           50               55               60  
       aag tca caa gaa ctg cag atc tca gct ggg ttt cag gag ctg tca ctg   421  
20       Lys Ser Gln Glu Leu Gln Ile Ser Ala Gly Phe Gln Glu Leu Ser Leu  
           65               70               75  
       gca gag aga gga ggg cgt cgc cga gac ttc cat gac ntt ggt gtg aac   469  
25       Ala Glu Arg Gly Gly Arg Arg Arg Asp Phe His Asp Xaa Gly Val Asn  
           80               85               90  
       acc aga cag aac ctt gac cat gtc aaa gag tca aag aca ggc tcc tct   517  
       Thr Arg Gln Asn Leu Asp His Val Lys Glu Ser Lys Thr Gly Ser Ser  
           95               100               105  
       ggc atc att gtg aag ctg agc acc aac cac ttc cgg ctg acc tcg cgc   565  
30       Gly Ile Ile Val Lys Leu Ser Thr Asn His Phe Arg Leu Thr Ser Arg  
           110               115               120               125  
       cca cag tgg gcc ctg tat cag tac cac atc gac tac aat ccc ctg atg   613  
       Pro Gln Trp Ala Leu Tyr Gln Tyr His Ile Asp Tyr Asn Pro Leu Met  
           130               135               140



-12-

	gag gcc cga agg ctt cgc tcc gca ctg ctc ttc cag cat gaa gac ctc 661 Glu Ala Arg Arg Leu Arg Ser Ala Leu Leu Phe Gln His Glu Asp Leu 145 150 155
5	att gga agg tgt cat gct ttc gat ggg aca ata ttg ttt tta cct aag 709 Ile Gly Arg Cys His Ala Phe Asp Gly Thr Ile Leu Phe Leu Pro Lys 160 165 170
	aga cta cag cac aag gtc aca gaa gta ttc agt cag act cgg aat ggg 757 Arg Leu Gln His Lys Val Thr Glu Val Phe Ser Gln Thr Arg Asn Gly 175 180 185
10	gaa cac gtg agg atc acc atc acc ctg acc aac gag ctg ccg ccc acc 805 Glu His Val Arg Ile Thr Ile Thr Leu Thr Asn Glu Leu Pro Pro Thr 190 195 200 205
15	tcg ccc acc tgc ctg cag ttc tat aac atc ntc ttc agg agg ctc ttg 853 Ser Pro Thr Cys Leu Gln Phe Tyr Asn Ile Xaa Phe Arg Arg Leu Leu 210 215 220
	aaa atc atg aat ttg caa caa att gga cgg aat tat tac aat cca agt 901 Lys Ile Met Asn Leu Gln Gln Ile Gly Arg Asn Tyr Tyr Asn Pro Ser 225 230 235
20	gac ccg att gat att cca aac cac agg ttg gtg atc tgg ccc ggc ttc 949 Asp Pro Ile Asp Ile Pro Asn His Arg Leu Val Ile Trp Pro Gly Phe 240 245 250
	acc acc tcc atc ctt cag tat gag aac aac atc atg ctc tgc aca gac 997 Thr Thr Ser Ile Leu Gln Tyr Glu Asn Asn Ile Met Leu Cys Thr Asp 255 260 265
25	gtc agc cac aag gtg ctc cgc agc gag act gtc cta gac ttc atg ttc 1045 Val Ser His Lys Val Leu Arg Ser Glu Thr Val Leu Asp Phe Met Phe 270 275 280 285
30	aat cta tac cag cag aca gag gag cac aag ttc cag gag caa gtg tcg 1093 Asn Leu Tyr Gln Gln Thr Glu Glu His Lys Phe Gln Glu Gln Val Ser 290 295 300
	aag gag ctc ata ggc ctc atc gtt ctc acc aag tac aat aac aag acc 1141 Lys Glu Leu Ile Gly Leu Ile Val Leu Thr Lys Tyr Asn Asn Lys Thr 305 310 315
35	tac cgg gtg gat gac att gac tgg gac cag aat cca aag agc acc ttc 1189 Tyr Arg Val Asp Asp Ile Asp Trp Asp Gln Asn Pro Lys Ser Thr Phe 320 325 330
	aag aag gcg gat ggc tcg gag gtc agc ttc ctg gag tac tac agg aag 1237 Lys Lys Ala Asp Gly Ser Glu Val Ser Phe Leu Glu Tyr Tyr Arg Lys 335 340 345

-13-

	caa tac aac cag gag atc acg gac ctg aag cag ccg gtg ctg gtg agc	1285
	Gln Tyr Asn Gln Glu Ile Thr Asp Leu Lys Gln Pro Val Leu Val Ser	
	350 355 360 365	
5	caa ccc aag cgg agg aga ggc ccc ggc ggc acc ctg cct ggc cca gct	1333
	Gln Pro Lys Arg Arg Arg Gly Pro Gly Gly Thr Leu Pro Gly Pro Ala	
	370 375 380	
	atg ntc atc cct gaa ctc tgc tat ctc aca ggc ctg act gat aaa atg	1381
	Met Xaa Ile Pro Glu Leu Cys Tyr Leu Thr Gly Leu Thr Asp Lys Met	
	385 390 395	
10	cgc aat gat ttc aat gtg atg aag gac ctg gca gtg cac acg cgg ctg	1429
	Arg Asn Asp Phe Asn Val Met Lys Asp Leu Ala Val His Thr Arg Leu	
	400 405 410	
	acc cct gag cag cgg cag cgg gag gtg ggc cgc ctc atc gac tac atc	1477
15	Thr Pro Glu Gln Arg Gln Arg Glu Val Gly Arg Leu Ile Asp Tyr Ile	
	415 420 425	
	cac aag gat gac aat gtg cag aga gag ctt cga gac tgg ggc ctg agc	1525
	His Lys Asp Asp Asn Val Gln Arg Glu Leu Arg Asp Trp Gly Leu Ser	
	430 435 440 445	
20	ttc gac tca aac ttg ctg tcc ttc tct gga aga atc tta caa tct gag	1573
	Phe Asp Ser Asn Leu Leu Ser Phe Ser Gly Arg Ile Leu Gln Ser Glu	
	450 455 460	
	aag atc cac cag ggc gga aag acg ttt gat tac aac cca caa ttt gca	1621
	Lys Ile His Gln Gly Gly Lys Thr Phe Asp Tyr Asn Pro Gln Phe Ala	
	465 470 475	
25	gac tgg tcc aaa gaa aca aga ggc gcg ccg ctg atc agc gtg aag cca	1669
	Asp Trp Ser Lys Glu Thr Arg Gly Ala Pro Leu Ile Ser Val Lys Pro	
	480 485 490	
	ttg gat aac tgg ctg ctg atc tat acc cgc agg aat tat gaa gca gcc	1717
30	Leu Asp Asn Trp Leu Leu Ile Tyr Thr Arg Arg Asn Tyr Glu Ala Ala	
	495 500 505	
	aac tca ctg ata cag aac ctg ttc aaa gtg act cca gcc atg ggc atc	1765
	Asn Ser Leu Ile Gln Asn Leu Phe Lys Val Thr Pro Ala Met Gly Ile	
	510 515 520 525	
35	cag atg aaa aag gca atc atg atc gag gtg gat gac aga aca gaa gct	1813
	Gln Met Lys Lys Ala Ile Met Ile Glu Val Asp Asp Arg Thr Glu Ala	
	530 535 540	
	tat ctg aga gcc ttg cag cag aag gtg acg tca gac act cag ata gtt	1861
	Tyr Leu Arg Ala Leu Gln Gln Lys Val Thr Ser Asp Thr Gln Ile Val	
	545 550 555	

-14-

	gtc tgt ctc ttg tca agt aat cgg aag gac aaa tat gat gcc atc aag	1909
	Val Cys Leu Leu Ser Ser Asn Arg Lys Asp Lys Tyr Asp Ala Ile Lys	
	560 565 570	
5	aag tac ttg tgt aca gac tgc ccc acc cca agt cag tgt gtg gtg gcc	1957
	Lys Tyr Leu Cys Thr Asp Cys Pro Thr Pro Ser Gln Cys Val Val Ala	
	575 580 585	
	cgg acc ctg ggc aag cag caa aca gtc atg gcc att gcc acc aag atc	2005
	Arg Thr Leu Gly Lys Gln Gln Thr Val Met Ala Ile Ala Thr Lys Ile	
	590 595 600 605	
10	gcc ctg cag atg aac tgc aag atg gga ggc gag ctc tgg cgg gtg gac	2053
	Ala Leu Gln Met Asn Cys Lys Met Gly Gly Glu Leu Trp Arg Val Asp	
	610 615 620	
	atg gcc ctg aaa ctg gca atg atc gtg ggc atc gac tgt tac cat gac	2101
15	Met Ala Leu Lys Leu Ala Met Ile Val Gly Ile Asp Cys Tyr His Asp	
	625 630 635	
	acc aca gct ggg cgg agg tcc atc gca gga ttc gtc gcc agc atc aat	2149
	Thr Thr Ala Gly Arg Arg Ser Ile Ala Gly Phe Val Ala Ser Ile Asn	
	640 645 650	
20	gaa ggg atg acc cgc tgg ttc tcc cgc tgc gtc ttt cag gac cgc ggg	2197
	Glu Gly Met Thr Arg Trp Phe Ser Arg Cys Val Phe Gln Asp Arg Gly	
	655 660 665	
	cag gag ctg gtg gat ggt ctc aag gtg tgc ttg caa gct gct ctg agg	2245
	Gln Glu Leu Val Asp Gly Leu Lys Val Cys Leu Gln Ala Ala Leu Arg	
	670 675 680 685	
25	gct tgg agt ggc tgc aat gaa tac atg ccc agc cgt gtc atc gtg tac	2293
	Ala Trp Ser Gly Cys Asn Glu Tyr Met Pro Ser Arg Val Ile Val Tyr	
	690 695 700	
	cga gac ggt gtg ggg gac ggg cag ctg aag acc ctg gtc aat tat gag	2341
30	Arg Asp Gly Val Gly Asp Gly Gln Leu Lys Thr Leu Val Asn Tyr Glu	
	705 710 715	
	gtc cca cag ttc cta gat tgc ctc aag tca gtc ggg aga ggt tac aac	2389
	Val Pro Gln Phe Leu Asp Cys Leu Lys Ser Val Gly Arg Gly Tyr Asn	
	720 725 730	
35	cca aga ctg act gta atc gtg gtg aag aag cgt gtc aat gcc agg ttt	2437
	Pro Arg Leu Thr Val Ile Val Val Lys Lys Arg Val Asn Ala Arg Phe	
	735 740 745	
	ttt gct cag tct ggg gga aga ctt cag aac cct ctt cca ggg aca gtc	2485
	Phe Ala Gln Ser Gly Gly Arg Leu Gln Asn Pro Leu Pro Gly Thr Val	
	750 755 760 765	

-15-

atc gat gtg gaa gtc acc aga cca gag tgg tat gac ttt ttc atc gtg 2533  
 Ile Asp Val Glu Val Thr Arg Pro Glu Trp Tyr Asp Phe Phe Ile Val  
 770 775 780

5 agc cag gca gtg aga agc ggg agt gtg tcc cca aca cac tac aat gtc 2581  
 Ser Gln Ala Val Arg Ser Gly Ser Val Ser Pro Thr His Tyr Asn Val  
 785 790 795

atc tat gac agc agt ggc ctg aag ccc gac cac atc cag cgg ctg aca 2629  
 Ile Tyr Asp Ser Ser Gly Leu Lys Pro Asp His Ile Gln Arg Leu Thr  
 800 805 810

10 tac aag ntc tgc cac gtg tac tat aat tgg cct gga gtc atc cga gtc 2677  
 Tyr Lys Xaa Cys His Val Tyr Tyr Asn Trp Pro Gly Val Ile Arg Val  
 815 820 825

cct gca cct tgc cag tat gca cac aag ctg gcc ttc ctc gtg ggc cag 2725  
 15 Pro Ala Pro Cys Gln Tyr Ala His Lys Leu Ala Phe Leu Val Gly Gln  
 830 835 840 845

agc atc cac aga gag cca aac ctc tcc ctg tcc aac cgc ctc tac tac 2773  
 Ser Ile His Arg Glu Pro Asn Leu Ser Leu Ser Asn Arg Leu Tyr Tyr  
 850 855 860

20 ctc taaccagcag caggggcccgg catgctgggt tccttcagag ctctgccaa 2826  
 Leu

tccttcagtt ctatttttca taggatgagg ttctagcggg atgttggggg taggggttgg 2886

gggccgctgt tttgttttgt tttgttttta gttgttggtg tgtagcggct atagagttaa 2946

ctaaggctta tgtttgcttt gtttctcatg gtgtgttggt acagtttgct tggcagagtg 3006

gtggcaaggg ccgtgttacc acagatagac tttcctaaag cagccgtgtt ggcaggttct 3066

25 tggaggtgct cctgggagca cctcctattg tacgtgctc tctctctctc tctctctctc 3126

tctctctctc tctctctctc tctctctctc tgcattgttg aattttaaag aggaaggac 3186

acaaggcaag aatgccaga gcctcctaga tgggtgctat atgggactct gacacctcag 3246

gttcttaaaag ataaaaagc cagaggtacc tttctgtaat tcttttaaga gttaggtcat 3306

aaggaatgaa aagagttact tttctccctc catgaaagtg ttttttaaga ctgacaaggc 3366

30 cgggtgtgga gtgagtgtg ttgttttgtt tcgcaatttt cttaccaagt gaaattactg 3426

accataattt tatttaatat tttttagttt ttgaaagcct gtgttttctt tgctttttaa 3486

ctacaggcga ccactctggg ataggattcc actcccaaaa gtaatgtgtt ggggtgtgtg 3546

-16-

gcacacgcct gtgatctcag gactcaggag gtgaagccag gggaaaccca agttcccgg 3606  
 cagcctaggc tacatagtag gactttgtct taacaaacag aaaaaaagaa aaagaagaa 3666  
 aaaaaaaga aagaaaaaaa aaaaaaaga aatggagcag tatgagttat gggtgccagt 3726  
 ttctgcagga gactttggga gtaagagctg cctctgttcc taagaggctg caaggctgcg 3786  
 5 gctggggggc cagttcaggt gccaggtag gtacggccac atctatttgc ctggctcttt 3846  
 gacaaagaga gcagcttaga gtggctagag tgtgatgagt ttacacaat ggcgatgtgt 3906  
 gtgtgtgccc ctggcacagc tcaataaagt ttctgtctca ctttaaaaaa aaaaaaaaaa 3966  
 aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa 4026  
 aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa aaaaaaagaa 4064

10 <210> 4  
 <211> 862  
 <212> PRT  
 <213> *Mus sp.*

&lt;400&gt; 4

15 Met Thr Gly Arg Ala Arg Ala Arg Ala Arg Gly Arg Ala Arg Gly Gln  
 1 5 10 15  
 Glu Thr Val Gln His Val Gly Ala Ala Ala Ser Gln Gln Pro Gly Tyr  
 20 25 30  
 20 Ile Pro Pro Arg Pro Gln Gln Ser Pro Thr Glu Gly Asp Leu Val Gly  
 35 40 45  
 Arg Gly Arg Gln Arg Gly Met Val Val Gly Ala Thr Ser Lys Ser Gln  
 50 55 60  
 Glu Leu Gln Ile Ser Ala Gly Phe Gln Glu Leu Ser Leu Ala Glu Arg  
 65 70 75 80  
 25 Gly Gly Arg Arg Arg Asp Phe His Asp Xaa Gly Val Asn Thr Arg Gln  
 85 90 95  
 Asn Leu Asp His Val Lys Glu Ser Lys Thr Gly Ser Ser Gly Ile Ile  
 100 105 110

-17-

Val Lys Leu Ser Thr Asn His Phe Arg Leu Thr Ser Arg Pro Gln Trp  
 115 120 125

Ala Leu Tyr Gln Tyr His Ile Asp Tyr Asn Pro Leu Met Glu Ala Arg  
 130 135 140

5 Arg Leu Arg Ser Ala Leu Leu Phe Gln His Glu Asp Leu Ile Gly Arg  
 145 150 155 160

Cys His Ala Phe Asp Gly Thr Ile Leu Phe Leu Pro Lys Arg Leu Gln  
 165 170 175

10 His Lys Val Thr Glu Val Phe Ser Gln Thr Arg Asn Gly Glu His Val  
 180 185 190

Arg Ile Thr Ile Thr Leu Thr Asn Glu Leu Pro Pro Thr Ser Pro Thr  
 195 200 205

Cys Leu Gln Phe Tyr Asn Ile Xaa Phe Arg Arg Leu Leu Lys Ile Met  
 210 215 220

15 Asn Leu Gln Gln Ile Gly Arg Asn Tyr Tyr Asn Pro Ser Asp Pro Ile  
 225 230 235 240

Asp Ile Pro Asn His Arg Leu Val Ile Trp Pro Gly Phe Thr Thr Ser  
 245 250 255

20 Ile Leu Gln Tyr Glu Asn Asn Ile Met Leu Cys Thr Asp Val Ser His  
 260 265 270

Lys Val Leu Arg Ser Glu Thr Val Leu Asp Phe Met Phe Asn Leu Tyr  
 275 280 285

Gln Gln Thr Glu Glu His Lys Phe Gln Glu Gln Val Ser Lys Glu Leu  
 290 295 300

25 Ile Gly Leu Ile Val Leu Thr Lys Tyr Asn Asn Lys Thr Tyr Arg Val  
 305 310 315 320

Asp Asp Ile Asp Trp Asp Gln Asn Pro Lys Ser Thr Phe Lys Lys Ala  
 325 330 335

30 Asp Gly Ser Glu Val Ser Phe Leu Glu Tyr Tyr Arg Lys Gln Tyr Asn  
 340 345 350

Gln Glu Ile Thr Asp Leu Lys Gln Pro Val Leu Val Ser Gln Pro Lys  
 355 360 365

Arg Arg Arg Gly Pro Gly Gly Thr Leu Pro Gly Pro Ala Met Xaa Ile  
 370 375 380

-18-

Pro Glu Leu Cys Tyr Leu Thr Gly Leu Thr Asp Lys Met Arg Asn Asp  
 385                      390                      395                      400

Phe Asn Val Met Lys Asp Leu Ala Val His Thr Arg Leu Thr Pro Glu  
                     405                      410                      415

5    Gln Arg Gln Arg Glu Val Gly Arg Leu Ile Asp Tyr Ile His Lys Asp  
                     420                      425                      430

Asp Asn Val Gln Arg Glu Leu Arg Asp Trp Gly Leu Ser Phe Asp Ser  
                     435                      440                      445

10   Asn Leu Leu Ser Phe Ser Gly Arg Ile Leu Gln Ser Glu Lys Ile His  
                     450                      455                      460

Gln Gly Gly Lys Thr Phe Asp Tyr Asn Pro Gln Phe Ala Asp Trp Ser  
 465                      470                      475                      480

Lys Glu Thr Arg Gly Ala Pro Leu Ile Ser Val Lys Pro Leu Asp Asn  
                     485                      490                      495

15   Trp Leu Leu Ile Tyr Thr Arg Arg Asn Tyr Glu Ala Ala Asn Ser Leu  
                     500                      505                      510

Ile Gln Asn Leu Phe Lys Val Thr Pro Ala Met Gly Ile Gln Met Lys  
                     515                      520                      525

20   Lys Ala Ile Met Ile Glu Val Asp Asp Arg Thr Glu Ala Tyr Leu Arg  
                     530                      535                      540

Ala Leu Gln Gln Lys Val Thr Ser Asp Thr Gln Ile Val Val Cys Leu  
 545                      550                      555                      560

Leu Ser Ser Asn Arg Lys Asp Lys Tyr Asp Ala Ile Lys Lys Tyr Leu  
                     565                      570                      575

25   Cys Thr Asp Cys Pro Thr Pro Ser Gln Cys Val Val Ala Arg Thr Leu  
                     580                      585                      590

Gly Lys Gln Gln Thr Val Met Ala Ile Ala Thr Lys Ile Ala Leu Gln  
                     595                      600                      605

30   Met Asn Cys Lys Met Gly Gly Glu Leu Trp Arg Val Asp Met Ala Leu  
                     610                      615                      620

Lys Leu Ala Met Ile Val Gly Ile Asp Cys Tyr His Asp Thr Thr Ala  
 625                      630                      635                      640

Gly Arg Arg Ser Ile Ala Gly Phe Val Ala Ser Ile Asn Glu Gly Met  
                     645                      650                      655

-19-

Thr Arg Trp Phe Ser Arg Cys Val Phe Gln Asp Arg Gly Gln Glu Leu  
 660 665 670  
 Val Asp Gly Leu Lys Val Cys Leu Gln Ala Ala Leu Arg Ala Trp Ser  
 675 680 685  
 5 Gly Cys Asn Glu Tyr Met Pro Ser Arg Val Ile Val Tyr Arg Asp Gly  
 690 695 700  
 Val Gly Asp Gly Gln Leu Lys Thr Leu Val Asn Tyr Glu Val Pro Gln  
 705 710 715 720  
 10 Phe Leu Asp Cys Leu Lys Ser Val Gly Arg Gly Tyr Asn Pro Arg Leu  
 725 730 735  
 Thr Val Ile Val Val Lys Lys Arg Val Asn Ala Arg Phe Phe Ala Gln  
 740 745 750  
 Ser Gly Gly Arg Leu Gln Asn Pro Leu Pro Gly Thr Val Ile Asp Val  
 755 760 765  
 15 Glu Val Thr Arg Pro Glu Trp Tyr Asp Phe Phe Ile Val Ser Gln Ala  
 770 775 780  
 Val Arg Ser Gly Ser Val Ser Pro Thr His Tyr Asn Val Ile Tyr Asp  
 785 790 795 800  
 20 Ser Ser Gly Leu Lys Pro Asp His Ile Gln Arg Leu Thr Tyr Lys Xaa  
 805 810 815  
 Cys His Val Tyr Tyr Asn Trp Pro Gly Val Ile Arg Val Pro Ala Pro  
 820 825 830  
 Cys Gln Tyr Ala His Lys Leu Ala Phe Leu Val Gly Gln Ser Ile His  
 835 840 845  
 25 Arg Glu Pro Asn Leu Ser Leu Ser Asn Arg Leu Tyr Tyr Leu  
 850 855 860

&lt;210&gt; 5

&lt;211&gt; 3472

&lt;212&gt; DNA

30 &lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS



-20-

&lt;222&gt; (167)..(2749)

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (392)

5 &lt;223&gt; n=t or a, Xaa=Leu or Ile

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1073)

&lt;223&gt; n=c or a, Xaa=Leu or Ile

10 &lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2369)

&lt;223&gt; n=c or a, Xaa=Leu or Ile

&lt;400&gt; 5

15 gggcgaattg ggcccacgt cgcattgtcc cggccgccat ggccggccgc ggaattcgat 60  
 tccatcctaa tacgactcac tatagggtc gagcggccgc ccgggcaggt ctgaggtgca 120  
 aggaccagga ctagggcgag ggcagcggtc caagaaatag aaaaca atg act ggg 175  
 Met Thr Gly  
 1

20 aga gcc cga gcc aga gcc aga gga agg gcc cgc ggt cag gag aca gcg 223  
 Arg Ala Arg Ala Arg Ala Arg Gly Arg Ala Arg Gly Gln Glu Thr Ala  
 5 10 15

cag ctg gtg ggc tcc act gcc agt cag caa cct ggt tat att cag cct 271  
 Gln Leu Val Gly Ser Thr Ala Ser Gln Gln Pro Gly Tyr Ile Gln Pro  
 20 25 30 35

25 agg cct cag ccg cca cca gca gag ggg gaa tta ttt ggc cgt gga cgg 319

-21-

	Arg Pro Gln Pro Pro Pro Ala Glu Gly Glu Leu Phe Gly Arg Gly Arg	
	40 45 50	
5	cag aga gga aca gca gga gga aca gcc aag tca caa gga ctc cag ata Gln Arg Gly Thr Ala Gly Gly Thr Ala Lys Ser Gln Gly Leu Gln Ile	367
	55 60 65	
	tct gct gga ttt cag gag tta tcg nta gca gag aga gga ggt cgt cgt Ser Ala Gly Phe Gln Glu Leu Ser Xaa Ala Glu Arg Gly Gly Arg Arg	415
	70 75 80	
10	aga gat ttt cat gat ctt ggt gtg aat aca agg cag aac cta gac cat Arg Asp Phe His Asp Leu Gly Val Asn Thr Arg Gln Asn Leu Asp His	463
	85 90 95	
	gtt aaa gaa tca aaa aca ggt tct tca ggc att ata gta agg tta agc Val Lys Glu Ser Lys Thr Gly Ser Ser Gly Ile Ile Val Arg Leu Ser	511
	100 105 110 115	
15	act aac cat ttc cgg ctg aca tcc cgt ccc cag tgg gcc tta tat cag Thr Asn His Phe Arg Leu Thr Ser Arg Pro Gln Trp Ala Leu Tyr Gln	559
	120 125 130	
20	tat cac att gac tat aac cca ctg atg gaa gcc aga aga ctc cgt tca Tyr His Ile Asp Tyr Asn Pro Leu Met Glu Ala Arg Arg Leu Arg Ser	607
	135 140 145	
	gct ctt ctt ttt caa cac gaa gat cta att gga aag tgt cat gct ttt Ala Leu Leu Phe Gln His Glu Asp Leu Ile Gly Lys Cys His Ala Phe	655
	150 155 160	
25	gat gga acg ata tta ttt tta cct aaa aga cta cag caa aag gtt act Asp Gly Thr Ile Leu Phe Leu Pro Lys Arg Leu Gln Gln Lys Val Thr	703
	165 170 175	
	gaa gtt ttt agt aag acc cgg aat gga gag gat gtg agg ata acg atc Glu Val Phe Ser Lys Thr Arg Asn Gly Glu Asp Val Arg Ile Thr Ile	751
	180 185 190 195	
30	act tta aca aat gaa ctt cca cct aca tca cca act tgt ttg cag ttc Thr Leu Thr Asn Glu Leu Pro Pro Thr Ser Pro Thr Cys Leu Gln Phe	799
	200 205 210	
35	tat aat att att ttc agg agg ctt ttg aaa atc atg aat ttg caa caa Tyr Asn Ile Ile Phe Arg Arg Leu Leu Lys Ile Met Asn Leu Gln Gln	847
	215 220 225	
	att gga cga aat tat tat aac cca aat gac cca att gat att cca agt Ile Gly Arg Asn Tyr Tyr Asn Pro Asn Asp Pro Ile Asp Ile Pro Ser	895
	230 235 240	

-22-

	cac agg ttg gtg att tgg cct ggc ttc act act tcc atc ctt cag tat	943
	His Arg Leu Val Ile Trp Pro Gly Phe Thr Thr Ser Ile Leu Gln Tyr	
	245 250 255	
5	gaa aac agc atc atg ctc tgc act gac gtt agc cat aaa gtc ctt cga	991
	Glu Asn Ser Ile Met Leu Cys Thr Asp Val Ser His Lys Val Leu Arg	
	260 265 270 275	
	agt gag act gtt ttg gat ttc atg ttc aac ttt tat cat cag aca gaa	1039
	Ser Glu Thr Val Leu Asp Phe Met Phe Asn Phe Tyr His Gln Thr Glu	
	280 285 290	
10	gaa cat aaa ttt caa gaa caa gtt tcc aaa gaa nta ata ggt tta gtt	1087
	Glu His Lys Phe Gln Glu Gln Val Ser Lys Glu Xaa Ile Gly Leu Val	
	295 300 305	
	gtt ctt acc aag tat aac att aag aca tac aga gtg gat gat att gac	1135
15	Val Leu Thr Lys Tyr Asn Ile Lys Thr Tyr Arg Val Asp Asp Ile Asp	
	310 315 320	
	tgg gac cag aat ccc aag agc acc ttt aag aaa gcc gac ggc tct ggg	1183
	Trp Asp Gln Asn Pro Lys Ser Thr Phe Lys Lys Ala Asp Gly Ser Gly	
	325 330 335	
20	gtc agc ttc tta gaa tac tac agg aag caa tac aac caa gag atc acc	1231
	Val Ser Phe Leu Glu Tyr Tyr Arg Lys Gln Tyr Asn Gln Glu Ile Thr	
	340 345 350 355	
	gac ttg aag cag cct gtc ttg gtc agc cag ccc aag aga agg cgg ggc	1279
	Asp Leu Lys Gln Pro Val Leu Val Ser Gln Pro Lys Arg Arg Arg Gly	
	360 365 370	
25	cct ggg ggg aca ctg cca ggg cct gcc atg ctc att cct gag ctc tgc	1327
	Pro Gly Gly Thr Leu Pro Gly Pro Ala Met Leu Ile Pro Glu Leu Cys	
	375 380 385	
	tat ctt aca ggt cta act gat aaa atg cgt aat gat ttt aac gtg atg	1375
30	Tyr Leu Thr Gly Leu Thr Asp Lys Met Arg Asn Asp Phe Asn Val Met	
	390 395 400	
	aaa gac tta gcc gtt cat aca aga cta act cca gag caa agg cag cgt	1423
	Lys Asp Leu Ala Val His Thr Arg Leu Thr Pro Glu Gln Arg Gln Arg	
	405 410 415	
35	gaa gtg gga cga ctc att gat tac att cat aaa aac gat aat gtt caa	1471
	Glu Val Gly Arg Leu Ile Asp Tyr Ile His Lys Asn Asp Asn Val Gln	
	420 425 430 435	
	agg gag ctt cga gac tgg ggt ttg agc ttt gat tcc aac tta ctg tcc	1519
	Arg Glu Leu Arg Asp Trp Gly Leu Ser Phe Asp Ser Asn Leu Leu Ser	
	440 445 450	

-23-

	ttc tca gga aga att ttg caa aca gaa aag att cac caa ggt gga aaa	1567
	Phe Ser Gly Arg Ile Leu Gln Thr Glu Lys Ile His Gln Gly Gly Lys	
	455 460 465	
5	aca ttt gat tac aat cca caa ttt gca gat tgg tcc aaa gaa aca aga	1615
	Thr Phe Asp Tyr Asn Pro Gln Phe Ala Asp Trp Ser Lys Glu Thr Arg	
	470 475 480	
	ggg gca cca tta att agt gtt aag cca cta gat aac tgg ctg ttg atc	1663
	Gly Ala Pro Leu Ile Ser Val Lys Pro Leu Asp Asn Trp Leu Leu Ile	
	485 490 495	
10	tat acg cga aga aat tat gaa gca gcc aat tca ttg ata caa aat cta	1711
	Tyr Thr Arg Arg Asn Tyr Glu Ala Ala Asn Ser Leu Ile Gln Asn Leu	
	500 505 510 515	
	ttt aaa gtt aca cca gcc atg ggc atg caa atg aga aaa gca ata atg	1759
	Phe Lys Val Thr Pro Ala Met Gly Met Gln Met Arg Lys Ala Ile Met	
15	520 525 530	
	att gaa gtg gat gac aga act gaa gcc tac tta aga gtc tta cag caa	1807
	Ile Glu Val Asp Asp Arg Thr Glu Ala Tyr Leu Arg Val Leu Gln Gln	
	535 540 545	
	aag gtc aca gca gac acc cag ata gtt gtc tgt ctg ttg tca agt aat	1855
20	Lys Val Thr Ala Asp Thr Gln Ile Val Val Cys Leu Leu Ser Ser Asn	
	550 555 560	
	cgg aag gac aaa tac gat gct att aaa aaa tac ctg tgt aca gat tgc	1903
	Arg Lys Asp Lys Tyr Asp Ala Ile Lys Lys Tyr Leu Cys Thr Asp Cys	
	565 570 575	
25	cct acc cca agt cag tgt gtg gtg gcc cga acc tta ggc aaa cag caa	1951
	Pro Thr Pro Ser Gln Cys Val Val Ala Arg Thr Leu Gly Lys Gln Gln	
	580 585 590 595	
	act gtc atg gcc att gct aca aag att gcc cta cag atg aac tgc aag	1999
	Thr Val Met Ala Ile Ala Thr Lys Ile Ala Leu Gln Met Asn Cys Lys	
30	600 605 610	
	atg gga gga gag ctc tgg agg gtg gac atc ccc ctg aag ctc gtg atg	2047
	Met Gly Gly Glu Leu Trp Arg Val Asp Ile Pro Leu Lys Leu Val Met	
	615 620 625	
	atc gtt ggc atc gat tgt tac cat gac atg aca gct ggg cgg agg tca	2095
	Ile Val Gly Ile Asp Cys Tyr His Asp Met Thr Ala Gly Arg Arg Ser	
35	630 635 640	
	atc gca gga ttt gtt gcc agc atc aat gaa ggg atg acc cgc tgg ttc	2143
	Ile Ala Gly Phe Val Ala Ser Ile Asn Glu Gly Met Thr Arg Trp Phe	
	645 650 655	

-24-

	tca cgc tgc ata ttt cag gat aga gga cag gag ctg gta gat ggg ctc	2191
	Ser Arg Cys Ile Phe Gln Asp Arg Gly Gln Glu Leu Val Asp Gly Leu	
	660 665 670 675	
5	aaa gtc tgc ctg caa gcg gct ctg agg gct tgg aat agc tgc aat gag	2239
	Lys Val Cys Leu Gln Ala Ala Leu Arg Ala Trp Asn Ser Cys Asn Glu	
	680 685 690	
	tac atg ccc agc cgg atc atc gtg tac cgc gat ggc gta gga gac ggc	2287
	Tyr Met Pro Ser Arg Ile Ile Val Tyr Arg Asp Gly Val Gly Asp Gly	
	695 700 705	
10	cag ctg aaa aca ctg gtg aac tac gaa gtg cca cag ttt ttg gat tgt	2335
	Gln Leu Lys Thr Leu Val Asn Tyr Glu Val Pro Gln Phe Leu Asp Cys	
	710 715 720	
	cta aaa tcc att ggt aga ggt tac aac cct aga nta acg gta att gtg	2383
15	Leu Lys Ser Ile Gly Arg Gly Tyr Asn Pro Arg Xaa Thr Val Ile Val	
	725 730 735	
	gtg aag aaa aga gtg aac acc aga ttt ttt gct cag tct gga gga aga	2431
	Val Lys Lys Arg Val Asn Thr Arg Phe Phe Ala Gln Ser Gly Gly Arg	
	740 745 750 755	
20	ctt cag aat cca ctt cct gga aca gtt att gat gta gag gtt acc aga	2479
	Leu Gln Asn Pro Leu Pro Gly Thr Val Ile Asp Val Glu Val Thr Arg	
	760 765 770	
	cca gaa tgg tat gac ttt ttt atc gtg agc cag gct gtg aga agt ggt	2527
	Pro Glu Trp Tyr Asp Phe Phe Ile Val Ser Gln Ala Val Arg Ser Gly	
	775 780 785	
25	agt gtt tct ccc aca cat tac aat gtc atc tat gac aac agc ggc ctg	2575
	Ser Val Ser Pro Thr His Tyr Asn Val Ile Tyr Asp Asn Ser Gly Leu	
	790 795 800	
	aag cca gac cac ata cag cgc ttg acc tac aag ctg tgc cac atc tat	2623
30	Lys Pro Asp His Ile Gln Arg Leu Thr Tyr Lys Leu Cys His Ile Tyr	
	805 810 815	
	tac aac tgg cca ggt gtc att cgt gtt cct gct cct tgc cag tac gcc	2671
	Tyr Asn Trp Pro Gly Val Ile Arg Val Pro Ala Pro Cys Gln Tyr Ala	
	820 825 830 835	
35	cac aag ctg gct ttt ctt gtt ggc cag agt att cac aga gag cca aat	2719
	His Lys Leu Ala Phe Leu Val Gly Gln Ser Ile His Arg Glu Pro Asn	
	840 845 850	
	ctg tca ctg tca aac cgc ctt tac tac ctc taacctgcag aagacgatgc	2769
	Leu Ser Leu Ser Asn Arg Leu Tyr Tyr Leu	
	855 860	

-25-

agccgctttt ctttttgaaa tgactttggg atttttttaa gcttttattt accttttttt 2829

taactgttat ctttctggat gaaacttggg aaggggatta ggagatctag cattttattt 2889

ctagcattgc tattcacggg cttccttatt ttatatgtaa aaattaagat tttatatttt 2949

atcttcttgt ttctcataga tttttgtga gcattttttt gtttattttg aagaaatgtg 3009

5 gataagatac ttggtagtat aaaacagact ctctgagagt atttgaatg tgtttggaga 3069

tttacttaaa cgtactttca ggagtgaaca agtcctactt ataaacctat attaaactta 3129

tttttgagat acctgttttg aatttaaagg agataagagg cgtaaagtag gatgctcact 3189

acaaccatag gtgggggttc agctcatatc ttaaagataa aaggctactat tatataacct 3249

atacacaaga tacaggagaa aatatgcttg atttttattt ggcagggggg ctagggttga 3309

10 tggggagtaaa aaaacattg aaaattttta aattgtccaa agaaacattt taagactctt 3369

taacaaaaaa ggccatgagt aaatctctat attaacatca ctattttattt tgttttggaa 3429

ctgggacatg attctatttg ttataaaata aaattgatgt ccc 3472

&lt;210&gt; 6

&lt;211&gt; 861

15 &lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Met Thr Gly Arg Ala Arg Ala Arg Ala Arg Gly Arg Ala Arg Gly Gln  
1 5 10 15

20 Glu Thr Ala Gln Leu Val Gly Ser Thr Ala Ser Gln Gln Pro Gly Tyr  
20 25 30

Ile Gln Pro Arg Pro Gln Pro Pro Pro Ala Glu Gly Glu Leu Phe Gly  
35 40 45

25 Arg Gly Arg Gln Arg Gly Thr Ala Gly Gly Thr Ala Lys Ser Gln Gly  
50 55 60

Leu Gln Ile Ser Ala Gly Phe Gln Glu Leu Ser Xaa Ala Glu Arg Gly  
65 70 75 80

-26-

	Gly Arg Arg Arg Asp Phe His Asp Leu Gly Val Asn Thr Arg Gln Asn	
	85 90 95	
	Leu Asp His Val Lys Glu Ser Lys Thr Gly Ser Ser Gly Ile Ile Val	
	100 105 110	
5	Arg Leu Ser Thr Asn His Phe Arg Leu Thr Ser Arg Pro Gln Trp Ala	
	115 120 125	
	Leu Tyr Gln Tyr His Ile Asp Tyr Asn Pro Leu Met Glu Ala Arg Arg	
	130 135 140	
10	Leu Arg Ser Ala Leu Leu Phe Gln His Glu Asp Leu Ile Gly Lys Cys	
	145 150 155 160	
	His Ala Phe Asp Gly Thr Ile Leu Phe Leu Pro Lys Arg Leu Gln Gln	
	165 170 175	
	Lys Val Thr Glu Val Phe Ser Lys Thr Arg Asn Gly Glu Asp Val Arg	
	180 185 190	
15	Ile Thr Ile Thr Leu Thr Asn Glu Leu Pro Pro Thr Ser Pro Thr Cys	
	195 200 205	
	Leu Gln Phe Tyr Asn Ile Ile Phe Arg Arg Leu Leu Lys Ile Met Asn	
	210 215 220	
20	Leu Gln Gln Ile Gly Arg Asn Tyr Tyr Asn Pro Asn Asp Pro Ile Asp	
	225 230 235 240	
	Ile Pro Ser His Arg Leu Val Ile Trp Pro Gly Phe Thr Thr Ser Ile	
	245 250 255	
	Leu Gln Tyr Glu Asn Ser Ile Met Leu Cys Thr Asp Val Ser His Lys	
	260 265 270	
25	Val Leu Arg Ser Glu Thr Val Leu Asp Phe Met Phe Asn Phe Tyr His	
	275 280 285	
	Gln Thr Glu Glu His Lys Phe Gln Glu Gln Val Ser Lys Glu Xaa Ile	
	290 295 300	
30	Gly Leu Val Val Leu Thr Lys Tyr Asn Ile Lys Thr Tyr Arg Val Asp	
	305 310 315 320	
	Asp Ile Asp Trp Asp Gln Asn Pro Lys Ser Thr Phe Lys Lys Ala Asp	
	325 330 335	
	Gly Ser Gly Val Ser Phe Leu Glu Tyr Tyr Arg Lys Gln Tyr Asn Gln	
	340 345 350	

-27-

Glu Ile Thr Asp Leu Lys Gln Pro Val Leu Val Ser Gln Pro Lys Arg  
 355 360 365

Arg Arg Gly Pro Gly Gly Thr Leu Pro Gly Pro Ala Met Leu Ile Pro  
 370 375 380

5 Glu Leu Cys Tyr Leu Thr Gly Leu Thr Asp Lys Met Arg Asn Asp Phe  
 385 390 395 400

Asn Val Met Lys Asp Leu Ala Val His Thr Arg Leu Thr Pro Glu Gln  
 405 410 415

10 Arg Gln Arg Glu Val Gly Arg Leu Ile Asp Tyr Ile His Lys Asn Asp  
 420 425 430

Asn Val Gln Arg Glu Leu Arg Asp Trp Gly Leu Ser Phe Asp Ser Asn  
 435 440 445

Leu Leu Ser Phe Ser Gly Arg Ile Leu Gln Thr Glu Lys Ile His Gln  
 450 455 460

15 Gly Gly Lys Thr Phe Asp Tyr Asn Pro Gln Phe Ala Asp Trp Ser Lys  
 465 470 475 480

Glu Thr Arg Gly Ala Pro Leu Ile Ser Val Lys Pro Leu Asp Asn Trp  
 485 490 495

20 Leu Leu Ile Tyr Thr Arg Arg Asn Tyr Glu Ala Ala Asn Ser Leu Ile  
 500 505 510

Gln Asn Leu Phe Lys Val Thr Pro Ala Met Gly Met Gln Met Arg Lys  
 515 520 525

Ala Ile Met Ile Glu Val Asp Asp Arg Thr Glu Ala Tyr Leu Arg Val  
 530 535 540

25 Leu Gln Gln Lys Val Thr Ala Asp Thr Gln Ile Val Val Cys Leu Leu  
 545 550 555 560

Ser Ser Asn Arg Lys Asp Lys Tyr Asp Ala Ile Lys Lys Tyr Leu Cys  
 565 570 575

30 Thr Asp Cys Pro Thr Pro Ser Gln Cys Val Val Ala Arg Thr Leu Gly  
 580 585 590

Lys Gln Gln Thr Val Met Ala Ile Ala Thr Lys Ile Ala Leu Gln Met  
 595 600 605

Asn Cys Lys Met Gly Gly Glu Leu Trp Arg Val Asp Ile Pro Leu Lys  
 610 615 620



-28-

Leu Val Met Ile Val Gly Ile Asp Cys Tyr His Asp Met Thr Ala Gly  
 625                      630                      635                      640

Arg Arg Ser Ile Ala Gly Phe Val Ala Ser Ile Asn Glu Gly Met Thr  
                     645                      650                      655

5    Arg Trp Phe Ser Arg Cys Ile Phe Gln Asp Arg Gly Gln Glu Leu Val  
                     660                      665                      670

Asp Gly Leu Lys Val Cys Leu Gln Ala Ala Leu Arg Ala Trp Asn Ser  
                     675                      680                      685

10    Cys Asn Glu Tyr Met Pro Ser Arg Ile Ile Val Tyr Arg Asp Gly Val  
                     690                      695                      700

Gly Asp Gly Gln Leu Lys Thr Leu Val Asn Tyr Glu Val Pro Gln Phe  
 705                      710                      715                      720

Leu Asp Cys Leu Lys Ser Ile Gly Arg Gly Tyr Asn Pro Arg Xaa Thr  
                     725                      730                      735

15    Val Ile Val Val Lys Lys Arg Val Asn Thr Arg Phe Phe Ala Gln Ser  
                     740                      745                      750

Gly Gly Arg Leu Gln Asn Pro Leu Pro Gly Thr Val Ile Asp Val Glu  
                     755                      760                      765

20    Val Thr Arg Pro Glu Trp Tyr Asp Phe Phe Ile Val Ser Gln Ala Val  
                     770                      775                      780

Arg Ser Gly Ser Val Ser Pro Thr His Tyr Asn Val Ile Tyr Asp Asn  
 785                      790                      795                      800

Ser Gly Leu Lys Pro Asp His Ile Gln Arg Leu Thr Tyr Lys Leu Cys  
                     805                      810                      815

25    His Ile Tyr Tyr Asn Trp Pro Gly Val Ile Arg Val Pro Ala Pro Cys  
                     820                      825                      830

Gln Tyr Ala His Lys Leu Ala Phe Leu Val Gly Gln Ser Ile His Arg  
                     835                      840                      845

30    Glu Pro Asn Leu Ser Leu Ser Asn Arg Leu Tyr Tyr Leu  
                     850                      855                      860

&lt;210&gt; 7

&lt;211&gt; 42

&lt;212&gt; DNA

-29-

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthesized  
Oligonucleotide Primer

5 &lt;400&gt; 7

gatcatatgg agcaaaagct tattagcgag gaagatctga at 42

&lt;210&gt; 8

&lt;211&gt; 42

&lt;212&gt; DNA

10 &lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthesized  
Oligonucleotide Primer

&lt;400&gt; 8

15 gatcattcag atcttctctcg ctaataagct ttgctccat at 42

&lt;210&gt; 9

&lt;211&gt; 45

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

20 &lt;220&gt;

<223> Description of Artificial Sequence: Synthesized  
Oligonucleotide Primer

&lt;400&gt; 9

-30-

ctagcatatg agcaaaagct tattagcgag gaagatctga ataag 45

<210> 10

<211> 45

<212> DNA

5 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesized  
Oligonucleotide Primer

<400> 10

10 ctagcttatt cagatcttcc tcgctaataa gcttttgctc atatg 45

<210> 11

<211> 17

<212> DNA

<213> Artificial Sequence

15 <220>

<223> Description of Artificial Sequence: Synthesized  
Oligonucleotide Primer

<400> 11

acgataagtt ctgttat 17

## INTERNATIONAL SEARCH REPORT

International application No.

PCT:US99/28764

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 424/93.21; 435/4.325.384; 514/1.21.44; 800/4, 13

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.21; 435/4.325.384; 514/1.21.44; 800/4, 13

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, biosis, embase, Derwent biotechnology abstract, medline, CAS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LIN et al. A novel group of pumilio mutations affects the asymmetric division of germline stem cells in the Drosophila ovary. Development. 1997, Vol. 124, pages 2463-2476, see the entire document.	46-65, 68-86, 89, 90, 93-96
Y	COX et al. A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes & Development. 1998, Vol. 12, pages 3715-3727, see the entire document.	46-65, 68-86, 89, 90, 93-96

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 APRIL 2000

Date of mailing of the international search report

15 MAY 2000

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRUCE CAMPELL

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/28764

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A01K 67/00; A01N 61/00, 63/00; A61K 38/00, 48/00; C12N 5/00, 5/02; C12P 21/00; C12Q 1/00